

Curriculum Vitae

Trisha Suppes, M.D., Ph.D.

BIOGRAPHICAL AND PERSONAL INFORMATION

Place of Birth: Palo Alto, California
Nationality: U.S. Citizen

ACADEMIC BACKGROUND

Stanford University, Stanford, California 09/69 – 06/73
B.A., Human Biology
University of California, Los Angeles, California 09/74 – 12/80
Ph.D., Department of Anatomy
Dartmouth Medical School, Hanover, New Hampshire 08/83 – 06/87
Medical Degree Program

CERTIFICATION

National Board of Medical Examiners
July, 1988

American Board of Psychiatry and Neurology
November, 1992

Massachusetts State Board of Medical Examiners
Currently Inactive

Texas State Board of Medical Examiners
Currently Closed

California State Board of Medical Examiners
G87908
Current

Drug Enforcement Administration
United States Department of Justice
BS0900767
Current

PROFESSIONAL EXPERIENCE

Appointments Held

01/71 – 06/71 & 01/72 – 06/73 Undergraduate Research Assistant, Dr. Donald Kennedy's Laboratory, Department of Biology, Stanford University

09/73 – 06/74 Research Assistant, Institute for Mathematical Studies in the Social Sciences, Stanford University

09/74 – 12/80 Graduate Student, Department of Anatomy, University of California, Los Angeles

09/77 – 12/80 Doctoral Candidate, Dr. Paul O'Lague's laboratory, Department of Biology, University of California, Los Angeles

06/81 – 08/83 Postdoctoral Fellow, Dr. David Prince's laboratory, Department of Neurology, Stanford University School of Medicine, Stanford, California

07/84 – 08/84 Research Associate, Neurochemical Pharmacology Unit of Medical Research at Addenbrooke's Hospital, Cambridge, England

07/87 – 06/91 Resident in Adult Psychiatry, McLean Hospital, Belmont, MA

07/87 – 06/92 Clinical Fellow in Psychiatry, Harvard Medical School, Boston, MA

07/90 – 06/91 Research Associate, Dr. Paul Rosenberg, Department of Neurology, Children's Hospital, Boston, MA

7/90 – 06/92 Neuroscience Fellow, Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA

07/92 – 10/94 Medical Director, Mental Health Mental Retardation Day Treatment Center, Dallas, Texas

07/92 – 08/98 Assistant Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas

10/97 – 06/00 Director, Bipolar Disorder Module, Texas Medication Algorithm Project (TMAP)

07/00 – 08/04 Director, Bipolar Disorder Module, Texas Implementation of Medication Algorithms (TIMA)

10/00 – 09/02 Project Director, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Women's Studies, NIMH Contract

04/96 – 05/2008 Director, Bipolar Disorder Research Program, Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas

09/98 – 08/05 Associate Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas

09/05 – 05/08 Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.

6/08- 05/09 Adjunct Professor, Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas

06/08 – Present Professor, Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Stanford, CA.

06/08 – 10/18 Director, Bipolar and Depression Research Program, VA Palo Alto Health Care System, Palo Alto, CA.

10/12 – Present Director, Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES), VA Palo Alto Health Care System, Palo Alto, CA

02/13 – 08/14 Director, Center for Clinical Research, VA Palo Alto Health Care System, Palo Alto, CA

11/18 – Present Director, Exploratory Therapeutics Laboratory

Appointments Held – Committee

1977 – 1978 Mental Health Training Program Executive Committee, Graduate Student Representative, Brain Research Institute, University of California, Los Angeles

- 1985 – 1986 Committee on Graduate Housing, Dartmouth College, Student Representative for Dartmouth Medical School, Hanover
- 1988 – 1989 Committee on Emergency Medical Care, McLean Hospital, Resident Representative
- 1989 – 1990 Treasurer, Resident's Association, McLean Hospital
- 1992 – 1998 Pharmacy Therapeutics Committee, Dallas County Mental Health Mental Retardation Department
- 1993 – 1994 Membership Committee for the Society of Biological Psychiatry
- 1994 – 1995 Co-chair, Membership Committee, Society of Biological Psychiatry.
- 1994 – 2000 Research Committee, Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX.
- 1994 – Present Scientific Advisory Board (SAB), Depression and Bipolar Support Alliance (DBSA) formerly National Depressive and Manic-Depressive Association (NDMDA).
- 1995 – 1996 Chair, Membership Committee, Society of Biological Psychiatry.
- 1997 – 1999 Member, Committee to Revise DSM-IV Mood Disorders, American Psychiatric Association.
- 1997 – 2003 Member, Committee on Research on Psychiatric Treatments, Council on Research, American Psychiatric Association (CCRPT).
- 1998 – 1999 Member, Committee on Psychiatric Knowledge and Skills Assessment Program (PKSAP), American Psychiatric Association.
- 1998 – 2001 Member, Executive Committee, Scientific Advisory Board, National Depressive and Manic-Depressive Association (NDMDA).
- 2000 – 2000 Committee Chair, Update on Texas Medication Algorithms, Dallas, TX.
- 2000 – 2001 Member, Bipolar Educational Awareness Material (BEAM) 4th & 5th Initiative Educational Panel, Janssen Pharmaceutica Research Foundation.
- 2000 – 2003 Member, Committee on Practice Guidelines for the Treatment of Patients with Bipolar Disorder, American Psychiatric Association.
- 2000 – 2001 Member, Task Force on Defining Response and Remission for Major Psychiatric Disorders, American College of Neuropsychopharmacology (ACNP).
- 2000 – 2005 Member, Advisory Council on STEP-BD Women Studies, National Institute of Mental Health (NIMH).
- 2001 Participant, Pharmacological and Somatic Treatment Development Workgroup, Molecular and Cellular Neuroscience Research Division, National Institute of Mental Health (NIMH).
- 2003 Chair, Bipolar Section on Co-occurring Disorders, COMAP: The Consensus Conference, Dallas, Texas.
- 2004 – 2005 Committee Chair, Updates on Texas Medication Algorithms, Dallas, Texas.
- 2004 – 2005 Member, Biostatistics and Clinical Science Advisory Committee, University of Texas Southwestern Medical Center at Dallas.
- 2005 – 2008 Member, Program Planning Committee, Society of Biological Psychiatry.
- 2005 – 2008 Member, Nomenclature Committee Project Development Meeting, International Society for Bipolar Disorder, Pittsburgh, PA.
- 2005 – 2008 Member, Outline for Diagnostic Committee Task Force Groups Meeting, International Society for Bipolar Disorder, Pittsburgh, PA.
- 2005 – 2008 Member, Departmental Appointments and Promotions Committee, Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX.
- 2006 – 2007 Member, Membership Committee, International Society of Bipolar Disorder.
- 2006 Member, Diagnostic Committee, Bipolar II Workgroup, Course and Outcome Nomenclature (CON), International Society of Bipolar Disorder.

- 2006 Member, Ad hoc Committee, Poster Judging, 2nd Biennial Conference of the International Society for Bipolar Disorders, Edinburgh, Scotland.
- 2006 – 2011 Member, Data Safety Monitoring Board for collaborative R01 grant [R01 MH 071762] Bipolar Disorder in Pregnancy and the Postpartum Period: Predictors of Morbidity (PI: Viguera and Newport).
- 2006 –2007 Member, UT Southwestern Medical Center at Dallas Institutional Review Board 4.
- 2006 – 2009 Member, Work Group for the Practice Guidelines for Bipolar Disorder, American Psychiatric Association.
- 2007 – 2012 Member, Workgroup for Mood Disorders, American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders 5 (DSM5).
- 2007 – 2012 Chair, Sub Workgroup for Bipolar Disorder, American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders 5 (DSM5).
- 2008 – 2011 Member, History Committee, American College of Neuropsychopharmacology.
- 2008 – 2014 Chair, Search Committees for two positions, Faculty for Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA.
- 2008 – 2012 Chair for Veterans Affairs and Department of Defense Bipolar Disorder Treatment Guidelines.
- 2009 – Present Member, Industry Academia Liaison Committee, International Society for Bipolar Disorders.
- 2009 – Present Member, Research Committee, International Society for Bipolar Disorders.
- 2009 – Present Member, Clinical Trials Working Group, International Society for Bipolar Disorders.
- 2009 – Present Member, Strategic Planning Committee, International Society for Bipolar Disorders.
- 2009 – Present Member, Scientific Planning Committee, International Society for Bipolar Disorders.
- 2007 – 2010 Member, Institutional Review Board, Panel 7, Stanford University, Stanford, CA.
- 2010 – Present Alternate, Faculty Senate, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA.
- 2010 – Present Member, Academic Progress—Appointments and Promotions Committee, Stanford University School of Medicine, Stanford, CA.
- 2011 - 2014 Member, Program Committee, American College of Neuropsychopharmacology (ACNP).
- 2011 – Present Member, R&D Committee, VA Palo Alto Health Care System, Palo Alto, CA.
- 2011 – Present Member, Scientific Advisory Board, International Forum on Mood and Anxiety Disorders (IFMAD).
- 2011 – Present Member, Executive Committee, Stanford Mood Disorders Center, Stanford University School of Medicine, Stanford, CA.
- 2010 – 2015 Member, Data Safety Monitoring Board for AHRQ R01 grant: Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (PI: Perlis)
- 2011 – 2014 Member, Membership Committee, Society of Biological Psychiatry (SOBP)
- 2011 – 2017 Member, Program Committee, Society of Biological Psychiatry (SOBP)
- 2011 – 2015 Co-Chair, Service Members, Veterans & Military Families Task Group, National Network of Depression Centers (NNDC)
- 2011 – Present Member, Bipolar Disorder Task Force, National Network of Depression Centers (NNDC)
- 2012 – 2013 Member, Selection Committee for Acting Chief of Staff (ACOS) of R&D, VA Palo Alto Health Care System, Palo Alto, CA.
- 2013 – Present Member, Research Planning Council (RPC), VA Palo Alto Health Care System, Palo Alto, CA.
- 2013 – Present Collaborator, Clinical Research Task Force, VA Palo Alto Health Care System, Palo Alto, CA.

2013 – 2015	Member, Scientific Program Committee, American College of Psychiatrists (ACP)
2014 – 2017,2019	Mentor, Research Colloquium for Junior Investigators, APA Annual Meeting
2015 – Present	Member, Professoriate Committee, Stanford University, Department of Psychiatry and Behavioral Health
2015 – Present	Member, Executive Research Advisory Council, VA Palo Alto Health Care System, Palo Alto, CA.
2015 – Present	ISBD Women’s Initiative, founder and continuing member
2016 – Present	Member, Executive Committee, Veteran Affairs, Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES)
2017 – Present	Alternate, A&P Committee, Stanford University, School of Medicine
2017 – 2019	Member, VA CSP Coordinating Center Palo Alto director search committee
2018	Member, VA Professoriate search committee focused on brain stimulation
2017-2019	ASCP CME Committee
2019	Member, International Scientific Program Committee for the World Congress of Biological Psychiatry

Awards

09/74 –08/78	Appointed to the Mental Health Training Program, Brain Research Institute, University of California, Los Angeles
06/80 – 12/80	Chancellor’s Patent Fund Grant, University of California, Los Angeles
06/81 – 06/83	McCormick Fellowship, Stanford University School of Medicine, Stanford
07/84 – 08/84	Summer Research Fellowship, Scottish Rite Foundation for Schizophrenic Research at Addenbrooke’s Hospital, Cambridge, England
07/90 – 06/92	Neuroscience Fellowship in Psychiatry, McLean and Massachusetts General Hospitals in the Department of Psychiatry, Harvard Medical School
05/91	Stanley Cobb Prize, Boston Society
05/92	Dista Travel Fellowship Award, Society of Biological Psychiatry
12/92	Outstanding Team Effort, AMH Contract Services, Dallas County Mental Health and Mental Retardation Center
07/93 – 06/95	Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (NARSAD)
05/94	Outstanding PGY-III Teacher of the Year Award 1993-94, Department of Psychiatry, UT Southwestern Medical Center
06/94	McCurley Award for Treatment of Patients with Rapid Cycling Bipolar Disorder
08/94 – 07/96	Scientist Development Award (1-K2-MH-01221-01), Principal Investigator, National Institute of Mental Health (NIMH)
07/95 – 06/97	Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (NARSAD)
05/95	Nominated for Outstanding PGY-III Teacher of the Year 1994-95, Department of Psychiatry, UT Southwestern Medical Center
1996	Co-recipient, 1996 Gerald L. Klerman Young Investigator Award, National Depressive and Manic-Depressive Association
1996-2010	Elected by peers for inclusion in the Best Doctors in America®
05/96	Outstanding PGY-III Teacher of the Year Award 1995-96, Department of Psychiatry, UT Southwestern Medical Center
05/02	Nominated PGY-IV Outstanding Teacher of the Year 2001-02, Department of Psychiatry, UT Southwestern Medical Center

05/04	Nominated PGY-IV Outstanding Teacher of the Year 2003-2004, Department of Psychiatry, UT Southwestern Medical Center
2005 – Present	Elected to Distinguished Fellow, American Psychiatric Association
05/05	Nominated for Outstanding PGY-IV Teacher of the Year 2004-2005, Department of Psychiatry, UT Southwestern Medical Center
2006 – 2008	Councilor, Board of Councilors, International Society for Bipolar Disorders.
2007	2007 <i>Texas Super Doctors</i> , Texas Monthly
2008	Recipient, 2008 Gerald L. Klerman Senior Investigator Award, Depression and Bipolar Support Alliance.
2009 – 2013	Councilor, Board of Councilors, International Society for Bipolar Disorders.
12/09	Elected to Fellow, American College of Neuropsychopharmacology (ACNP)
2010	Selected by the Consumers' Research Council of <i>American Psychiatric Association</i> as one of America's Top Psychiatrists.
2013	Elected as a member, American College of Psychiatrists
2014-2015	Elected as Treasurer/Secretary to International Society of Bipolar Disorders
2014	Reuter's Top 1% Globally Influential Psychiatrists Over Last 10 Years
2014-2017	Chair, Finance Committee, International Society for Bipolar Disorder
2016	Elected to Distinguished Life Fellow, American Psychiatric Association
2016	Chair, Program Committee, Washington DC meeting, International Society for Bipolar Disorders
2016-2017	Reelected as Treasurer/Secretary to International Society of Bipolar Disorders
2017-2025	Elected to American Society of Clinical Psychopharmacology (ASCP) Board Member
2018-2020	Elected President to International Society of Bipolar Disorders

Pharmaceutical Advisory Board

1999 – 2001	Bipolar Disorder Advisory Board, Pharmaceutical Research Institute
06/98 – 2006	US Bipolar Advisory Board Committee, Eli Lilly and Company, Indianapolis, IN
1998 – 2006	Bipolar Disorder Advisory Board, GlaxoSmithKline
1998 – 04/07	Bipolar Disorder Advisory Board, Abbott Laboratories
1998 – 2005	Bipolar Disorder Advisory Board, Janssen Pharmaceutica Products
1999 – 2006	Bipolar Disorder and National Advisory Board, AstraZeneca
2000 – 2003	Bipolar Advisory Board, Johnson and Johnson Pharmaceutical Research and Development
2000 – 2006	Bipolar Advisory Board, Novartis Pharmaceuticals
2000 – 2006	Bipolar Advisory Board, Bristol-Myers Squibb
2001 – 2006	Geodon Bipolar Disorder Advisory Board, Pfizer US Pharmaceuticals
2002 – 2005	Bipolar Disorder Advisory Board, UCB Pharmaceutical
2004 – 2005	Bipolar Disorder Advisory Board, Shire Inc.
2008 – 2008	Bipolar Disorder Advisory Board, Orexin Therapeutics Inc.
2012 –2015	Bipolar Disorder Advisory Board, Sunovion Pharmaceuticals Inc.
2014 -2015	Merck, Clinical Insomnia US Advisory Board
2018	Allergan Advisory Board

Editorial Boards

9/99 – 7/00	Section Editor, Nonschizophrenic Psychotic Disorders, <i>Current Science</i>
4/00 – 2001	Editorial Board Member, <i>Psychiatric Practice Success</i> Newsletters

10/00 – Present	Editorial Board, <i>Bipolar Disorders – An International Journal of Psychiatry and Neurosciences</i>
02/01 – Present	Editorial Board, <i>Clinical Approaches in Bipolar Disorders Journal</i>
2007 – 2014	Associate Editor, <i>American Journal of Psychiatry</i>
2007 – Present	Advisory Board Member, <i>bp Magazine</i>
2012 – Present	Editorial Board Member, <i>Depression and Anxiety</i>
2012—2016	Editorial Board Member, <i>International Journal of Bipolar Disorders</i>
2016 – Present	Associate Editor, <i>International Journal of Bipolar Disorders</i>
2018	Editorial Board Member, <i>Bipolar Disorders</i>

Ad-Hoc Editorial Review

1993	The Medical Letter
1995 – Present	The Journal of Psychiatric Research
2003 – Present	Neuropsychopharmacology & Biological Psychiatry
1993 – Present	The Journal of Clinical Psychiatry
1993 – Present	Biological Psychiatry
1996 – Present	Psychiatric Services
1996 – Present	Neuropsychopharmacology
1996 – Present	Journal of Clinical Psychopharmacology
1998 – Present	Psychological Medicine
1998 – Present	Comprehensive Psychiatry
1999 – Present	Journal of Affective Disorders
1999 – Present	International Clinical Psychopharmacology
1999 – Present	Bipolar Disorders
1999 – Present	American Journal of Psychiatry
2004 – Present	Expert Consensus Guidelines
2004 – Present	Archives of General Psychiatry (JAMA, Psychiatry)
2005 – Present	CNS Drugs
2007 – Present	Schizophrenia Bulletin
2007 – Present	International Journal of Neuropsychopharmacology
2009 – Present	Journal of Psychopharmacology
2009 – Present	Journal of Traumatic Stress
2015 – Present	Nordic Journal of Psychiatry

Review Committee Duties

1995	Scientific Abstract Reviewer, 35th Annual New Clinical Drug Evaluation Unit (NCDEU)
1999	Reviewer (one of 10 invited experts nationally), National Clinical Treatment Guidelines for Bipolar Disorder, Department of Veterans Affairs
2001	Reviewer, National Institute of Mental Health Intramural Program
2003 – Present	Scientific Abstract Reviewer, 43rd Annual New Clinical Drug Evaluation Unit (NCDEU)
2002-2005	Secretarial Appointee, Department of Veterans Affairs Medical Research Service Merit Review Subcommittee for Mental Health and Behavioral Science
2005-2007	Member, Special Emphasis Panel, National Institutes of Health Extramural Loan Repayment Program
10/19/06-10/20/06	Chairperson, National Institutes of Health, Special Emphasis Panel, Child Psychopathology and Developmental Disabilities study section

11/20/06-11/21/06	Reviewer, National Institute of Mental Health, Mental Health Centers for Intervention Development & Applied Research (CIDAR)
2007	Reviewer, National Institute of Mental Health, Loan Repayment Program
10/18/07	Reviewer, National Institute of Mental Health, Mental Health Centers for Intervention Development & Applied Research (CIDAR)
2010	Reviewer, National Institute of Mental Health, Loan Repayment Program (LRP)
2010	Reviewer, National Institute of Mental Health, Special Emphasis Panel/ Scientific Review Group
2012	Reviewer, National Institute of Mental Health, Loan Repayment Program (LRP)
2013-present	Reviewer, National Institute of Mental Health, Special Emphasis Panel/ Scientific Review Group
2016	Reviewer, National Institute of Mental Health, Fellowship

Professional Society Memberships

1973 – 1999	Member, Society of Neuroscience
1981 – 1998, 2016 – 2018	Member, American Association for the Advancement of Science
1986 – 1997	Member, New York Academy of Science
1997 – 2001	Associate Member, American College of Neuropsychopharmacology (ACNP)
1996 – 2002	Member, Texas Society of Psychiatric Physicians
1998 – 2014	Member, American Medical Association
1984 – 2016	Distinguished Fellow, American Psychiatric Association (APA)
1995 – 2008	Member, Dallas Area Women Psychiatrists
1995 – Present	Member, Society of Biological Psychiatry (SOBP)
1998 – 2008	Member, Dallas County Medical Association
2000 – 2008	Member, International Society for Affective Disorders
2001 – Present	Member, International Society for Bipolar Disorders
2005 – 2009	Member, American College of Neuropsychopharmacology (ACNP)
2009 – Present	Fellow, American College of Neuropsychopharmacology (ACNP)
2010 – 2014	Member, World Federation of Societies of Biological Psychiatry (WFSBP)
2010 – 2016	Distinguished Fellow, Northern California Psychiatric Society (NCPS)
2016 – Present	Lifetime Distinguished Fellow, American Psychiatric Association (APA)
2018	American College of Neuropsychopharmacology (ACNP)
2019	Emeritus Member, American College of Psychiatrists (ACP)

Teaching

09/75 – 03/76	Gross Anatomy, Department of Anatomy, School of Medicine, University of California, Los Angeles, California
03/76 – 05/76	Neurology for Medical Students, Department of Anatomy, School of Medicine, University of California, Los Angeles, California
09/76 – 12/76	Microscopic Anatomy, Department of Anatomy, School of Medicine, University of California, Los Angeles, California
09/77 – 12/77	Introduction to Neurobiology, Department of Biology, University of California, Los Angeles, California
09/91 – 11/91	Human Nervous System and Behavior, Harvard Medical School, Boston, Massachusetts
12/92	PGY-II Clinical Neuroscience Mood Disorders Module: Biology of Mania, UT Southwestern Medical Center, Dallas, Texas

- 06/93 – 06/95 Introductory Lecture on Psychopharmacology – PGY-II Level – six times per year, UT Southwestern Medical Center, Dallas, Texas
- 12/93 Mental Health Mental Retardation Training Session, Schizoaffective Disorders, UT Southwestern Medical Center, Dallas, Texas
- 03/94 – 2000 Yearly PGY-III Advanced Clinical Neuroscience Section on Bipolar Disorder, UT Southwestern Medical Center, Department of Psychiatry, Dallas, Texas (4-5 lectures per year)
- 08/94 Schizoaffective and Bipolar Mood Disorders, Psychopathology and Treatment Course, UT Southwestern Medical Center, Dallas, Texas
- 1994 Quarterly Case Conference, Mental Health Connection, St. Paul's Hospital, UT Southwestern Medical Center, Department of Psychiatry, Dallas, Texas
- 1994 – 5/2008 Case Conference, Parkland Psychiatry Outpatient Service
- 08/95 Lecture on Treatment-Resistant Bipolar Disorder, Parkland Memorial Hospital, Dallas, Texas
- 12/6/96 Update on Medication Treatment for Bipolar Disorder Workshop, Texas Medication Algorithm Project (TMAP), San Antonio (see various lectures in Texas on Medication Algorithms for Bipolar Disorder Center), Dallas, Texas
- 1998 – 2003 PGY-IV Advanced Complicated Bipolar Disorder, UT Southwestern Medical, Dallas, Texas, 1 lecture/year.
- 11/00 Consultation Liaison Medical Update, UT Southwestern Medical Center, Dallas, Texas
- 2001 “How to Integrate a Clinical and Research Career”, Faculty Workshop, UT Southwestern Medical Center, Dallas, Texas
- 01/2001 – 07/2007 Course Co-Director, PGY-II – PGY-III (18-month) of Clinical Neuroscience at UT Southwestern Medical Center, Department of Psychiatry, Dallas, Texas
- 01/2001 – 05/2008 PGY-II Lecturer on Bipolar Disorder (4-5 lectures each year) at UT Southwestern Medical Center, Department of Psychiatry, Dallas, Texas
- 2002 **Suppes T**, Cullum M. “How to Integrate a Clinical and Research Career”, Faculty Workshop, UT Southwestern Medical Center, Dallas, Texas
- 2002 PGY-IV Lecture on Psychopharmacology II: Bipolar Disorder, UT Southwestern Medical Center, Dallas, Texas
- 2002 Lecture on Bipolar Disorder for Neurology Residents, UT Southwestern Medical Center, Dallas, Texas
- 2003 Lecture on Research in Bipolar Disorders, UT Southwestern Medical Center, Dallas, Texas
- 2003 MS3 Summer Internship Lecture on Research in BP Disorders, UT Southwestern Medical Center, Dallas, Texas
- 2003 – 05/2008 Yearly lectures for Research Track, Psychiatric Residents, UT Southwestern Medical Center, Dallas, Texas
- 2003 – 05/2008 Yearly PGY-IV Lecture: “Mechanisms of Action of Mood Stabilizers,” UT Southwestern Medical Center, Dallas, Texas
- 2004 – 05/2008 MS3 Yearly Lecture on Bipolar Disorders, UT Southwestern Medical Center, Dallas, Texas

Mentees

- 1993 – 1994 Psychopharmacology Supervision of Catherine Fontaine, M.D., Ava Lee, M.D., and Charles Mathis, M.D., PGY-III UTSW Psychiatric Residents.
- 1994 – 1995 Supervision of Ray Clark, M.D. and Valerie Meshack, M.D., PGY-III UTSW Psychiatric Residents.

- 1994 – 1995 Louis Costello, M.D., PGY-III – A clinically significant interaction between clozapine and valproate (Letter). *Journal of Clinical Psychopharmacology*, 1995,15(2):139-141.
- 1994 – 1995 E. Sherwood Brown, Ph.D., M.D., PGY-II – Development of scientific interest and completion of publication: Capgras’ and Fregoli’s syndromes in one family (Letter). *Journal of Clinical Psychiatry*, 1995; 57(3):137-138.
- 1995 Psychotherapy Supervision of Esther Cooper, M.D. and Ray Clark, M.D., PGY-IV Psychiatric Residents (6 months Psychotherapy).
- 1995 – 1996 Psychopharmacology Supervision of Antonio Roman, M.D. and Vidyasagar Vangala, M.D., PGY-III Psychiatric Residents.
- 1996 – 1997 Research and Psychopharmacology Supervision of E. Sherwood Brown, Ph.D., M.D., PGY-IV Psychiatric Resident (Research Track).
- 1996 – 1997 Psychopharmacology Supervision of James Knoll, M.D., PGY-III Psychiatric Resident.
- 1996 – 1998 Research Supervision of E. Sherwood Brown, Ph.D., M.D., Mentorship of NIMH Fellowship (see references for publications)
- 1997 – 1998 Research and Psychopharmacology Supervision of Phyll Zuberi, M.D., PGY-IV Psychiatric Resident (Research Track).
- 1999 – 2003 Mentorship of Ellen B. Dennehy, Ph.D., NARSAD Young Investigator Award.
- 2000 Supervision of Melissa de la Garza, Stanley Summer Scholars Program, Southern Methodist University.
- 2001 – 2002 Research Mentorship of Robert Gonzalez, PGY-I Psychiatric Resident.
- 2001 – 2002 Clinical Supervision of PGY-IV Psychiatric Resident: Daralynn Deardorff and R. Surya
- 2001 – 2003 Research Supervision of Mehmet Ozcan, M.D., Psychopharmacology Fellowship, Department of Psychiatry, UT Southwestern Medical Center
- 2002 Clinical Supervision of PGY-IV Psychiatric Resident: Laura Beard
- 2002 Research and Clinical Supervision of Southern Methodist University Department of Psychology master’s level psychology students; Fallon Cluxton and Lori Cohen
- 2002 Research and Clinical Supervision of Michael Lutter, Medical Student IV, Medical electives.
- 2002 Clinical Supervision of Michael Shiekh, PGY-IV Psychiatric Resident.
- 2003 Eric Curley, MS I Summer Internship Program.
- 2003 – 2004 Mentorship of Lisa Monteggia, Ph.D., Assistant Professor, Department of Psychiatry, UT Southwestern Medical Center.
- 2003 – 2004 Research and Clinical Supervision of Geetha Shivakumar, PGY-IV Psychiatric Resident.
- 2003 – 2004 Clinical Supervision of Rob Garrett, PGY-IV Psychiatric Resident.
- 2000 – 2004 Research Mentorship of PGY Resident: Paul Carlson, M.D. and mentor for APA Janssen Fellowship for Research in Severe Mental Illness, New Clinical Drug Evaluation Unit (NCDEU) New Investigator Award, 2003.
- 2003 – 2008 Mentorship of Kathleen Saine, Ph.D., UT Southwestern Medical Center.
- 2003 – 2005 Mentorship of Heidi Jacobe, M.D., Assistant Professor of Dermatology, UT Southwestern Medical Center.
- 2003 – 2006 Mentorship of Laura Lacritz, Ph.D., Assistant Professor of Psychology, UT Southwestern Medical Center.
- 2003 – 2005 Mentorship of Vicki Nejtck, Ph.D., Assistant Professor, Department of Psychiatry, UT Southwestern Medical Center.
- 2003 – 2006 Research and Clinical Supervision of Guohua Xia and Robert Gonzales (July 2004, PGY-III), PGY-II Psychiatric Residents.
- 2003 – 2006 Research and Clinical Supervision of Kevin Majeres, PGY-III Psychiatric Resident (July 2004, PGY-IV, Research Track).

- 2004 – 2006 Research Supervision of Geetha Shivakumar, M.D., Mood Disorders Clinical Intervention Training Program, NIMH Fellowship.
- 2004 – 2005 Research and Clinical Supervision of Erich Swafford and Scott Bartley, PGY-IV Psychiatric Residents.
- 2004 – 2006 Research and Clinical Supervision of Ryan Estevez, PGY-III Psychiatric Resident; Stanley Medical Research Institute Grant to pursue his research interests in his PGY-IV year.
- 2005 – 2006 Mentorship of Ryan Estevez: Janssen Resident Psychiatric Research Scholar.
- 2005 – Present Research and Clinical Supervision of F. Andrew Kozel, M.D., M.S.C.R., Director of TMS Clinic & Staff Psychiatrist in Mental Health and Behavioral Sciences, Associate Investigator in HSR&D Center of Innovation on Disability and Rehabilitation Research, James A. Haley VAH; Associate Professor, Department of Psychiatry and Behavioral Sciences, University of South Florida
- 2006 – 2008 Research and Clinical Supervision of Robert Gonzalez, M.D. NIMH Research Fellow.
- 2006 – Present Research and Clinical Supervision of Robert Gonzalez, M.D. Supervision as Medical Student; Resident; Research Fellow; and continued mentorship of his academic work. Dr. Gonzalez is currently an Associate Professor, Tenure-Track Department of Psychiatry and Neural and Behavioral Sciences, Penn State College of Medicine, Milton S. Hershey Medical Center
- 2006 – 2008 Research and Clinical Supervision of Ryan Estevez, M.D., Ph.D., Instructor in Psychiatry, UT Southwestern Medical Center.
- 2006 – 2008 Mentorship of Kirti Saxena, M.D., Assistant Professor of Psychiatry, UT Southwestern Medical Center.
- 2006 – present Mentorship of Geetha Shivakumar, M.D., Assistant Professor of Psychiatry, UT Southwestern Medical Center, currently at the rank of Associate Professor.
- 2007 MS I Summer Internship Program, Xi Luo.
- 2007 MS I Summer Internship Program, Elizabeth Carroll.
- 2009 – 2012 Research and Clinical Supervision of Huaiyu Yang, M.D., MIRECC Fellow.
- 2009 – 2010 Mentorship of Jeong Seok Seo, M.D., Visiting Associate Professor, Department of Psychiatry and Behavioral Sciences, Stanford University.
- 2011 – 2013 Jennifer Dore, Pgy II Resident
- 2011 – 2014 Michael Ostacher, MD, MPH, MMSc, Assistant Professor, Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Staff Physician at VA Palo Alto Health Care System
- 2014 - Present Michael Ostacher, MD, MPH, MMSc, Associate Professor, Psychiatry and Behavioral Sciences, Stanford University School of Medicine, currently at the rank of Professor.
- 2009 – Present Victoria Cosgrove, PhD, Postdoctoral Fellow War Related Illness and Injury Center, VA Health Sciences Center Palo Alto (2009-2012); Instructor, Psychiatry and Behavioral Sciences, Stanford University School of Medicine (2012-2014); and currently Clinical Assistant Professor, Psychiatry and Behavioral Sciences, Stanford University School of Medicine
- 2012 – 2014 Shefali Miller, MD, MIREC PostDoctoral Fellow, VA Palo Alto Health Care System
- 2014 – 2018 Shefali Miller, MD, Clinical Assistant Professor, Psychiatry and Behavioral Sciences, Stanford University School of Medicine
- 2011-2017 Natalie Feldman, Research Assistant
- 2011-2018 Emma Gliddon, Research Assistant
- 2013-2016 David Grimm, Research Assistant
- 2015 Kaegan Engstrom-Garner, Research Assistant

2016-2017 Talya Feldman, Research Assistant
2016-Present Allyson Rosen, PhD, ABPP Clinical Associate Professor (Affiliated)
Department of Psychiatry and Behavioral Sciences, Stanford University School of
Medicine
2017-Present Nicole Kramer-Lange, Research Assistant and Psy-D student Palo Alto University
2017-Present Jihun “Jay” Lyu, graduate student at Palo Alto University
2017-2019 Ben Hambro, MD, pre-residency in Psychiatry
2017-Present Serena Tally, pre-medical student
2018-2019 Mette Fredskild, Lundbeck Foundation Scholar, Psychiatry and Behavioral Sciences

RESEARCH SUPPORT

Current Research Support (Principal Investigator)

Merck&Co.9760

A double-blind, randomized, placebo-controlled trial of adjunctive suvorexant for treatment-resistant insomnia in patients with bipolar disorder, (PI)

2018- present

PRIME Care (Precision Medicine in Mental Health)

This project is designed to evaluate the utility of PGx testing in treating Major Depressive Disorder, (PI)

6/21/17- present

VA Cooperative Studies Program

NODES (Network of Dedicated Enrollment Sites) Renewal (Director)

2016-2019

Current Research Support (Co-investigator/other)

APP1169845

The Candesartan Adjunctive bipolar DEpression Trial – CADET (CI)

MRFF - Research Grants

2019-2024

PI-Berk

Palo Alto Health Sciences, Inc.

Investigation of the Freespira Breathing System in the Treatment of PTSD

Goal: Trial of a novel breathing device to treat PTSD. (Co-I)

11/2016 - present

VA Cooperative Studies Program

CSP 590, Lithium for Suicidal Behavior in Mood Disorders (Li+) (Co-I)

2015- present

1UH2AG052163-01

Engaging self-regulation targets to understand the mechanisms of behavior change and improve mood and weight outcomes (Consultant)

Goal: To assess if measures tailored to specific brain mechanisms would improve behavior change.

08/2015 - present

NIDA 1R34DA040119

Web-based ACT for smoking cessation in bipolar disorder (Co-I)

Goal: To test an internet intervention using motivational interviewing to support smoking cessation

05/2015 – present

NIMH ROI MH1010496

Neural Dimensions of Threat Reactivity and Regulation for Understanding Anxiety (Co-I)

Goal: Identifying the neural basis of anxiety.

08/2013-present

1 I01 RX003152-01

Targeting Functional Improvement in rTMS Therapy (Co-I)

01/01/2019 till 12/31/2022

PI- Rosen

Pending Research Support (Principal Investigator/other)

RX002652

Improving Implementation of Clinical rTMS Targeting, (Consultant)

7/1/18-6/30/22

PI-Rosen

Past Research Support (Principal Investigator)

NIH - Grant: 1R34MH091284 - 01A1

A Randomized trial of internet based interventions for bipolar disorder (PI)

2012 - 2018

Stanley Medical Research Institute

A Multisite, Randomized, Double Blind Placebo controlled 12 weeks Study Evaluating the Efficacy, Safety and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression, (PI)

2015 – 2018

Pathway Genomics

Pharmacogenetics in Treatment Refractory Depression, Replication Study, (PI)

Goal: If genetics information of medication side effects was available will prescriber patterns be impacted?

2015- 2018

Year Initiated – 2012

NIH - Grant: 1R34MH091284 - 01A1

A Randomized trial of internet based interventions for bipolar disorder (PI)

2012-2018

Industry Funding

Sunovion Pharmaceuticals Inc.

March 2012 – 2016

04.17.19

D1050296 – A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects with Bipolar I Disorder.

Sunovion Pharmaceuticals Inc.

August 2012 – 2016

D1050308 – A multicenter, open-label, flexible-dose extension study of lurasidone adjunctive to lithium or divalproex in subjects with bipolar I disorder.

Elan Pharmaceuticals, Inc.

September 2012 –2014

ELND005-BPD201: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder

Federal/State Funding

National Institute of Mental Health

April 2011 – March 2014

Collaborative R34 (NIMH # MH091284) – A Randomized Trial of Internet-based Interventions for Bipolar Disorder.

Federal Funding

Veterans Administrations Cooperative Studies Program

Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES)

Veterans Administrations Cooperative Studies Program

August 2012 – 2016

CSP #576: VA Augmentation and Switching Strategies for Improvement of Depression Treatment (VAST Improvement-D).

Veterans Administrations Cooperative Studies Program

August 2012 –2014

CSP #572: Genetics of Functional Disability in Bipolar Illness and Schizophrenia

Foundation

Marriott Award in Individualized Medicine

Fall 2008

(Mark Frye, MD and Joanna Biernacka, Ph.D., PIs)

The Mayo Bipolar Collaborative NetworkCore Biorepository (Consultant).

Federal Funding

National Institute of Mental Health

December 2010 – November 2012

(Roy H. Perlis, MD MSc, PI)

AHRQ R01 – Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder (DSMB Consultant).

National Institute of Mental Health

December 2007 – November 2012

(C. Tamminga, MD, PI)
Collaborative R01 – Bipolar & Schizophrenia Consortium for Parsing Endophenotypes (Consultant).

Year Initiated – 2011

Industry Funding

Sunovion Pharmaceuticals Inc.

August 2011 – 2016

D1050304 – A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features.

Sunovion Pharmaceuticals Inc.

August 2011 – 20116

D1050306 – A 12-Week, Open-Label Extension Study for the Treatment of Major Depressive Disorder with Mixed Features

Year Initiated – 2009

Industry Funding

Pfizer, Inc.

December 2009 – June 2011

A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder with Comorbid Lifetime Panic or Generalized Anxiety Disorder.

Year Initiated – 2007

Federal Funding

National Institute of Mental Health (NIMH)

July 2004 – June 2009

NIMH # R01 MH69801-01 – Bipolar I Mania: Open label Divalproex and Randomized, Double-Blind Placebo, Lithium, or Quetiapine for Treatment of Mania.

Industry Funding

AstraZeneca

August 2007 – July 2009

A Randomized, Double-Blind, Placebo-Controlled Study of Quetiapine SR Monotherapy and Divalproex Sodium ER Monotherapy in Ambulatory Bipolar Disorder with Current at least Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder.

AstraZeneca

February 1, 2007 – May 31, 2007

A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained-release as Monotherapy in Adult Patients with Acute Bipolar Depression.

Year Initiated – 2006

Foundation Funding

Stanley Medical Research Institute

July 2006 – December 2007

rTMS for Acute Treatment of Depressed Phase of Bipolar Disorder Type II (A. Kozel, M.D., PI).

Industry Funding

04.17.19

Pfizer, Inc.

September 2006 – August 2007

A Phase 3, Randomized, 6-month, Double Blind Trial in Subjects with Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer (vs. Placebo Plus a Mood Stabilizer) Following a Minimum of 2 Months of Response to Open-Label Treatment with Both Agents (A1281137)

Federal Funding

National Institutes of Mental Health

July 1, 2006 – June 30, 2012

NIMH # 5R01MH74928-3 – Bipolar II Depression: Randomized, Double-Blind Study of Lithium, SSRI, or the Combination for Treatment of Depression.

Year Initiated – 2005

Foundation Funding

Stanley Medical Research Institute

March 1, 2005 – February 28, 2008

A Preliminary Study of the Effectiveness and Tolerability of 4-Aminopyridine in Bipolar Depression (Estevez, M.D., Ph.D., PI)

Industry Funding

Wyeth Research Division of Wyeth Pharmaceuticals Inc.

August 2005 – April 2007

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients with Bipolar Disorder

Novartis

January 2005 – November 2007

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Licarbazepine 750-2500 mg/d Combined with Lithium or Valproate in the Treatment of Manic Episodes of Bipolar I Disorder over 6 weeks.

Novartis

January 2005 – November 2007

A 52-Week, Open-Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750/2000 mg/d Combined with Lithium or Valproate in the Treatment of Manic Episodes of Bipolar I Disorder Over 6 Weeks

Year Initiated – 2004

Foundation Funding

Stanley Medical Research Institute

April 2004 – July 2007

Changes in Cerebral Glucose Metabolism as Potential Predictor of Treatment Response to Medication Treatment in Bipolar II Depression (C. Tamminga, M.D., PI)

Industry Funding

AstraZeneca

September 2004 – September 2007

A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients

Janssen Pharmaceuticals
October 2004 – October 2005

A Randomized, Double-blind, Placebo-controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder with Current at least Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

Year Initiated – 2003

Federal/State Funding

National Institute of Mental Health (NIMH)

August 2003 – August 2006

R-21 - Acute Treatment of Bipolar II Depression

Foundation Funding

Stanley Medical Research Institute

January 2003 – January 2006

BPN Data Collection at Dallas serves as a permanent repository for data collected at the Dallas site of patient demographic information and study-related data. Funding is used to interface with the database center at UCLA and to share this information with other Stanley-funded research institutes when explicit queries are made.

Stanley Medical Research Institute

January 2003 – January 2005

Modafinil (Provigil) in the Treatment of Bipolar Depression Inadequately Responsive to Current Therapy: A Placebo-controlled Investigation

Stanley Medical Research Institute

January 2003 – January 2005

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

Year Initiated – 2002

Foundation Funding

Stanley Medical Research Institute

August 2002 – August 2005

A Two-site, Randomized Comparison of Lamotrigine and Lithium in 80 Patients with Bipolar Type II Depression

Year Initiated – 2001

Federal/State Funding

Texas Department Mental Health and Mental Retardation (TDMHMR)

September 2001 – August 2004

Texas Implementation of Medication Algorithms (TIMA)

R03 - NIMH (National Institute of Mental Health)

February 2001 – February 2004

Adjunctive Acupuncture as a Treatment for Bipolar Depression, National Institute of Mental Health

Foundation Funding

Stanley Medical Research Institute

July 2002 – July 2004

Low-dose Testosterone Augmentation Therapy in Depressed Patients with Bipolar Disorder

Stanley Foundation Bipolar Network

January 2001 – December 2001

Long Term Follow-up of Patients with Bipolar Disorders

Industry Funding

Novartis

April 2001 – January 2003

An Open Add-On Study of Trileptal vs. Depakote for Hypomania in Patients with Bipolar Disorder

Glaxo Wellcome, Inc.

January 2001 – January 2003

A Multicenter, Double-blind, Placebo-controlled, Fixed-dose Evaluation of the Safety, Efficacy and Tolerability of Lamictal (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients with Type I Bipolar Disorder

AstraZeneca Pharmaceuticals

January 2001 – August 2001

Evaluating the Effects of Add-On Seroquel for Patients with Bipolar Disorder

Year Initiated – 2000

Federal/State Funding

NIMH (National Institute of Mental Health)

October 2000 – October 2002

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (N01-MH60006)

Foundation Funding

Stanley Foundation Bipolar Network

August 2000 – March 2005

A Pilot Safety and Efficacy Study of Vagus Nerve Stimulation in Patients with Rapid Cycling Bipolar Disorder

Forrest C. Lattner Foundation, Inc.

January 2000 – January 2001

Complementary Therapies for Treatment of Bipolar Disorder

Industry Funding

AstraZeneca Pharmaceuticals LP

September 2000 – November 2001

A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Safety and Efficacy of Seroquel, as Add On therapy with Lithium and Divalproex in Treatment of Acute Mania (5077IL-0099)

Bristol-Myers Squibb
June 2000 – May 2002

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Aripiprazole in the Maintenance Treatment of Patients with Bipolar Disorder (CN138-010)

Bristol-Myers Squibb
June 2000 – May 2002

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Flexible Doses of Aripiprazole in the Treatment of Patients with Acute Mania (CN138-009)

Janssen Pharmaceutica Products
March 2000 – March 2001

Development of a Pilot Tool for Diagnosis of Bipolar Disorder

Year Initiated – 1999

Foundation Funding

Timberlawn Psychiatric Research Foundation, Inc.

September 1999 – April 2002

Usefulness of Psychoeducational Group Therapy for Patients with Bipolar Disorder

Stanley Foundation Bipolar Network,
August 1999 – March 2004

Acupuncture to Treat Mood Lability in Bipolar Disorder

Industry Funding

Eli Lilly

May 1999 – November 1999

Olanzapine vs. Divalproex in the Treatment of Acute Mania (F1D-US-HGHQ)

Abbott Laboratories

March 1999 – March 2000

Divalproex vs. Placebo for the Treatment of Bipolar Disorder (M96-493)

Year Initiated – 1998

Industry Funding

Eli Lilly

April 1998 – August 1999

Olanzapine Adjunctive Treatment in Patients with Nonpsychotic Bipolar Disorder (F1D-MC-X099)

Year Initiated – 1997

Federal/State Funding

Dallas County Mental Health Mental Retardation (Mental Health Connections),

September 1997 – August 1998

Bipolar Disorder - Comprehensive Treatment Algorithm Project

Industry Funding

Eli Lilly

September 1997 – August 1999

Olanzapine Added to Mood Stabilizers in the Treatment of Bipolar Disorder (F1D-MC-HGFU)

Glaxo Wellcome

September 1997 – August 1998

A Multicenter, Double-blind, Placebo-controlled, Fixed-dose Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Long Term Prevention of Mood Episodes in Patients with Bipolar Disorder with Rapid Cycling: Incorporating Participation in Genotype Research - Optional for Both Patients and Sites (Incorporating Amendment #1) Protocol 105-614 (SCAA2012)

Abbott Laboratories

January 1997 – December 1998

An Open-Label Assessment of the Long Term Safety of Sertindole in the Treatment of Patients with Schizophrenia and Other Psychotic Disorders, Protocol M94-222-Extension Amendment

Year Initiated – 1996

Federal/State Funding

Dallas County Mental Health Mental Retardation (Mental Health Connections)

September 1996 – August 1997

Comprehensive Treatment Algorithm Project

Industry Funding

Glaxo Wellcome

July 1996 – June 1997

LAMICTAL (Lamotrigine) Bipolar Disorder Continuation Study (Protocol 105-604)

Glaxo Wellcome

May 1996 – June 1997

A Multicenter, Double-blind, Placebo-controlled, Fixed-dose Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of a Major Depressive Episode in Patients Suffering From Bipolar Disorder (Protocol 105-602)

Parke-Davis Pharmaceuticals

March 1996 – September 1997

Gabapentin Adjunctive Treatment in Patients with Bipolar Disorder (Protocol 945-209)

Year Initiated – 1995

Foundation Funding

National Alliance for Research on Schizophrenia and Depression (NARSAD)

July 1995 – June 1997

Long Term Efficacy of Clozapine and the Use of a Treatment Algorithm in Affectively III Patients

Foundation Funding

Stanley Foundation Bipolar Network

January 1995 – December 2000

Long Term Follow-up of Patients with Bipolar Disorders

Industry Funding

Abbott Laboratories

January 1995 – December 1996

An Open-Label Assessment of the Long Term Safety of Sertindole in the Treatment of Patients with Schizophrenia and Other Psychotic Disorders, Protocol M94-222

Year Initiated – 1994

Federal/State Funding

National Institute of Mental Health (NIMH)

August 1994 – July 1996

K Award - Treatment of Bipolar I Disorder, Depressed Phase (MH01221)

Foundation Funding

Forrest C. Lattner Foundation, Inc.

January 1994 – December 1996

Direct Cost: \$66,000

Treatment Optimization for Patients with Schizophrenia and Bipolar Disorder

Forrest C. Lattner Foundation, Inc. Award

January 1994 – December 1995

Treatment Optimization for Patients with Schizophrenia and Bipolar Disorder

Industry Funding

SmithKline-Beecham Pharmaceuticals

January 1994 – April 1995

A Double-blind, Placebo-controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression, Protocol 29060/352

Abbott Laboratories

January 1994 – February 1995

An Open-Label Assessment of the Long Term Safety of Sertindole in the Treatment of Patients with Schizophrenia and Other Psychotic Disorders, Protocol M93-061

Year Initiated – 1993

Federal/State Funding

National Alliance for Research on Schizophrenia and Depression (NARSAD) – K Award

July 1993 – June 1995

Clozapine Treatment of Schizoaffective and Bipolar Disorder Patients

Year Initiated – 1992

Federal/State Funding

Dallas County Mental Health Mental Retardation

September 1992 – August 1996

Clozapine in Schizoaffective and Treatment-Resistant Bipolar Disorder Patients

Past Research Support (Co-investigator/Other)

Year Initiated – 2008

Federal/State Funding

National Institutes of Health

Fall 2008

Key Note Speaker (C. Bowden, MD, PI)

R13 - The Bipolar Statistical Summit: Methodologies to Advance Long Term Intervention Trials.

NARSAD

July 2008 – June 2010

Mentor (R. Gonzalez, MD, PI)

A Study Examining the Association between the Gene Clock and Clinical Chronotypic Parameters in Bipolar I Disorder.

Year Initiated - 2004

Industry Funding

AstraZeneca

April 2004 – July 2009

A Double-blind, Placebo-controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients. Investigator-initiated, primary site of two-site study.

Year Initiated – 2003

Federal/State Funding

University of Connecticut Health Center

July 1, 2003 – July 1, 2008

Consultant (R. Trestman, M.D., Ph.D., PI)

1R24 - Mental Health Research Infrastructure in Corrections.

National Institute of Mental Health (NIMH)

July 2003 – June 2008

Senior Investigator/ Training Mentor (A. John Rush, M.D., PI)

T32 – Mood Disorders Clinical Intervention Training Program.

National Institute of Mental Health (NIMH)

August 2003 – April 2008

(A. John Rush, M.D., PI)

R25 – Psychiatric Research Education Program (PREP) (Director of Clinical Research Unit).

Year Initiated – 2000

Foundation Funding

The Robert Wood Johnson Foundation

September 1, 2000 – August 31, 2002

Co-Investigator (A.J. Rush, M.D., PI)

Analysis of the Texas Medication Algorithm Project (TMAP) Dataset.

Federal/State Funding

National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD)

July 2000 – June 2002

Mentor (E.B. Dennehy, Ph.D., PI)

The Measurement of Physician Adherence to a Guideline for Treatment of Bipolar Disorder, Young Investigator Award.

National Institute of Mental Health (NIMH)

December 1, 2000 – June 2003

(R. Scheffer, M.D., PI)

Pediatric Bipolar Collaborative Mood Stabilizer Trial.

Year Initiated – 1997

Federal/State Funding

National Alliance for the Mentally III (NAMI)

Stanley Foundation Research Award Program

August 1997 – July 1999

Co-Investigator (M. Fulton, PI)

Quantitative Sleep EEG Abnormalities in Bipolar Disorders (Co-Investigator).

Foundation Funding

The Robert Wood Johnson Foundation

September 1, 1997 - August 31, 2000,

Co-Investigator (A.J. Rush, PI)

The Texas Medication Algorithm Project (TMAP): Phase 3. An Evaluation of the Clinical and Economic Impact of Medication Algorithms in Public Sector Patients with Severe and Persistent Mental Illness.

National Alliance for the Mentally III (NAMI)

Stanley Foundation Research Award Program

August 1997 - July 1998

Co-investigator (A.J. Rush, PI)

Medication Treatment Algorithms for Bipolar, Schizophrenic, and Severe Major Depressive Disorders.

Industry Funding

Organon

April 1997 - September 1998

Co-Investigator (H.K. Manji, PI)

Efficacy of Mirtazapine (Remeron) in the Treatment of Bipolar Depression.

Year Initiated – 1996

Federal/State Funding

National Institute of Mental Health Research Fellowship Award

December 1996 - November 1998

Sponsor (E.S. Brown, PI)

Do Corticosteroids Provide a Model for Bipolar Disorder?

National Alliance for Research on Schizophrenia and Depression

July 1996 - June 1998

Sponsor (E.S. Brown, PI)

Do Exogenously Given Corticosteroids Provide a Model for Bipolar Disorder in Humans?

Foundation Funding

Stanley Foundation

August 1996 - September 1998

(R. Kowatch, PI)

Development of a Treatment Algorithm for Child and Adolescent Bipolar Disorders

PUBLISHED SCIENTIFIC REPORTS

Journal Peer-Reviewed

1983

Kriegstein AR, **Suppes T**, Prince DA. Cholinergic enhancement of penicillin-induced epileptiform discharges in guinea pig hippocampus are enhanced by application of acetylcholine. *Brain Research*, 1983; 266: 137-142.

1984

Suppes T. A late slow depolarization unmasked in the presence of tetraethylammonium in rat sympathetic neurons in vitro. *Brain Research*, 1984; 293: 269-278.

1985

Suppes T, Kriegstein AR, Prince DA. The influence of dopamine on epileptiform burst activity in hippocampal pyramidal neurons. *Brain Research*, 1985; 326: 273-280.

1987

Suppes T., Pinnock RD. Sensitivity of neuronal dopamine response in the substantia nigra and ventral tementum to clozapine, metoclopramide and SCH 23390. *Neuropharmacology*, 1987; 26(4): 331-337.

Kriegstein AR, **Suppes T**, Prince DA. Cellular and synaptic physiology and epileptogenesis of developing rat neocortical neurons in vitro. *Developmental Brain Research*, 1987; 34: 161-171.

Castiglione C, **Suppes T**, Macaulay W. Intraluminal Duodenal Diverticulum. *Contemporary Surgery*, 1987; 32: 83-90.

1991

Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. *Archives General Psychiatry*, 1991; 48: 1082-1088.

1992

Suppes T, McElroy S, Gilbert J, Dessain E, Cole J. Clozapine in the treatment of dysphoric mania. *Biological Psychiatry*, 1992; 32: 270-280.

1993

Faedda GL, Tondo L, Baldessarini RJ, **Suppes T**, Tohen M. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar disorders. *Archives of General Psychiatry*, 1993; 50: 448-455.

Frankenburg FR, **Suppes T**, McLean PE. Combined clozapine and electroconvulsive therapy. *Convulsive Therapy*, 1993; 9(3): 176-180.

Jackson PS, **Suppes T**, Harris KM. Stereotypical changes in the pattern and duration of long-term potentiation expressed at postnatal days 11 and 15 in the rat hippocampus. *Journal of Neurophysiology*, 1993; 70(4): 1412-1419.

Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: Risks and implications. *Harvard Review of Psychiatry*, 1993; 1(3): 131-144.

1994

Suppes T, Phillips K, Judd C. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: A report of three cases. *Biological Psychiatry*, 1994; 36(5): 338-340.

Stoll AL, Banov M, Kolbrener BA, Mayer PV, Tohen M, Strakowski SM, Castillo J, **Suppes T**, Cohen B. Neurological factors predict a favorable valproate response in bipolar and schizoaffective disorder. *Journal of Clinical Psychopharmacology*, 1994; 14: 311-313.

1995

Kowatch RA, **Suppes T**, Gilfillan SK, Fuentes RM. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. *Journal of Child and Adolescent Psychopharmacology*, 1995; 5(4): 241-253.

Suppes T, Calabrese JR, Mitchell PB, Pazzaglia PJ, Potter WZ, Zarin DA. Algorithms for the treatment of bipolar, manic-depressive illness. *Psychopharmacology Bulletin*, 1995; 31(3): 469-474, 491-500.

Faedda GL, Baldessarini RJ, **Suppes T**, Tondo L, Becker I, Lipschitz DS. Pediatric-onset bipolar disorder: A neglected clinical and public health problem. *Harvard Review of Psychiatry*, 1995; 3(4): 171-195.

Suppes T. New horizons in management and treatment of bipolar disease. *Journal of the California Alliance for the Mentally Ill*, 1995; 6(2): 14-17

1996

Baldessarini RJ, Tondo L, Faedda GL, **Suppes T**, Floris G, Rudas N. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. *Journal of Clinical Psychiatry*, 1996; 57(10): 441-448.

Baldessarini RJ, **Suppes T**, Tondo L. Lithium withdrawal in bipolar disorder: Implications for clinical practice and experimental therapeutics research. *American Journal of Therapeutics*, 1996; 3(7): 492-496.

Suppes T, Webb A, Carmody T, Gordon E, Gutierrez-Esteinou R, Hudson JI, Pope HG Jr. Is postictal electrical silence a predictor of response to electroconvulsive therapy? *Journal of Affective Disorders*, 1996; 41(1): 55-58.

Baldessarini RJ, **Suppes T**, Tondo L. Lithium withdrawal in bipolar disorder: Implications for clinical practice and experimental therapeutics research. *American Journal of Therapeutics*, 1996; 3(7): 492-496.

1997

Lee AM, Knoll J, **Suppes T**. The atypical antipsychotic sertindole: A case series. *Journal of Clinical Psychiatry*, 1997; 58(9): 410-416.

Suppes T, Baldessarini RJ, Motohashi N, Tondo L, Viguera AC. Special treatment issues: Maintaining and discontinuing psychotropic medications. *Modern Problems in Pharmacopsychiatry*, 1997; 25: 235-254.

Suppes T. Management of treatment-resistant bipolar and schizoaffective disorder. *Essential Psychopharmacology*, 1997; 2(1):53-70.

Bennett J, Goldman WT, **Suppes T**. Gabapentin for Treatment of Bipolar and Schizoaffective Disorders. *Journal of Clinical Psychopharmacology*, 1997, 17(2):141-142.

1998

Brown ES, **Suppes T**. Mood symptoms during corticosteroid therapy: A review. *Harvard Review of Psychiatry*, 1998; 5(5): 239-46

- Sherwood Brown E, Shellhorn E, **Suppes T**. Gastrointestinal side effects after switch to generic valproic acid. *Pharmacopsychiatry*, 1998; 31: 114.
- Knoll J, Stegman K, **Suppes T**. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania. *Journal of Affective Disorders*, 1998; 49(3): 229-233.
- Pearsall R, Glick ID, Pickar D, **Suppes T**, Tauscher J, Jobson KO. A new algorithm for treating schizophrenia. *Psychopharmacology Bulletin*, 1998; 34(3): 349-353.
- Suppes T**, Rush AJ, Kraemer H, Webb A. Treatment algorithm use to optimize management of symptomatic patients with a history of mania. *Journal of Clinical Psychiatry*, 1998; 59(2): 89-96.
- McElroy SL, Frye MA, Denicoff KD, Altshuler LL, Nolen WA, Kupka R, **Suppes T**, Keck PE, Leverich GS, Kmetz GF, Post RM. Olanzapine in treatment-resistant bipolar disorder. *Journal of Affective Disorders*, 1998; 49(2): 119-122.

1999

- Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, **Suppes T**, Miller AL, Trivedi MH, Swann AC, Biggs MM, Shores-Wilson K, Kashner TM, Pigott T, Chiles JA, Gilbert DA, Altshuler KZ. Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project. *Journal of Clinical Psychiatry*, 1999; 60(5): 284-291.
- Rush AJ, Crismon ML, Toprac MG, Shon SP, Rago WV, Miller AL, **Suppes T**, Trivedi MH, Biggs MM, Shores-Wilson K, Kashner TM, Altshuler KZ. Implementing guidelines and systems of care: Experiences with the Texas Medication Algorithm Project TMAP. *Journal of Practical Psychiatry & Behavioral Health*, 1999; 5(2): 75-86.
- Suppes T**, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized one-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. *American Journal of Psychiatry*, 1999; 156(8): 1164-1169.
- Altshuler LL, Keck PE, McElroy SL, **Suppes T**, Brown ES, Denicoff K, Frye M, Gitlin M, Hwang S, Goodman R, Leverich G, Nolen W, Kupka R, Post R. Gabapentin in the acute treatment of refractory bipolar disorder. *Bipolar Disorders*, 1999; 1: 61-65.
- Kashner TM, **Suppes T**, Rush AJ, Altshuler KZ. Measuring use of outpatient care among mentally ill individuals: A comparison of self reports and provider records. *Evaluation and Program Planning*, 1999; 22(1): 31-39.
- Leibenluft E, **Suppes T**. Treating bipolar illness: Focus on treatment algorithms and management of the sleep-wake cycle. *American Journal of Psychiatry*, 1999; 156(12): 1976-1979.
- Suppes T**, Brown ES, McElroy, Keck PE, Nolen W, Kupka R, Denicoff KD, Altshuler L, Leverich GS, Post R. Lamotrigine for the treatment of bipolar disorders: A clinical case series. *Journal of Affective Disorders*, 1999; 53(1): 95-98.
- Shon SP, Crismon ML, Toprac MG, Trivedi M, Miller AL, **Suppes T**, Rush AJ. Mental health care from the public perspective: The Texas Medication Algorithm Project. *Journal of Clinical Psychiatry*, 1999, 60(suppl 3): 16-21.
- Bowden CL, Mitchell P, **Suppes T**. Lamotrigine in the treatment of bipolar depression. *European Neuropsychopharmacology*, 1999; 9(suppl 4): S113-S117.
- Dennehy E, **Suppes T**. Medication algorithms for bipolar disorder. *Journal of Practical Psychiatry and Behavioral Health*, 1999; 5(3): 142-152.
- Vangala VR, Brown ES, **Suppes T**. Clozapine associated with decreased suicidality in bipolar disorder: A case report. *Bipolar Disorders*, 1999; 1(2): 123-4.

2000

- Suppes T**. Rapid cycling bipolar disorder: A new treatment option. *Current Psychiatry Reports*, 2000; 2(4): 283-285.

- Bogan AM, Shellhorn E, Brown ES, McDonald C, **Suppes T**. Switching outpatients between atypical antipsychotics. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 2000; 24(2): 351-355.
- Tohen M, Hennen J, Zarate C, Baldessarini R, Strakowski S, Stoll A, Faedda G, **Suppes T**, Gebre-Medhin P, Cohen B. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. *American Journal of Psychiatry*, 2000; 157(2): 220-228.
- McElroy SL, **Suppes T**, Keck PE, Frye M, Denicoff K, Altshuler L, Brown ES, Nolen WA, Kupka R, Rochussen J, Leverich GS, Post RM. Open-label adjunctive topiramate in the treatment of bipolar disorders. *Biological Psychiatry*, 2000; 47(12): 1025-1033.
- Kowatch RA, **Suppes T**, Carmody TJ, Bucci JP, Hume JH, Kromelis M, Emslie GJ, Weinberg WA, Rush AJ. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. *Journal of the American Academy of Child and Adolescent Psychiatry*, 2000; 39(6): 713-720.
- Brown ES, Bauer MS, **Suppes T**, Khan DA, Carmody T. Comparison of the Internal State Scale to clinician-administered scales in asthma patients receiving corticosteroid therapy. *General Hospital Psychiatry*, 2000; 22(3): 180-183.
- Tohen M, Strakowski SM, Zarate C Jr., Hennen J, Stoll AL, **Suppes T**, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ. The McLean-Harvard First-Episode Project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. *Biological Psychiatry*, 2000; 48(6): 467-476.
- Calabrese JR, **Suppes T**, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET. A double blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. *Journal of Clinical Psychiatry*, 2000; 61(11): 841-850.
- Bogan A, Brown ES, **Suppes T**. Efficacy of divalproex therapy for schizoaffective disorders. *Journal of Clinical Psychopharmacology*, 2000; 20(5): 520-522.
- Keck PE, Mendlwicz J, Calabrese J, Fawcett J, **Suppes T**, Vestergaard P, Carbonell C. A review of randomized controlled clinical trials in acute mania. *Journal of Affective Disorders*, 2000; 59(suppl 1): S31-S37.
- Suppes T**, Dennehy EB, Gibbons EW. The longitudinal course of bipolar disorder. *Journal of Clinical Psychiatry*, 2000; 61(suppl 9): 23-30.
- Denicoff KD, Leverich GS, Nolen W, Rush AJ, McElroy SL, Keck PE, **Suppes T**, Altshuler LL, Kupka R, Frye MA, Hafez J, Brotman MA, Post RM. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-super(TM)-p) for longitudinal assessment of bipolar illness. *Psychological Medicine*, 2000; 30(6): 1391-1397.
- Rush AJ, Post RM, Nolen WA, Keck PE, **Suppes T**, Altshuler L, McElroy SL. Methodological issues in developing new acute treatments for patients with bipolar illness. *Biological Psychiatry*, 2000; 48(6): 615-624.

2001

- Leverich GS, Nolen W, Rush AJ, McElroy S, Keck PE, Denicoff KD, **Suppes T**, Altshuler L, Kupka R, Kramlinger K, Post RM. The Stanley Foundation Bipolar Treatment Outcome Network: 1. Longitudinal methodology. *Journal of Affective Disorders*, 2001; 67(1-3): 33-44.
- Suppes T**, Leverich GS, Keck PE Jr, Nolen W, Denicoff KD, Altshuler LL, McElroy SL, Rush AJ, Kupka R, Frye MA, Bickel M, Post RM. The Stanley Foundation Bipolar Network. II. Demographics and illness characteristics of the first 261 patients with bipolar disorder. *Journal of Affective Disorders*, 2001; 67(1-3): 45-59.
- Post R, Altshuler L, Frye M, **Suppes T**, Rush AJ, Keck PE, McElroy S, Denicoff K, Leverich G, Kupka R, Nolen A. Rate of switch in bipolar patients prospectively treated with second generation antidepressants as augmentation to mood stabilizers. *Bipolar Disorders*, 2001; 3: 259-265.

- McElroy S, Altshuler L, **Suppes T**, Keck PE, Frye M, Denicoff K, Nolen W, Kupka R, Leverich G, Rochussen J, Rush AJ, Post R. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. *American Journal of Psychiatry*, 2001; 158(3): 420-426.
- Glick ID, **Suppes T**, DeBattista C, Hu RJ, Marder S. Psychopharmacologic treatment strategies for depression, bipolar disorder and schizophrenia. *Annals of Internal Medicine*, 2001; 134: 47-60.
- Brown ES, **Suppes T**, Adinoff B, Thomas NR. Drug abuse and bipolar disorder: Comorbidity or misdiagnosis? *Journal of Affective Disorders*, 2001; 65(2): 105-115.
- Suppes T**, Swann A, Dennehy EB, Habermacher E, Mason M, Crismon L, Toprac M, Rush AJ, Shon S, Altshuler KZ. Texas Medication Algorithm Project: Development and feasibility testing of a treatment algorithm for patients with bipolar disorder. *Journal of Clinical Psychiatry*, 2001; 62(6): 439-447.
- Montgomery S, Van Zwieten-Boot B, Angst J, Bowden CL, Calabrese JR, Chengappa R, Goodwin G, Lecrubier Y, Licht R, Nolen WA, Sachs G, Saint Raymond A, Storosum J, **Suppes P**, Van Ree JM. ECNP Consensus Meeting March 2000 Nice Guidelines for investigating efficacy in bipolar disorder. *European Neuro-Psychopharmacology*, 2001; 11: 79-88.
- Calabrese JR, Shelton MD, Bowden CL, Rapport DJ, **Suppes T**, Shirley ER, Kimmel SE, Caban SJ. Bipolar rapid cycling: Focus on depression as its hallmark. *Journal of Clinical Psychiatry*, 2001; 62(suppl 14): 34-41.
- Post RM, Nolen WA, Kupka RW, Denicoff KD, Leverich GS, Keck PE Jr, McElroy SL, Rush AJ, **Suppes T**, Altshuler LL, Frye MA, Grunze H, Walden J. The Stanley Foundation Bipolar Network. 1. Rationale and methods. *British Journal Psychiatry*, 2001; 41: s169-76.
- Kupka R, Nolen W, Altshuler L, Denicoff K, Frye M, Leverich G, Keck PE, McElroy S, Rush AJ, **Suppes T**, Post R. The Stanley Foundation Bipolar Network. 2. Preliminary summary of demographics, course of illness and response to novel treatments. *British Journal of Psychiatry*, 2001; 41: s177-83.

2002

- Post RM, Leverich GS, Denicoff KD, Altshuler LL, Frye MA, Rush J, **Suppes T**, Kramlinger K, Keck PE Jr, McElroy SL, Nolen WA, Kupka R, Walden J, Grunze H. The Stanley Foundation Bipolar Network. Pt 1: New findings on suicide attempts, substance abuse, obesity, and more. *Current Psychiatry*, 2002; 1: 26-32.
- Post RM, Leverich GS, Denicoff KD, Altshuler LL, Frye MA, Rush J, **Suppes T**, Kramlinger K, Keck PE Jr, McElroy SL, Nolen WA, Kupka R, Walden J, Grunze H. The Stanley Foundation Bipolar Network. Pt. 2: Efficacy of adjunctive therapies for treatment-resistant patients. *Current Psychiatry*, 2002; 1: 36-44.
- Calabrese JR, Sullivan J, Bowden CL, **Suppes T**, Sachs G, Goldberg J, Shelton M, Kusumakar V. Rash in multicenter trials of lamotrigine mood disorder: Clinical relevance and management. *Journal of Clinical Psychiatry*, 2002; 63(11): 1012-1019.
- Suppes T**, Chisholm KA, Dhavale D, Frye MA, Altshuler LL, McElroy S, Keck PE, Nolen WA, Kupka R, Denicoff K, Leverich G, Rush AJ, Post R. Tiagabine in treatment refractory bipolar disorder: A clinical case series. *Bipolar Disorders*, 2002; 4(5): 283.
- Tohen M, Baker RW, Altshuler L, Zarate CA, **Suppes T**, Ketter TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GA. Olanzapine versus divalproex in the treatment of acute mania. *American Journal of Psychiatry*, 2002; 159(6): 1011-1017.
- Tohen M, Chengappa R, **Suppes T**, Zarate C, Calabrese J, Bowden C, Sachs G, Kupfer D, Baker R, Risser R, Keeter E, Feldman P, Tollefson G, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. *Archives of General Psychiatry*, 2002; 59(1):62-69.
- Dennehy EB, Webb A, **Suppes T**. Assessment of beliefs in the effectiveness of acupuncture for treatment of psychiatric symptoms. *Journal of Alternative and Complementary Medicine*, 2002; 8:421-426.

- Suppes T**, Dennehy EB. Evidence-based long-term treatment of bipolar II disorder. *Journal of Clinical Psychiatry*, 2002; 63(suppl 10): 29-333.
- McElroy S, Frye M, **Suppes T**, Dhavale D, Keck PE, Leverich G, Altshuler L, Denicoff K, Nolen W, Kupka R, Grunze H, Walden J, Post R. Correlates of overweight and obesity in 644 patients with bipolar disorder. *Journal of Clinical Psychiatry*, 2002; 63(3): 207-213.
- Tamminga C, Nemeroff C, Blakely R, Brady L, Carter C, Davis K, Dingledine R, Gorman J, Griforiadis D, Henderson D, Innis R, Killen J, Langhren T, McDonald W, Murphy G, Paul S, Rudorfer M, Sausville E, Schatzberg, Scolnick E, **Suppes T**. Developing novel treatments for mood disorders: Accelerating discovery. *Biological Psychiatry*, 2002; 52(6): 589-609.
- Brown ES, **Suppes T**, Khan DA, Carmody TJ. Mood changes during prednisone bursts in outpatients with asthma. *Journal of Clinical Psychopharmacology*, 2002; 22(1): 55-61.
- Leverich G, McElroy S, **Suppes T**, Keck PE, Denicoff K, Nolen W, Altshuler L, Rush AJ, Kupka R, Frye M, Autio K, Post R. Early physical and sexual abuse associated with an adverse course of bipolar illness. *Biological Psychiatry*, 2002; 51(4): 273-346.
- Suppes T**, Dennehy EB, Swann AC, Bowden C, Calabrese J, Hirschfeld R, Keck PE, Sachs G, Shon SP. Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder 2000. *Journal of Clinical Psychiatry*, 2002; 63(4): 288-298.
- Bowden C, Goodwin F, Keck PE, Calabrese J, **Suppes T**. Long-term use of mood stabilizers in bipolar disorder. *Journal of Clinical Psychiatry*, 2002; 5(suppl 6): audiograph.
- Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE Jr, Leverich GS, Rush AJ, **Suppes T**, Pollio C, Drexhage HA. High rate of autoimmune thyroiditis in bipolar disorder: Lack of association with lithium exposure. *Biological Psychiatry*, 2002; 51(4): 305-311.
- Suppes T**. Review of the use of topiramate for treatment of bipolar disorder. *Journal of Clinical Psychopharmacology*, 2002; 22(6): 599-609.
- American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). *American Journal of Psychiatry*, 2002, 159, 1-50.

2003

- Suppes T**, Webb A, Paul B, Carmody T, Kraemer H, Rush JA. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. *Focus. The Journal of Lifelong Learning in Psychiatry*, 2003; 1(1): 37-43.
- Brown SE, Rush JA, Biggs MM, Shores-Wilson K, Carmody TJ, **Suppes T**. Clinician ratings versus global ratings of symptom severity: A comparison of symptom measures in the bipolar disorder module, Phase II, Texas Medication Algorithm Project. *Psychiatry Research*, 2003; 117: 167-175.
- Altshuler L, **Suppes T**, Black D, Nolen WA, Keck PE Jr, Frye MA, McElroy S, Kupka R, Grunze H, Walden J, Leverich G, Denicoff K, Luckenbaugh D, Post R. Impact of antidepressant discontinuation after acute remission from bipolar depression on rates of depressive relapse at one-year follow-up. *American Journal of Psychiatry*, 2003; 160(7): 1252-1262.
- Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, **Suppes T**, Rush AJ, Keck PE Jr, McElroy SL, Luckenbaugh DA, Pollio C, Kupka R, Nolen WA. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. *Journal of Clinical Psychiatry*, 2003; 64(6): 680-690.
- Leverich GS, Altshuler LL, Frye MA, **Suppes T**, Keck PE, McElroy SL, Denicoff KD, Obrocea B, Nolen WA, Kupka R, Walden J, Grunze H, Perez S, Luckenbaugh DA, Post RM. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. *Journal of Clinical Psychiatry*, 2003; 64(5): 506-515.

- Frye MA, Altshuler LL, McElroy SL, **Suppes T**, Keck PE, Denicoff K, Nolen WA, Kupka R, Leverich GS, Pollio C, Grunze H, Walden J, Post RM. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. *American Journal of Psychiatry*, 2003; 160(5): 883-889.
- Tohen M, Ketter TA., Zarate CA., **Suppes T**, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. *American Journal of Psychiatry*, 2003; 160: 1263-1271
- Dennehy E, Doyle K, **Suppes T**. The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting. *International Clinical Psychopharmacology*, 2003; 18(3): 143-145.
- Rush JA, Crismon LM, Kashner MT, Toprac MG, Carmody TJ, Trivedi MH, **Suppes T**, Miller AL, Biggs MM, Shores-Wilson K, Witte BP, Shon SP. Texas Medication Algorithm Project, Phase 3 (TMAP-3): Rationale and study design. *Journal of Clinical Psychiatry*, 2003; 64(4): 357-369.
- Suppes T**, Rush JA, Dennehy EB, Crismon LM, Kashner MT, Toprac MG, Carmody TJ, Brown SE, Biggs MM, Shores-Wilson K, Witte B, Trivedi M, Miller AL, Altshuler KZ, Shon SP. Texas Medication Algorithm Project, phase 3 (TMAP-3): Clinical results for patients with a history of mania. *Journal of Clinical Psychiatry*, 2003; 64(4): 370-382.
- Breunis NN, Kupka RW, Nolen WA., **Suppes T**, Denicoff KD., Leverich GS., Post RM., Drexhage HA. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. *Biological Psychiatry*, 2003; 53(2): 157-165.
- Keck PE Jr, McElroy SL, Havens JR, Altshuler LL, Nolen WA, Frye MA, **Suppes T**, Denicoff KD, Kupka R, Leverich GS, Rush AJ, Post RM. Psychosis in bipolar disorder: Phenomenology and impact on morbidity and course of illness. *Comprehensive Psychiatry*, 2003; 44(4): 263-269.
- Kashner TM, Carmody TJ, **Suppes T**, Rush AJ, Crismon ML, Miller AL, Toprac M, Trivedi M. Catching up on health outcomes: The Texas Medication Algorithm Project. *Health Services Research*, 2003; 38(1 pt 1): 331-331. PMID: PMC1360886.
- Post RM, Leverich GS, Altshuler LL, Frye MA, **Suppes T**, Keck PE Jr, McElroy SL, Kupka R, Nolen WA, Grunze H, Walden J. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). *Bipolar Disorders*, 2003; 5: 310-319.
- Post R, Leverich G, Nolen W, Kupka R, Altshuler L, Frye M, **Suppes T**, McElroy S, Keck PE, Grunze H, Walden J. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: Data from the Stanley Foundation Bipolar Network. *Bipolar Disorders*, 2003; 5: 396-406.

2004

- Shivakumar G, **Suppes T**. Bipolar update: Evidence is driving change in mania, depression algorithms. *Current Psychiatry*, 2004; 3(2): 22-23, 35-36, 39.
- Trivedi M, Rush A, Ibrahim H, Carmody T, Biggs M, **Suppes T**, Crismon M, Shores-Wilson K, Toprac M, Dennehy E, Witte B, Kashner T. Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. *Psychological Medicine*, 2004; 34: 73-82.
- McElroy SL, Zarate CA, Cookson J, **Suppes T**, Huffman RF, Greene P, Ascher J. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. *Journal of Clinical Psychiatry*, 2004; 65: 204-210.
- Yonkers K, Wisner K, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, **Suppes T**, Altshuler L. Management of bipolar disorder during pregnancy and the postpartum period. *American Journal of Psychiatry*, 2004; 161: 608-620.
- Tohen M, Chengappa KN, **Suppes T**, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month

- comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. *British Journal of Psychiatry*, 2004; 184: 337-345.
- Dennehy E, **Suppes T**, Rush J, Crismon L, Witte B, Webster J. Development of a computerized assessment of clinician adherence to a treatment guideline for patients with bipolar disorder. *Journal of Psychiatric Research*, 2004; 38: 285-294.
- Sachs G, Chengappa R, **Suppes T**, Mullen J, Brecher M, Devine N, Sweitzer D. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. *Bipolar Disorders*, 2004; 6: 213-223.
- Suppes T**, McElroy S, Keck PE, Altshuler L, Frye M, Grunze H, Leverich G, Nolen W, Chisholm K, Dennehy E, Post R. Use of quetiapine in bipolar disorder: A case series with prospective evaluation. *International Clinical Psychopharmacology*, 2004; 19(3): 173-174.
- Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B, **Suppes T**, Miller AL, Altshuler KZ, and Shon SP. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project (TMAP). *Archives of General Psychiatry*, 2004; 61(7): 669-680.
- Dennehy EB, **Suppes T**, Crismon ML, Toprac M, Carmody TJ, Rush AJ. Development of the Brief Bipolar Disorder Symptom Scale (BDSS) for patients with bipolar disorder. *Psychiatry Research*, 2004; 127: 137-145.
- Suppes T**, Ozcan E, Carmody T. Response to clozapine of rapid cycling vs. noncycling patients with a history of mania. *Bipolar Disorders*, 2004; 6(4): 329-332.
- Post RM, Chang KD, **Suppes T**. Treatment of rapid-cycling bipolar disorder. *CNS Spectrum*, 2004; 9(2): 1-11.
- Nolen WA, Luckenbaugh DA, Altshuler LL, **Suppes T**, McElroy SL, Frye MA, Kupka RW, Keck PE, Jr., Leverich GS, Post RM. Correlates of 1-year prospective outcome in bipolar disorder: Results from the Stanley Foundation Bipolar Network. *American Journal of Psychiatry*, 2004; 161(8): 1447-1454.
- Carlson P, Merlock M, **Suppes T**. Adjunctive stimulant use in patients with bipolar disorder: Treatment of residual depression and sedation. *Bipolar Disorders*, 2004; 6(5): 416-420.
- Armitage R, Cole D, **Suppes T**, Ozcan E. Effects of clozapine on sleep in bipolar and schizoaffective disorders. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 2004; 28: 1065-1070.
- Miller A, Crismon L, Rush J, Chiles J, Kashner M, Toprac M, Carmody T, Biggs M, Shores-Wilson K, Chiles J, Witte B, Bow-Thomas C, Velligan D, Trivedi M, **Suppes T**, Shon S. The Texas Medication Algorithm Project: Clinical results for schizophrenia. *Schizophrenia Bulletin*, 2004; 30(3): 627-647.
- Wang PW, **Suppes T**, Ketter TA. Pharmacotherapy in bipolar depression. *Depression: Mind and Body*, 2004; 1(3): 89-97.
- Chengappa KN, **Suppes T**, Berk M. Treatment of bipolar mania with atypical antipsychotics. *Expert Review of Neurotherapeutics*, 2004, 4(6 Suppl 2): S17-S25.

2005

- Post RM, Altshuler LL, Frye MS, **Suppes T**, Keck PE Jr, McElroy SL, Leverich GS, Nolen WA, Kupka R, Walden J, Grunze H. An overview of recent findings of the Stanley Foundation Bipolar Network (SFBN) (Part II): Focus on anticonvulsants. *Aspects of Affect*, 2005; 1(1): 8-17.
- Leverich GS, McElroy SL, Altshuler LL, Frye MA, Grunze H, Keck Jr. PE, Kupka RW, Nolen WA, **Suppes T**, Walden J, Post RM. The anticonvulsant zonisamide in bipolar illness: clinical response and weight loss. *Aspects of Affect*, 2005; 1(1): 53-56.
- Post RM, Altshuler LL, Frye MA, **Suppes T**, McElroy SL, Keck PE Jr, Leverich GS, Kupka R, Nolen WA, Luckenbaugh DA, Walden J, Grunze H. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. *Journal of Clinical Psychiatry*, 2005; 66(3): 370-374.

- Fehr BS, Ozcan ME, **Suppes T**. Low doses of clozapine may stabilize treatment-resistant bipolar patients. *European Archives of Psychiatry and Clinical Neuroscience*, 2005; 255(1): 10-14.
- Golden R, Gaynes B, Ekstrom D, Hamer R, Jacobsen F, Nemeroff C, **Suppes T**, Wisner K, Nemeroff CB. The efficacy of light therapy in the treatment of mood disorders: A review and meta-analysis of the evidence. *American Journal of Psychiatry*, 2005; 162(4): 656-662.
- McElroy SL, **Suppes T**, Keck PE, Black D, Frye MA, Altshuler LL, Nolen WA, Kupka RW, Leverich GS, Walden J, Grunze H, Post RM. Open-label adjunctive zonisamide in the treatment of bipolar disorders: A prospective trial. *Journal of Clinical Psychiatry*, 2005; 65(5):617-624.
- Rasgon NL, Altshuler LL, Fairbanks L, Elman S, Bitran J, Labarca R, Saad M, Kupka R, Nolen WA, Frye MA, **Suppes T**, McElroy SL, Keck PE Jr., Leverich G, Grunze H, Walden J, Post R, Mintz J. Reproductive function and risk for PCOS in women treated for bipolar disorder. *Bipolar Disorders*, 2005; 7(3): 246-259.
- Velligan D, Prihoda T, Dennehy E, Biggs M, Shores-Wilson K, Crismon ML, Rush AJ, Miller A, **Suppes T**, Trivedi M, Kashner TM, Witte B, Toprac M, Carmody T, Chiles J, Shon S. Brief Psychiatric Rating Scale Expanded Version: How do new items affect factor structure? *Psychiatry Research*, 2005; 135(3): 217-228.
- Kupka RW, Luckenbaugh DA, Post RM, **Suppes T**, Altshuler LL, Keck PE Jr., Frye MA, Denicoff KD, Grunze H, Leverich GS, McElroy SL, Walden J, Nolen WA. Comparison of rapid and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. *American Journal of Psychiatry*, 2005; 162(7): 1273-1280.
- Suppes T**, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs G, Swann AC for the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas Implementation of Medication Algorithms: Update to the algorithms for treatment of bipolar I disorder. *Journal of Clinical Psychiatry*, 2005; 66(7): 870-886.
- Suppes T**, Kelly DI, Perla JM. Challenges in the management of bipolar depression. *Journal of Clinical Psychiatry*, 2005; 66(suppl 5):11-16.
- Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, **Suppes T**, Calabrese JR. Atypical antipsychotics in bipolar depression: potential mechanisms of action. *Journal of Clinical Psychiatry*, 2005; 66(suppl 5): 40-48.
- Duffy FF, Narrow W, West JC, Fochtmann LJ, Kahn DA, **Suppes T**, Oldham JM, McIntyre JS, Manderscheid RW, Sirovatka P, Regier D. Quality of care measures for the treatment of bipolar disorder. *The Psychiatric Quarterly*, 2005; 76(3): 213-230.
- Dennehy EB, **Suppes T**, Rush AJ, Miller AL, Trivedi MH, Crismon ML, Carmody TJ, Kashner TM. Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. *Psychological Medicine*, 2005, 35(12), 1695-1706.
- Suppes T**, Mintz J, McElroy SL, Altshuler LL, Kupka RW, Frye MA, Keck PE, Nolen WA, Leverich GS, Grunze H, Rush AJ, Post RM. Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Bipolar Treatment Network: A sex-specific phenomenon. *Archives of General Psychiatry*, 2005, 62(10), 1089-1096.
- Suppes T**, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc analyses of 47-week data. *Journal of Affective Disorders*, 2005, 89(1-3), 69-77.

2006

- Joffe H, Cohen LS, **Suppes T**, McLaughlin WL, Lavori P, Adams JM, Hwang CH, Hall JE, Sachs GS. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. *Biological Psychiatry*, 2006; 59(11): 1078-86. Epub: Jan 31, 2006; doi:10.1016/j.biopsych.2005.10.017.
- Leverich GS, Altshuler LL, Frye MA, **Suppes T**, McElroy SL, Keck PE Jr, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. *American Journal of Psychiatry*, 2006; 163(2): 232-9. doi: 10.1176/appi.ajp.163.2.232.
- Altshuler LL, **Suppes T**, Black DO, Nolen WA, Leverich G, Keck PE Jr, Frye MA, Kupka R, McElroy SL, Grunze H, Kitchen CM, Post R. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. *American Journal of Psychiatry*, 2006; 163(2): 313-5. doi: 10.1176/appi.ajp.163.2.313.
- Ketter TA, **Suppes T**, Morrell MJ, Rasgon N, Cohen LS, Viguera AC. Reproductive health and bipolar disorder. *CNS Spectrums*, 2006; 11(5 Suppl 5): 1-16.
- Kashner TM, Rush AJ, Crismon ML, Toprac M, Carmody TJ, Miller AL, Trivedi MH, Wicker A, **Suppes T**. An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. *Psychiatric Services*, 2006; May 57(5): 648-59. doi: 10.1176/appi.ps.57.5.648.
- Calabrese JR, Goldberg JF, Ketter TA, **Suppes T**, Frye M, White R, DeVaugh-Geiss A, Thompson TR. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. *Biological Psychiatry*, 2006; 59(11): 1061-4. Epub: June 10, 2006; doi: 10.1016/j.biopsych.2006.02.034.
- Keck PE, Mintz J, McElroy SL, Freeman MP, **Suppes T**, Frye MA, Altshuler LL, Kupka R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Walden J, Duan N, Post RM. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. *Biological Psychiatry*, 2006; 60(9): 1020-1022. Epub: Jun 30, 2006; doi: 10.1016/j.biopsych.2006.03.056.
- Post RM, Altshuler LL, Leverich GS, Frye MA, Nolen WA, Kupka RW, **Suppes T**, McElroy S, Keck PE, Denicoff KD, Grunze H, Walden J, Kitchen CMR, Mintz J. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. *British Journal of Psychiatry*, 2006; 189(2): 124-131. doi :10.1192/bjp.bp.105.013045. Erratum in: *Br J Psychiatry*, 2006; 189: 569.
- Marangell LB, **Suppes T**, Ketter TA, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, Calabrese J, Wisniewski SR, Sachs G. Omega-3 fatty acids in bipolar disorder: clinical and research considerations. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 2006; 75: 315-321. Epub: Aug 22, 2006; doi: 10.1016/j.plefa.2006.07.008.
- Ozcan ME, Shivakumar G, **Suppes T**. Treating rapid cycling bipolar disorder with novel medications. *Current Psychiatry Reviews*, 2006; 2(3): 361-369.
- Joffe H, Cohen LS, **Suppes T**, Hwang CH, Molay F, Adams JM, Sachs GS, Hall JE. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A preliminary report. *Biological Psychiatry*, 2006; 60(12): 1378-81. Epub: Sept 1, 2006; doi: 10.1016/j.biopsych.2006.05.027.
- Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, **Suppes T**, Rush AJ. Implementation of the Texas Medication Algorithm Project Patient and Family Education Program. *Journal of Clinical Psychiatry*, 2006; 67(9): 1362-1372.
- Altshuler LL, Post RM, Black DO, Keck PE, Nolen WA, Frye MA, **Suppes T**, Grunze H, Kupka RW, Leverich GS, McElroy SL, Walden J, Mintz J: Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder. *Journal of Clinical Psychiatry*, 2006; 67(10): 1551-1560.

- Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, **Suppes T**, Adams BE, Thompson TR. Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: An evaluation of two placebo-controlled maintenance trials. *Journal of Clinical Psychiatry*, 2006; 67(11): 1721-8.
- Post RM, Altshuler LL, Frye MA, **Suppes T**, McElroy S, Keck PE Jr, Leverich GS, Kupka R, Nolen WA, Grunze H. New Findings from the Bipolar Collaborative Network: Clinical implications for therapeutics. *Current Psychiatry Reports*, 2006; 8(6): 489-97.

2007

- Levander E, Frye MA, McElroy S, **Suppes T**, Grunze H, Nolen WA, Kupka R, Keck PE Jr, Leverich GS, Altshuler LL, Hwuang S, Mintz J, and Post RM. Alcoholism and anxiety in bipolar illness: Differential lifetime anxiety comorbidity in bipolar I women with and without alcoholism. *Journal of Affective Disorders*, 2007; 101(1-3): 211-7. Epub: Jan 23, 2007; doi: 10.1016/j.jad.2006.11.023.
- McElroy SL, **Suppes T**, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE Jr. Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. *Journal of Affective Disorders*, 2007; 101(1-3): 275-281. Epub: Jan 16, 2007; doi: 10.1016/j.jad.2006.11.025.
- McElroy SL, Frye MA, Altshuler LL, **Suppes T**, Hellemann G, Black D, Mintz J, Kupka R, Nolen W, Leverich GS, Denicoff KD, Post RM, Keck PE Jr. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. *Bipolar Disorders*, 2007; 9(4): 426-434. doi: 10.1111/j.1399-5618.2007.00488.x.
- Nolen WA, Kupka RW, Hellemann G, Frye MA, Altshuler LL, Leverich GS, **Suppes T**, Keck PE Jr, McElroy S, Grunze H, Mintz J, Post RM. Tranylcypromine versus lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. *Acta Psychiatrica Scandinavica*, 2007; 115(5): 360-5. doi: 10.1111/j.1600-0447.2007.00993.x.
- Suppes T**, Kelly DI, Hynan LS, Snow DE, Sureddi S, Foster B, Curley E. Comparison of two anticonvulsants in a randomized, single-blind treatment of hypomanic symptoms in patients with bipolar disorder. *Australian and New Zealand Journal of Psychiatry*, 2007; 41(5): 397-402. Epub: May 1, 2007; doi: 10.1080/00048670701261186.
- Leverich GS, Post RM, Keck PE Jr, Altshuler LL, Frye MA, Kupka RW, Nolen WA, **Suppes T**, McElroy SL, Grunze H, Denicoff K, Moravec MK, Luckenbaugh D. The poor prognosis of childhood-onset bipolar Disorder. *Journal of Pediatrics*, 2007; 150(5): 485-90. Epub: April 21, 2007; doi: 10.1016/j.jpeds.2006.10.070.
- Suppes T**, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. *Psychopharmacology Bulletin*, 2007; 40(2): 22-37.
- Allardyce J, **Suppes T**, Van OS J. Dimensions and the Psychosis Phenotype. *International Journal of Methods in Psychiatric Research*, 2007, 16(S1): S34-S40. doi: 10.1002/mpr.214.
- Frye MA, Grunze H, **Suppes T**, McElroy SL, Keck PE Jr., Walden J, Leverich GS, Altshuler LL, Nakelsky S, Hwuang S, Mintz J, Post RM. A Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression. *American Journal of Psychiatry*, 2007; 164(8): 1242-1249. doi: 10.1176/appi.ajp.2007.06060981.
- Kupka RW, Altshuler LL, Nolen WA, **Suppes T**, Luckenbaugh DA, Leverich GS, Frye MA, Keck Jr. PE, McElroy SL, Grunze H, Post RM. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. *Bipolar Disorders*, 2007; 9: 531-535. doi: 10.1111/j.1399-5618.2007.00467.x.
- Suppes T**, Keck PE Jr., McElroy SL, Altshuler LL, Frye MA, Nolen WA, Kupka RW, Grunze H, Leverich GS, Mintz J, Luckenbaugh DA, Kelly DI, Post RM. Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network.

International Clinical Psychopharmacology, 2007 Nov; 22(6):376-81. doi: 10.1097/YIC.0b013e3281c55f63.

Byerly M, **Suppes T**, Pikalov AA III, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. *Journal of Clinical Psychopharmacology*, 2007; 27(6):639-61. doi: 10.1097/jcp.0b013e31815ac4e5.

2008

Suppes T, Hirschfeld R, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. *World Journal of Biological Psychiatry*, 2008; 9(3): 198-211. doi: 10.1080/15622970701317265.

Bauer M, Lecrubier Y, **Suppes T**. Awareness of metabolic concerns in patients with bipolar disorder: a survey of European psychiatrists. *European Psychiatry*, 2008 Apr; 23(3):169-77. Epub: Dec 21, 2007; doi: 10.1016/j.eurpsy.2007.10.007.

Marangell LB, **Suppes T**, Zboyan H, Prashad SJ, Fischer EG, Snow D, Sureddi S, Allen JC Jr. A 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid cycling bipolar disorder. *Journal Clinical Psychiatry*, 2008 Feb; 69(2); 183-89. Epub: Jan, 16 2008.

Goldberg JF, Bowden CL, Calabrese JR, Ketter TA, Dann RS, Frye MA, **Suppes T**, Post RM. Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. *Biological Psychiatry*, 2008 Jan; 63:125-130. Epub: June 1, 2007; doi: 10.1016/j.biopsych.2006.12.031.

Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. *Journal of Affective Disorders*, 2008 Apr; 107(1-3): 145-154. Epub: Sept 27, 2007; doi: 10.1016/j.jad.2007.08.015.

Post RM, Luckenbaugh DA, Leverich GS, Altshuler LL, Frye MA, **Suppes T**, Keck PE Jr, McElroy SL, Nolen WA, Kupka R, Grunze H, Walden J. Incidence of childhood-onset bipolar illness in the USA and Europe. *British Journal of Psychiatry*, 2008 Feb; 192:150-1. doi: 10.1192/bjp.bp.107.037820.

Shivakumar G, Bernstein IH, **Suppes T**, Stanley Foundation Bipolar Network. Are bipolar mood symptoms affected by the phase of the menstrual cycle? *Journal of Women's Health*, 2008 Apr; 17(3): 473-8. Epub: Mar 8, 2008; doi: 10.1089/jwh.2007.0466.

Ghaemi SN, Bauer M, Cassidy F, Malhi GS, Mitchell P, Phelps J, Vieta E, Youngstrom E; ISBD Diagnostic Guidelines Task Force. Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. *Bipolar Disorders*, 2008 Feb; 10(1 Pt 2):117-28. doi: 10.1111/j.1399-5618.2007.00556.x. (Collaborator).

Vieta E, **Suppes T**. Bipolar II disorder: Arguments for and against a distinct diagnostic entity. *Bipolar Disorders*, 2008 Feb; 10(1 Pt 2): 163-78. doi: 10.1111/j.1399-5618.2007.00561.x.

Suppes T, Marangell LB, Bernstein IH, Kelly DI, Fischer EG, Zboyan HA, Snow DE, Martinez M, Al Jurdi, R, Sureddi S, Gonzalez R. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. *Journal of Affective Disorders*, 2008 Dec; 111(2-3): 334-43. Epub: Mar 20, 2008; doi: 10.1016/j.jad.2008.02.004. PMID: PMC2646842.

Vieta E, **Suppes T**, Eggens I, Persson I, Paulsson B, Brecher M, on behalf of the Trial 126 Study Investigators. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (International Trial 126). *Journal of Affective Disorders*, 2008 Aug; 109 (3): 251-63. Epub: Jun 24, 2008; doi: 10.1016/j.jad.2008.06.001.

Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, **Suppes T**. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: combined results from two double-blind, randomized, placebo-controlled studies. *Journal of Clinical Psychiatry*, 2008 May; 69 (5): 769-82. Epub: April 29, 2008.

Gonzales R, **Suppes T**. Stimulants for Adult Bipolar Disorder? *Current Psychiatry*, 2008, 7(11): 33-46.

2009

- Frye MA, Helleman G, McElroy S, Black D, Altshuler LL, Keck PE Jr., Nolan W, Kupka R, Leverich GS, Grunze H, Mintz J, Post RM, **Suppes T**. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. *American Journal of Psychiatry*, 2009 Feb; 166: 164-172. Epub: November 17, 2008; doi: 10.1176/appi.ajp.2008.08030322.
- Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE Jr., Janavs J, Rogers J, Gonzalez R, Shivakumar G, **Suppes T**. Randomized, Placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. *Journal of Affective Disorders*, 2009 Jun; 115(3): 376-85. Epub: November 29, 2008; doi: 10.1016/j.jad.2008.10.005.
- Frye MA, Yatham L, Ketter TA, Goldberg J, **Suppes T**, Calabrese JR, Bowden CL, Bourne E, Bahn R, Adam B. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. *Acta Psychiatrica Scandinavica*, 2009 Jul; 120(1): 10-3. Epub: Jan 31, 2009; doi: 10.1111/j.1600-0447.2008.01343.x.
- Suppes T**, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance Treatment for Patients with Bipolar I Disorder: Results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). *American Journal of Psychiatry*, 2009 Apr; 166(4): 476-88. Epub: Mar 16, 2009; doi: 10.1176/appi.ajp.2008.08020189.
- Altshuler L, Post RM, Helleman G, Leverich GS, Nolen W, Frye M, Keck PE Jr, Kupka R, Grunze H, Elroy SL, Sugar C, **Suppes T**. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: A blinded, randomized study. *Journal of Clinical Psychiatry*, 2009 Apr; 70(4): 450-7. Epub: April 7, 2009; doi: 10.4088/JCP.08m04191.
- Dennehy EB, Schnyer R, Bernstein IH, Gonzalez R, Shivakumar G, Kelly DI, Snow DE, Sureddi S, **Suppes T**. The safety, acceptability, and effectiveness of acupuncture as an adjunctive treatment for bipolar disorder. *Journal of Clinical Psychiatry*, 2009 Jun; 70(6): 897-905. Epub: May 5, 2009; doi:10.4088/JCP.08m04208.
- Bernstein IH, Rush AJ, **Suppes T**, Trivedi MH, Woo A, Yasushi K, Crismon ML, Dennehy E, Carmody TJ. A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C₁₆) in bipolar patients. *International Journal of Methods in Psychiatric Research*, 2009 Jun; 18(2): 138-146. Epub: Nov 29, 2008; doi: 10.1002/mpr.285.
- Tohen M, Frank E, Bowden CL, Colom F, Ghaemi NS, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, **Suppes T**, Sachs GS, Chengappa KNR, Grunze H, Mitchell PB, Kanba S, Berk M. The International Society of Bipolar Disorders (ISBD) Task Force on the nomenclature of course and outcome in bipolar disorders. *Bipolar Disorders*, 2009 Aug; 11(5): 453-473. doi: 10.1111/j.1399-5618.2009.00726.x.
- Goldberg JF, Calabrese JR, Saville BR, Frye MA, Ketter TA, **Suppes T**, Post RM, Goodwin FK. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. *Journal of Clinical Psychiatry*, 2009 Sep; 70(9):1273-80. Epub: August 11, 2009; doi: 10.4088/JCP.08m04381.

2010

- Suppes T**, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (Trial D144CC00002), *Journal of Affective Disorders*, 2010 Feb; 121(1-2): 106-115. Epub: November 8, 2009; doi: 10.1016/j.jad.2009.10.007.

- Ivleva, EI, Morris DW, Moates AF, **Suppes T**, Thaker GK, Tamminga CA. Genetics and intermediate phenotypes of the schizophrenia-bipolar boundary. *Neuroscience and Biobehavioral Reviews*, 2010 May; 34(6): 897-921. Epub: November 30, 2009; doi: 10.1016/j.neubiorev.2009.11.022.
- Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, Nolen WA, Grunze H, Leverich GS, Keck PE Jr, Zerneno M, Post RM, **Suppes T**. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network. *American Journal of Psychiatry*, 2010 Jun; 167(6): 708-15. Epub: March 15, 2010; doi: 10.1176/appi.ajp.2009.09010105.
- Bernstein I, Rish J, **Suppes T**, Kyotoku Y, Warden D. The Quick Inventory of Depressive Symptomatology (Clinician and Self-Report Versions) in patients with bipolar disorder. *CNS Spectrums*, 2010 Jun, 15(6): 136-73.
- Post RM, Leverich GS, Kupka RW, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Luckenbaugh DA, Rowe M, Grunze H, **Suppes T**, Nolen WA. Early onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. *Journal of Clinical Psychiatry*, 2010 Jul, 71(7): 846-72.
- Post RM, Altshuler LL, Frye MA, **Suppes T**, Keck PE Jr, McElroy SL, Leverich GS, Luckenbaugh DA, Rowe M, Pizzarello S, Kupka RW, Grunze H, Nolen WA. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. *Journal of Clinical Psychiatry*, 2010 Sep, 71(9): 1176-86.

2011

- McElroy SL, Frye MA, Hellemann G, Altshuler L, Leverich GS, **Suppes T**, Keck PE, Nolen WA, Kupka R, Post RM. Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. *Journal of Affective Disorders*, 2011 Feb, 128(3): 191-8. Epub: July 29, 2010; doi: 10.1016/j.jad.2010.06.037.
- Post RM, Leverich GS, Altshuler LL, Frye MA, **Suppes T**, Keck PE, McElroy SL, Nolen WA, Kupka R, Grunze H, Walden J, Rowe M. Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. *International Clinical Psychopharmacology*, 2011 Mar, 26(2): 96-106.
- Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, Goldstein BI, Harvey A, Laghrissi-Thode F, Leboyer M, Ostacher MJ, Sibille E, Strakowski SM, **Suppes T**, Tohen M, Yolken RH, Young LT, Zarate CA. Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder. *Annals of the New York Academy of Sciences*. 2011 Dec, 1242(1): 1-25. Doi: 10.1111/j.1749-6632.2011.06336.x.

2012

- Feldman N, Gwizdowski IS, Fischer EG, Yang H, **Suppes T**. Co-occurrence of serious or undiagnosed medical conditions with bipolar disorder preventing clinical trial randomization: A case series. *Journal of Clinical Psychiatry*, 2012 June; 73(6):874-7. Epub: March 20, 2012.
- Post RM, Leverich GS, Altshuler LL, Frye MA, **Suppes T**, McElroy SL, Nolen WA, Rowe M, Kupka R, Grunze H, Goodwin FK. Relationship of prior antidepressant exposure to longterm prospective outcome in bipolar I outpatients. *Journal of Clinical Psychiatry*, 2012 Aug; 73(7):924-30. Epub: March 20, 2012.
- Vieta E, **Suppes T**, Ekholm B, Udd M, Gustafsson U. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. *Journal of Affective Disorders*, 2012; 142(1-3): 36-44. Epub October 9, 2012. Doi: 10.1016/j.jad.2012.04.014.

2013

- Seo JS, Jamieson K, Cosgrove V, Gwizdowski IS, Yang H, Sheehan DV, McElroy SL, **Suppes T**. Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring

- bipolar disorder and anxiety disorder, *European Psychiatry*, 2013; 28(3): 190-6. Epub: November 28, 2011. doi: 10.1016/j.eurpsy.2011.08.001.
- Swann AC, Lafer B, Perugi G, Frye MA, Bauer M, Bahk WM, Scott J, Ha K, **Suppes T**. Bipolar mixed states: An International Society for Bipolar Disorders Task Force Report of Symptom Structure, Course of Illness, and Diagnosis. *American Journal of Psychiatry*, 2013; 170(1): 31-42. Epub: December 7, 2012. Doi: 10.1176/appi.ajp.2012.12030301.
- Swann AC, **Suppes T**, Ostacher MJ, Eudicone J, McQuade R, Forbes A, Carlson BX. Multivariate analysis of bipolar mania: Retrospectively assessed structure of bipolar I manic episodes in randomized clinical trial participants. *Journal of Affective Disorders*, 2013; 144(1-2): 59-64. Epub: August 1, 2012. Doi: 10.1016/j.jad.2012.05.061.
- Post RM, Altshuler L, Leverich G, Frye MS, **Suppes T**, McElroy S, Keck P, Nolan W, Kupka R, Grunze H, Rowe M. The role of childhood adversity in the development of medical co-morbidities associated with bipolar disorder. *Journal of Affective Disorders*, 2013; 147(1-3): 288-94.. Epub: January 18, 2013. Doi: 10.1016/j.jad.2012.11.020.
- Sheehan DV, Harnett-Sheehan K, Hidalgo RB, Janavs J, McElroy SL, Amado D, **Suppes T**. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. *Journal of Affective Disorders*, 2013; 145(1):83-94. Epub: August 21, 2012. Doi: 10.1016/j.jad.2012.07.016.
- Gonzalez R, Tohen M, **Suppes T**, Tamminga C. Comparison of objective and subjective assessments of sleep time in subjects with bipolar disorder. *Journal of Affective Disorders*, 2013, 149(1-3):363-6. Epub: March 11, 2013. doi: 10.1016/j.jad.2013.02.013.
- Cosgrove VE, **Suppes T**. Informing DSM 5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia. *BMC Medicine*, 2013; 11: 127. Epub: May 14, 2013. Doi: 10.1186/1741-7015-11-127.
- Suppes T**, Vieta E, Gustafsson U, Udd M. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of 2 large placebo controlled trials. *Depression and Anxiety*, Epub: June 12, 2013. Doi: 10.1002/da.2213.
- Hernandez JM, Cordova MJ, Ruzek J, Reiser R, Gwizdowski IS, **Suppes T**, Ostacher MJ. Presentation and Prevalence of PTSD in a Bipolar Disorder Population: A STEP-BD examination. *Journal of Affective Disorders*, Epub: May 23, 2013. Doi: 10.1016/j.jad.2013.04.038.
- Suppes T**, Ketter TA, Gwizdowski IS, Dennehy EB, Hill SJ, Fischer EG, Snow DE, Gonzalez R, Sureddi S, Shivakumar G, Cosgrove VE. First controlled treatment trial of bipolar II mixed hypomania: Quetiapine versus placebo, *Journal of Affective Disorders*, 2013, Epub: March 19, 2013. doi:pil: S0165-0327(13)00191-2. 10.1016/j.jad.2013.02.031.
- Post RM, Leverich GS, Kupka R, Keck P, McElroy S, Altshuler L, Frye MA, Luckenbaugh DA, Rowe M, Grunze H, **Suppes T**, NolenWA. Increased parental history of bipolar disorder in the U.S.: Association with early age of onset. *Acta Psychiatrica Scandinavica*, 2012, Epub: October 19, 2013. doi: 10.1111/acps.12208
- Post RM, Leverich GS, Kupka R, Keck P, McElroy S, Altshuler L, Frye MA, Luckenbaugh DA, Rowe M, Grunze H, **Suppes T**, NolenWA. More stressors prior to and during the course of bipolar illness in patients from the United States compared with the Netherlands and Germany. *Psychiatry Research*, 2013. Epub: September 8, 2013. doi: 10.1016/j.psychres.2013.08.007
- Young AH, Calabrese JR, Gustafsson U, Berk M, McElroy S, Thase ME, **Suppes T**, Earley W. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. July 2013. doi: 10.1186/2194-7511-1-10
- Post RM, Kupka RW, Nolen WA, Altshuler LA, **Suppes T**, Frye MA, McElroy SL, Keck PE Jr, Leverich GS, Grunze H, Rowe M. Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. *Depression and Anxiety*, 2013.

Gonzalez R, Tohen M, **Suppes T**, Tamminga C. The effects of manic and depressive symptoms on the rhythmicity of activity levels in bipolar disorder. *Journal of Clinical Psychiatry*, 2013

2014

Hsin H, **Suppes T**. Psychopharmacology of bipolar II depression and bipolar depression with mixed features. *Focus*. 2014 April; 136-145

Dell'Osso B, Dobra C, Palazzo MC, Cremaschi L, Benatti B, Camuri G, Arici C, **Suppes, T**, and Altamura AC. Neuroimaging procedures and related acquisitions in bipolar disorder. *Depression and Anxiety*, 2014 Jan-Feb;49(1):2-11

Post RM, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Leverich G, Grunze H, **Suppes T**, Keck P, Nolen W. Verbal abuse, like physical and sexual abuse, in childhood is associated with an earlier onset and more difficult course of bipolar disorder. *Bipolar Disorders*, 2014: Oct 13. doi: 10.1111/bdi.12268.

Gonzalez R, Tamminga C, Tohen M, **Suppes T**. The relationship between affective state and the rhythmicity of activity in bipolar disease. *Journal of Clinical Psychiatry*. 2014 Apr;75(4):e317-22. doi: 10.4088/JCP.13m08506.

Post RM, Altshuler L, Leverich GS, Frye MA, **Suppes T**, McElroy SL, Keck PE Jr, Nolen WA, Kupka RW, Grunze H, Rowe M. Relationship of clinical course of illness variables to medical comorbidities in 300 adult outpatients with bipolar disorder. *Compr Psychiatry*, 2014 August; 56-59

Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. *Journal of Affect Disorder*. 2014 Oct;168:485-93.

Post Rm, Alshuler L, Kupka R, McElroy S, Frye MA, Rowe M, Leverich GS, Grunze H, **Suppes T**, Keck PE Jr, Nolen WA. More pernicious course of bipolar disorder in the United States than in many European countries: implications and policy and treatment. *Journal of Affective Disorders*, 2014 Feb; 160:27-33.

Suppes T, McElroy S, Sheehan D, Hidalgo R, Cosgrove V, Gwizdowski I, Feldman N. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co occurring lifetime panic or generalized anxiety disorder. *Journal of Clinical Psychiatry*. 2014 Jan;75(1):77-84. doi: 10.4088/JCP.12m08297.

2015

Post Rm, Alshuler L, Leverich GS, Frye MA, **Suppes T**, McElroy SL, Keck PE Jr, Nolen WA, Kupka RW, Grunze H, Rowe M. Relationship of clinical course of illness variables to medical comorbidities in 900 adult outpatients with bipolar disorder. *Journal of Compr Psychiatry*. 2015 January; 56:21-8

Ostacher M, **Suppes T**, Swann A, Eudicone J, Landsberg W, Baker R, Carlson B. Patterns of response to aripiprazole, lithium, haloperidol and placebo across factor scores of mania. *International Journal of Bipolar Disorders* 2015 May;3:11

Post RM, Leverich GS, Kupka R, Keck PE, McElroy SL, Altshuler LL, Frye MA, Rower M, Grunze H, **Suppes T**, Nolen WA. Increases in multiple psychiatric disorders in parents and grandparents of patients with bipolar disorder from the USA compared with The Netherlands and Germany. *Journal of Psychiatry Genetics*. 2015 October; 194–200

Post RM, Altshuler L, Kupka R. McElroy SL, Frye MA, Rowe, M, Grunze H, **Suppes T**, Keck PE Jr, Leverich GS, Nolen WA. Verbal Abuse, like physical and sexual abuse, in childhood is associated with an earlier noset and more difficult course of bipolar disorder. *Bipolar Disorders*. 2015 May;17(3):323-30

Post RM, Altshuler L, Kupka R. McElroy SL, Frye MA, Rowe, M, Grunze H, **Suppes T**, Keck PE Jr, Leverich GS, Nolen WA. Multigenerational Positive Family History of Psychiatric Disorders Is Associated with a Poor Prognosis in Bipolar Disorder. *Journal of Neuropsychiatry* 2015 Oct; 194–200

Colom F., Vieta E., **Suppes T**. Predominant polarity in bipolar disorders: refining or re-defining diagnosis?

(September 2015) *Acta Psychiatrica Scandinavica* Sept 2015; 132: 324-326

Ostacher M, Tandon R, **Suppes T**. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Bipolar Disorder. *Journal of Clinical Psychiatry. J Clin Psychiatry*. 2015 Jul;77(7):920-6

2016

Suppes T. A brief commentary on the Bipolar CHOICE study. *J Clin Psychiatry*. Jan 2016; 77(1): e43-4

Cosgrove VE, Kelsoe JR, **Suppes T**. Toward a Valid Animal Model of Bipolar Disorder: How the Research Domain Criteria Help Bridge the Clinical-Basic Science Divide. *Biol Psychiatry* Jan 2016; 79 (1): 62-70

Post RM, Altshuler LL, Jupka R, McElroy SL, Frye MA, Rowe M, Grunze H, **Suppes T**, Keck PE, Leverich GS, Nolen WA. More illness in offspring of bipolar patients from the US compared to Europe. *J Affect Disorders*. February 2016; 191: 180-6

Miller S, Dennehy EB, **Suppes T**. The Prevalence and Diagnostic Validity of Short-Duration Hypomanic Episodes and Major Depressive Episodes. *Curr Psychiatry Rep*. March 2016; 18(3):27

Suppes T, Kroger H, Pikalov A, Loebel A. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. *J Psychiatry Res*. March 2016;78:86-93

Suppes T, Silva R, Cucchiaro J, Mao Y, targum S, Streicher C, Pikalov A, Loebel A. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. *Am J Psychiatry*. April 2016;173(4):400-7

Miller S, **Suppes T**, Mintz J, Hellemann G, Frye MA, McElroy SL, Nolen WA, Kupka R, Leverich GS, Grunze H, Alshuler LL, Keck PE Jr, Post RM. Mixed Depression in Bipolar Disorder: Prevalence Rate and Clinical Correlates During Naturalistic Follow-Up in the Stanley Bipolar Network. *Am J Psychiatry*. October 2016. 173 (10):1015-1023.

Post RM, Leverich GS, Kupka R, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Rowe M, Grunze H, **Suppes T**, Nolen WA. Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. *Compr Psychiatry*. April 2016; 66: 146-56

Targum SD, **Suppes T**, Pendergrass JC, Lee S, Silva R, Cucchiaro J, Loebel A. Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional, placebo-control study. *Prog Neuropsychopharmacol Biol Psychiatry*. July 2016;68-9:9-14

Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, Grunze H, **Suppes T**, leverich GS, Nolen WA. Age of onset of bipolar disorder: Combined effect of childhood adversity and familial loading of psychiatric disorders. *J Psychiatry Res*. June 2016; 81: 63-70

Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, Grunze H, **Suppes T**, leverich GS, Nolen WA. Further Evidence of a Cohort Effect in Bipolar Disorder: More Early Onsets and Family History of Psychiatric Illness in More Recent Epochs. *J Clin Psychiatry* Jul 2016. (epub ahead of print)

Carter JM, Arentsen TJ, Cordova MJ, Ruzek J, Reiser R, **Suppes T**, Ostacher MJ. Increased Suicidal Ideation in Patients with Co-Occurring Bipolar Disorder and Posttraumatic Stress Disorder. *Arch Suicide Res* June 2016 (epub ahead of print)

Williams LM, Goldstein –Piekarski An, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O’Hara R, Schatzberg AF, **Suppes T**, Yesavage J. Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression (“RAD”) project. *BMC Psychiatry*. March 2016; 16:68

Goldstein-Piekarski A, Korgaonkar M, Green E , **Suppes T**, Schatzberg A , Hastie T ,Nemeroff C, Williams L. Human Amygdala Engagement moderated by Early Life Stress Exposure is a Biobehavioral Target for Predicting Recovery on Antidepressants. *PNAS* 113(42)11955-11960.

Machado-Vieira, Luckenbaugh DA, Ballard ED, Henter ID, Tohen M, **Suppes T**, Zarate C. Increased activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. *AJP* August 2016; doi: 10.1176/appi.ajp.2016.15091132

2017

- Buoli M, Dell-Osso B, Caldiroli A, Carnevali G, Serati M, **Suppes T**, Ketter T, Altamura A. Obesity and obstetric complications are associated with rapid-cycling in Italian patients with bipolar disorder. *Journal of Affective Disorders*. January 2017; doi: 10.1016/j.jad.2016.10.010.
- Bartoli F, Dell’Osso B, Crocarno C, Fiorillo A, Ketter TA, **Suppes T**, Clerici M, Carra G. Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis. *Journal of Psychiatric Research*. January 2017; ;88:38-46. doi: 10.1016/j.jpsychires.2016.12.021.
- Post RM, Altshuler LL, Kupka R, McElroy SL, Frye MA, Rowe M, Grunze H, **Suppes T**, Keck PE Jr, Nolen WA. Illnesses in siblings of US patients with bipolar disorder relate to multigenerational family history and patients severity of illness. *Journal of Affective Disorders*. 2017 Jan 1;207:313-319. doi: 10.1016/j.jad.2016.09.042
- Post RM, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Grunze H, **Suppes T**, Keck PE Jr, Leverich G, Nolen WA. More childhood onset bipolar disorder in the United States than Canada or Europe: Implications for treatment and prevention. *Neuroscience and Biobehavioral Reviews*. 74 (204-213) January 2017.
- Altshuler L, Sugar C, McElroy S, Calimlim B, Gitlin M, Keck P, Aquino-Elias A, Martens B, Fischer E, English T, Roach J, **Suppes T**. Switch rates during acute treatment for bipolar II depression with lithium, sertraline or the combination for bipolar II depression: a randomized, double-blind comparison. *Am J Psychiatry*. January 2017 174:3, 266-276
- Riemann G, Weisscher N, Post RM, Altshuler L, McElroy S, Frye MA, Keck PE, Leverich GS, **Suppes T**, Grunze H, Nolen WA, Kupka RW. The relationship between self-reported borderline personality features and prospective illness course in bipolar disorder. *Int J Bipolar Disord*. 2017 Sep 25;5(1):31.
- Dodd S, Mitchell PB, Bauer M, Yatham L, Young AH, Kennedy SH, Williams L, **Suppes T**, Lopez Jaramillo C, Trivedi MH, Fava M, Rush AJ, McIntyre RS, Thase ME, Lam RW, Severus E, Kasper S, Berk M. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. *World J Biol Psychiatry*. 2017 Oct 06:1-19.
- McIntyre R, Tandon R, Ostacher M, **Suppes T**. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder. *Journal of Clinical Psychiatry*. October 2016;77(7):920–926
- Suppes, T.**, Ostacher M. Mixed Features in Major Depressive Disorder: Diagnoses and Treatments. *CNS Spectrums and The Canadian Journal of Neurological Sciences*. April 2017
- Suppes, T.**, Eberhard J, Lemming O, Young AH, McIntyre RS. Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials. *Int J Bipolar Disord*. 6 November 2017; 5(1):36
- Carter JM, Arentsen TJ, Cordova MJ, Ruzek J, Reiser R, **Suppes T**, Ostacher MJ. Increased suicidal ideation in patients with co-occurring bipolar disorder and post-traumatic stress disorder. *Archives of suicide research*. Volume 21, 2017 – issue 4. doi.org/10.1080/13811118.2016.1199986
- Lauder S, Cosgrove V, Gliddon E, Grimm D, Dodd S, Berk L, Castle D, **Suppes T**, Berk M. Progressing Moodswings. The upgrade and evaluations of Moodswings 2.0: An online intervention for Bipolar Disorder. *Contemporary Clinical Trials*. 2017; 56:18-24.

Cosgrove V, Gliddon E, Berk L, Grimm D, Lauder S, Dodd S, Berk M, **Suppes T**. Online ethics: where will the interface of mental health and the internet lead us? *Int J Bipolar Disord*. 2017 Dec; 5(1):26.

2018

Vieta E, Salagre E, Grande I, Carvalho AF, Fernandes BS, Berk M, Birmaher B, Tohen M, **Suppes T**. Early Intervention in Bipolar Disorder. *Am J Psychiatry*. 2018 Jan 24: appiajp201717090972.

Post RM, Leverich GS, McElroy S, Kupka R, **Suppes T**, Altshuler L, Nolen W, Frye M, Kech P, Grunza H, Helleman G. Prevalence of Axis II Comorbidities in Bipolar Disorder: Relationship to Mood State. *Bipolar disorders*. 25 Jan 2018; Epub doi: 10.1111/bdi.12596

Williams LM, Pines A, Goldstein-Piekarski AN, Rosas LG, Kullar M, Sacchet MD, Gevaert O, Bailenson J, Lavori PW, Dagum P, Wandell B, Correa C, Greenleaf W, **Suppes T**, Perry LM, Smyth JM, Lewis MA, Venditti EM, Snowden M, Simmons JM, Ma J. The ENGAGE study: Integrating neuroimaging, virtual reality and smartphone sensing to understand self-regulation for managing depression and obesity in a precision medicine model. *Behav Res Ther*. 2018 Feb; 101:58-70.

Gonzalez R, **Suppes T**, Zeitzer J, McClung C, Tamminga C, Tohen M, Forero A, Dwivedi A, Alvarado A. The association between mood state and chronobiological characteristics in bipolar I disorder: A naturalistic, variable cluster analysis-based study. *International Journal of Bipolar Disorders*. 19 February 2018; 6:5

Yatham L, Kennedy S, Parikh S, Schaffer A, Bond D, Frey B, Sharma V, Goldstein B, Rej S, Beaulieu S, Alda M, MacQueen G, Milev R, Ravindran A, O'Donovan C, McIntosh D, Lam R, Vazquez G, Kapczinski F, McIntyre R, Kozicky J, Kanba S, Lafer B, **Suppes T**, Calabrese J, Vieta E, Malhi G, Post R, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT)/International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disorders*. 13 March 2018; DOI: 10.1111/bdi.12609

Vieta E, Berk M, Schulze TG, Carvalho AF, **Suppes T**, Calabrese JR, Gao K, Miskowiak KW, Grande I. Bipolar Disorder. *Nature Reviews Disease Primers*, 8 March 2018; doi:10.1038/nrdp.2018.8

Post R, Leverich G, McElroy S, Kupka R, **Suppes T**, Altshuler L, Nolen W, Frye M, Keck P, Grunze H, Helleman G. Prevalence of axis II comorbidities in bipolar disorder: relationship to mood state. *Bipolar Disorders*. 10 June 2018; 20(4):303-312; doi.org/10.1111/bdi.12596

Post R, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Grunze H, **Suppes T**, Keck Jr P, Leverich G, Nolen W. Multigenerational Transmission of Liability To Psychiatric Illness In Offspring Of Parents With Bipolar Disorder. *Bipolar Disorders*. 21 June 2018; 10.1111/bdi.12668

Gliddon E, Cosgrove V, Berk L, Lauder S, Mohebbi M, Grimm D, Dodd S, Coulson C, Raju K, **Suppes T**, Berk M. A Randomized Controlled Trial of MoodSwings 2.0: An Internet-Based Self-Management Program for Bipolar Disorder. *Bipolar Disorders*. 21 June 2018

Findling R, Earley W, **Suppes T**, Patel M, Wu X, Chang C, McIntyre R. Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. *Neuropsychiatric Disease and Treatment*. 2 August 2018

Post R, Altshuler L, Kupka R, McElroy S, Frye M, Rowe M, Grunze H, **Suppes T**, Keck P, Nolen W. More Assortative Mating in Parents and Spouses of US Compared to European Patients with Bipolar Disorder: Implications for psychiatric illness in the offspring. *European Archives of Psychiatry and Clinical Neuroscience*. 11 August 2018

Van der Markt A, Klumpers UMH, Draisma S, Dols A, Nolen WA, Post RM, Altshuler LL, Frye MA, Grunze H, Keck PE, McElroy SL, **Suppes T**, Beekman ATF, Kupka RW. Testing a Clinical Staging Model for Bipolar Disorder using Longitudinal Life Chart Data. *Bipolar Disorders*. 17 November 2018. DOI: 10.1111/bdi.12727

2019

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Di Florio A, Dietch D, Geddes JR, Goodwin GM, Heinz Grunze H, Joseph F. Hayes, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, **Suppes T**, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. *BJPsych*. January 2019; 214, 27-35. 35. doi: 10.1192/bjp.2018.257

Kramer NE, Cosgrove VE, Dunlop K, Subramaniapillai M, McIntyre RS, **Suppes T**. A clinical model for identifying an inflammatory phenotype in mood disorders. *Journal of Psychiatric Research*. 10 February 2019; 113: 148-158. doi: 10.1016/j.jpsychires.2019.02.005

Gonzalez R, Suzanne D. Gonzalez SD, Guptae J, Mallawaarachchic I, **Suppes T**. The relationship between circadian gene single nucleotide polymorphisms and clinical and behavioral assessments of sleep and rhythms and course of illness characteristics in subjects with bipolar type I disorder. *Personalized Medicine in Psychiatry*. 12 February 2019; 13-14 (2019) 11-18.
<https://doi.org/10.1016/j.pmip.2019.01.001>

In Press

McIntyre R, Subramaniapillai M, Lee Y, Pan Z, Carmona N, Shekotikhina M, Rosenblat J, Brietzke E, Soczynska J, Cosgrove V, Miller S, Fischer E, Kramer-Lange N, Dunlap K, Suppes T, Mansur R. A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Infliximab in the Treatment of Adults with Bipolar I/II Depression: Efficacy in Persons Reporting Childhood Trauma. *JAMA, Psychiatry*, 2019

In Submission

Bennett F, Hodgetts S, Altshuler L, Close A, Frye M, Grunze H, Keck P, Kupka R, Leverich G, McElroy S, Nolen W, Post R, Schäfer L, **Suppes T**, Sharma A. Predictors of Psychosocial Outcome of bipolar disorder: Results from the Stanley Foundation Bipolar Network. Submitted February 2018

Earley W, Burgess MV, Khan B, Reveda L, **Suppes T**, Mauricio Tohen M, Calabrese JR. Cariprazine Treatment of Bipolar I Depression: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study. Submitted December 2018

McIntyre RS, Suppes, Hankinson A, Calabrese J, Burgess M, Yatham L, Reveda L. A Pooled Post Hoc Analysis Evaluating the Safety of Cariprazine in Bipolar Depression. Submitted March 2019

Fredskild MU, Mintz J, Frye MA, MD, McElroy SL, Nolen WA, Kupka R, Grunze H, Keck PE, Post RM, Kessing LV, Suppes T. Hypomania/Mania by DSM-5 Definition Evaluated in 907 Patients from the Stanley Foundation Bipolar Treatment Network: Does adding Energy/Activity to Criterion (A) Matter? Submitted March 2019

Letters

- Costello LE, **Suppes T**. A clinically significant interaction between clozapine and valproate. *Journal of Clinical Psychopharmacology*, 1995; 15(2): 139-141.
- Brown ES, Thompson R, **Suppes T**. Capgras' and Fregoli's syndromes in one family. *Journal of Clinical Psychiatry*, 1996; 57(3): 137-138.
- Suppes T**, Rush AJ. Medication optimization during clozapine treatment. *Journal of Clinical Psychiatry*, 1996; 57(7): 307-308.
- Bennett J, Goldman WT, **Suppes T**. Gabapentin for treatment of bipolar and schizoaffective disorders. *Journal of Clinical Psychopharmacology*, 1997; 17(2): 141-142.
- Rush AJ, **Suppes T**. What are the new treatments for bipolar disorder? In: Grinspoon L ed. *The Harvard Mental Health Letter*, 1998; 14(11): 8.
- Brown ES, Shellhorn E, **Suppes T**. Gastrointestinal side-effects after switch to generic valproic acid. *Pharmacopsychiatry*, 1998; 31: 114.
- Brown ES, Khan DA, **Suppes T**. Treatment of corticosteroid-induced mood changes with olanzapine. *American Journal of Psychiatry*, 1999; 156(6): 968.
- Brown ES, **Suppes T**. What are the mental health complications of steroid therapy? *Harvard Mental Health Letter*, 2000; 16(8): 8.
- Ozcan ME, Shiekh M, Suppes T. How rare is bipolar disorder not otherwise specified? *Bipolar Disorders*, 2003; 5(3): 226-7. Doi: 10.1034/j.1399-5618.2003.00039.x.
- Dennehy E, Gonzalez R, **Suppes T**. Self-reported participation in nonpharmacologic treatments for bipolar disorder. Letter to the Editor, *Journal of Clinical Psychiatry*, 2004; 65(2): 278.
- Altshuler L, **Suppes T**, Black D, Luckenbaugh D, Post R. Dr. Altshuler and colleagues reply. *American Journal of Psychiatry*, 2004; 161(7): 1313.
- Majeres KD, **Suppes T**. A cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis. Letter to the Editor, *Journal of Clinical Psychiatry*, 2004, 65(12): 1720.
- Frye MA, Grunze H, **Suppes T**, McElroy SL, Keck PE Jr., Walden J, Leverich GS, Altshuler LL, Nakelsky S, Hwuang S, Mintz J, Post RM. Treatment emergent hypomania or mania with modafinil. Letter to the Editor, *American Journal of Psychiatry*, 2008, 165(1): 35.
- Gonzalez R, Bernstein IH, **Suppes T**. An investigation of water lithium concentrations and rates of violent acts in 11 Texas counties: can an association be easily shown? Research Support Letter, *Journal of Clinical Psychiatry*, 2008; 69(2): 325-6.
- Suppes T**, McElroy SL, Hirschfeld R. Glucose Testing in Patients Receiving Antipsychotic Pharmacotherapy: Author Reply. *Psychopharmacology Bulletin*, 2008; 41(2): 7-8.
- Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Andreasen NC, Brady KT, Brent DA, Brzustowicz L, Carter CS, Eisenberg L, Goldman H, Javitt DC, Leibenluft E, Lieberman JA, Milrod B, Oquendo MA, Rosenbaum JF, Rush AJ, Siever LJ, **Suppes P**, Weissman MM, Roy MD, Scully JH Jr, Yager J. Conflict of interest—an issue for every psychiatrist. Commentary, *American Journal of Psychiatry*, 2009; 166(3): 274.
- Suppes T**, Vieta E. Maintenance Treatment for Patients with Bipolar I Disorder: Results from a North American study of quetiapine in combination with lithium or divalproex: Author Reply. *American Journal of Psychiatry*, 2009; 166(10): 1186-7. doi: 10.1176/appi.ajp.2009.09060846.

Suppes T, Frank E, DePaulo R, Davis L, Zarate C, Angst J, Fawcett J. Letter to the Editor of Bioploar Disorder in response to 2012 article by Alan Frances: Author Reply. *Bipolar Disorders*, 2013.

Books

Macken E, Van den Heuvel R, Suppes P, **Suppes T**. Home Based Education: Needs and Technological Opportunities - National Institute of Education, U.S. Department of H.E.W., April 1976. 220 pp.

Suppes P. The Effects of Tetraethylammonium on the Electrophysiological Properties of Sympathetic Neurons Isolated from the Superior Cervical Ganglia of Neonatal Rats Grown in Cell Culture. Doctoral Thesis, University of California, Los Angeles, 172 pp., filed 1980.

Suppes T, Keck PE. Bipolar Disorder: Treatment and Management. Compact Clinicals, 2005.

Suppes T, Dennehy E. Bipolar Disorder: The Latest Diagnostic and Treatment Strategy, Compact Clinicals, 2005.

Suppes T, Manning JS, Keck PE Jr. Decoding Bipolar Disorder, Compact Clinicals, 2006.

Suppes T, Dennehy E. Bipolar Disorder Assessment and Treatment, Second Edition, Jones and Bartlett, 2012. Reiser R, Thompson L.

Reiser RP, Thompson LW, Johnson SL, **Suppes T**. Bipolar Disorder: Advances in Psychotherapy: Evidence-Based Practice, Second Edition, Hogrefe Publishing Group, 2017

Swartz HA, **Suppes T**, eds. *Bipolar II Disorder: Recognition, Understanding, and Treatment*. APA Publishing, In Press 2019

Book Chapters and Invited Articles

Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Excerpted in: Talbott JA, ed. The Yearbook of Psychiatry and Applied Mental Health. St. Louis: Mosby; 1994.

Baldessarini RJ, **Suppes T**, Tondo L, Faedda G, Viguera A, Tohen M. Risks of interrupting maintenance therapy with psychotropic drugs. In: Flach F, ed. Directions in Psychiatry, Volume 15. New York, NY: The Hatherleigh Company; January 1995.

Suppes T. New findings about rapidly cycling bipolars and an atypical antipsychotic medication. The Journal of the California Alliance for the Mentally Ill. Sacramento, CA: California Alliance for the Mentally Ill 1995; 6(2).

Suppes T, Rush AJ. Evolving clinical characteristics or distinct disorders? In: Shulman K, Tohen M, Kutcher S, eds. Mood Disorders Across the Life Span. New York: John Wiley & Sons; 1996:3-16.

Baldessarini RJ, Tondo L, **Suppes T**, Faedda GL, Tohen M. Pharmacological treatment of bipolar disorder throughout the life cycle. In: Shulman K, Tohen M, Kutcher S, eds. Mood Disorders Across the Life Span. New York: John Wiley & Sons 1996:299-338.

Suppes T, Baldessarini RJ, Motohashi N, Tondo L, Viguera AC. Special treatment issues: Maintaining and discontinuing psychotropic medications. In: Rush AJ, ed. Mood Disorders: Systematic Medication Management. Modern Problems of Pharmacopsychiatry, Vol 25. Basel, Switzerland: S. Karger AG 1997:235-254.

Suppes T. Pharmacotherapy of bipolar disorder, depressed phase. In: Rush AJ, ed. Women's Health Care Newsletter. Case Conferences on Mood and Anxiety Disorders. St. Louis College of Pharmacy, Women's Health Platform <http://www.stlcp.edu/whp/whp.html>, 1997.

Brown S, **Suppes T**. Bipolar disorders. In: Dunner D, Rosenbaum J eds. Psychiatric Clinics of North America: Annual of Drug Therapy. Philadelphia, PA: W.B. Saunders 1998:154-160.

Glick ID, Marder S, Janowsky D, **Suppes T**, DeBattista C. New short- and long-term psychopharmacologic treatment strategies for schizophrenia, bipolar disorder and depressive disorder. In: Watson SJ, Deutch A, eds. Psychopharmacology: The Fourth Generation of Progress CD-ROM. Philadelphia, PA: Lippincott-Raven 1998.

- Suppes T**, Habermacher E, Potter W. Treatment algorithms and guidelines for bipolar disorder. In: Jobson K, Stein D, Fawcett J, eds. *Treatment Algorithms in Clinical Psychopharmacology*. New York: John Wiley & Sons 1999.
- Suppes T**. Management of treatment-resistant bipolar and schizoaffective disorders. *The Hatherleigh Guide to Psychopharmacology. The Hatherleigh Guides Series, Vol II*. New York, NY: Hatherleigh Press 1999:169-188.
- Trivedi M, **Suppes T**. Nefazodone, mirtazapine and venlafaxine: Clinical use and experience. In: Buckley P, Waddington J, Baldessarini R, eds. *Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice*. Oxford: Butterworth-Heinemann 2000.
- Suppes T**. Management of treatment-resistant bipolar and schizoaffective disorders. In: Flach F, ed. *The Hatherleigh Guide to Psychiatric Disorders, Part II. The Hatherleigh Guides Series*. Long Island City, NY: Dymock's Book Arcade 2000:128-144.
- Calabrese JR, Goodwin GM, Manji HK, **Suppes T**, and Zarate CA. Current Options for the Treatment of Bipolar Disorder. *CNS News Special Report. CME Accredited*. Dec. 2001: 1-7.
- Frye M, Berlant J, **Suppes T**. Health Learning Systems monograph, *Managing Bipolar Disorder and Related Comorbidities with Anticonvulsant Drugs*, June 2002.
- Post RM, Chang KD, **Suppes T**, Ginsberg DL. Treatment of Rapid-Cycling Bipolar Disorder. *CME Accredited Monograph. CNS Spectrums* 2004; 9(2):1-12.
- Mondimore F, **Suppes T**, Ketter T. *Optimizing Pharmacotherapy in bipolar depression*. Euro RSCG Life Genecom, Johns Hopkins University, 2004.
- McIntyre RS, **Suppes T**. *Management of Bipolar Psychosis: Diagnosis and Treatment Strategies*. A CME-Certified Monograph. November 2006.
- Hirschfeld RMA, Bowden CL, Ketter TA, Kowatch RA, McIntyre RS, Post RM, Sachs GS, **Suppes T**, Wagner K. *Bipolar Disorder: A Critical Appraisal of Current Practice*. The Proceedings of the Bipolar Summit 2006. *CME Accredited Clinical Monograph*. December 2006.
- Suppes T**, Kelly DI. *Treatment and Monitoring Guidelines for the Patient with Bipolar Disorder*. *US Psychiatry Review*. November 2008.
- Estevez RF, **Suppes T**. *Maintenance Treatments in Bipolar Disorder*. In: *Bipolar Disorder: A Clinician's Guide to Management*, 2nd edition. Eds. Yatham L, Kusumakar V. New York, NY: Routledge 2009: 107-152.
- Suppes T**. *Is There a Role for Antidepressants in the Treatment of Bipolar II Depression?* Invited Editorial, *American Journal of Psychiatry*, 2010; 167(7): 738-40. doi: 10.1176/appi.ajp.2010.10040590.
- Cosgrove VE, Seo JS, Yang H, **Suppes, T**. Clinical utility of clozapine in bipolar disorder. In HS Akiskal & M Tohen (Ed.), *Bipolar Psychopharmacotherapy: Caring for the Patient Second Edition*, San Francisco: John Wiley & Sons, Ltd, 2011.
- Kudlow PA, Cha DS, McIntyre RS, **Suppes T**. *Maintenance Treatments in Bipolar Disorder*. In: *The Bipolar Book*. Oxford University Press, 2015
- Suppes T**. *Fangou Chapter Life*. December 2015.
- Miller S, Ostacher M, **Suppes T**. *Bipolar and Related Disorders*. In APA 7th edition. February 2018.
- Cosgrove V, **Suppes T**, Schaffer A, Baker A, Kramer N. *Bipolar Spectrum Disorders*. In: *Textbook of Suicide Assessment and Management*, 3rd edition, *Bipolar spectrum disorders*. 2019
- Lange, N, Suppes T. *Diagnosing Bipolar II Disorder*. In: *Bipolar II Disorder: Recognition, Understanding, and Treatment*. APA Publishing, In Press 2019

News Releases/Interviews

- Suppes T** (interview). *Anxiety in bipolar disorder: Balancing benefits*. *Practical Psychopharmacology*, C. Sherman, contributing writer, 2005.
- Suppes T** (interview). *Maintenance Treatment of Bipolar Disorder: An Expert Interview With Trisha Suppes, MD, PhD*. Medscape 2007. <http://www.medscape.com/viewarticle/552834>

- Parikh AR. Pharmaceutical Industry and Academic Psychiatry: Invited interview with **Dr. Suppes**. *American Journal of Psychiatry*, 2008; 3(5): 1-3. <http://ajp.psychiatryonline.org/cgi/data/165/5/A62/DC2/1>
- Suppes T** (interview) Therapeutic Switching in Bipolar Disorder: An Expert Interview with Dr. Trisha Suppes, M.D., Ph.D. *Medscape* 2008. <http://www.medscape.com/viewprogram/17462>
- Suppes T** (interview) Hope for Alternative Medicine Still to be Validated. *Psychiatric News*, 2010; 45(2): 10. <http://pn.psychiatryonline.org/content/45/2/10.full>
- Suppes T** (interview) Depression and Bipolar Support Alliance 2009 Klerman Award Winner. National Public Radio, 2009.

Selected Abstracts

- Roth RL, **Suppes P**. Postembryonic addition of neurons to the nerve cord of the crayfish. *Anatomical Record* 1973; 175: 430.
- Suppes T**, O'Lague PH. Electrophysiological properties of isolated sympathetic neurons developing in microculture. *Society for Neurosciences Meeting* 1978; 4: 139.5.
- Suppes T**. In the presence of tetraethylammonium, a late delayed depolarization follows the action potential of rat sympathetic neurons grown in cell culture. *Society for Neurosciences Meeting* 1980; 6: 281.8.
- Kriegstein AR, **Suppes T**, Prince DA. Cholinergic enhancement of penicillin-induced epileptiform discharges in pyramidal neurons of the guinea pig hippocampus. *Society for Neuroscience Meeting* 1982; 8:259.5.
- Kriegstein AR, **Suppes T**, Prince DA. Cellular physiology of the developing rat neocortex in vitro. *Society for Neurosciences Meeting* 1983; 9:178.7
- Suppes T**, Tohen M, Faedda G, Baldessarini RJ. Risk of discontinuation of lithium in bipolar disorder. *American Psychiatric Association Meeting*, 1991. New Research Poster.
- Jackson PS, **Suppes T**, Harris KM. Dramatic differences in the magnitude and temporal development of long-term potentiation (LTP) in rat hippocampal area CA1 at postnatal days 11 and 15. *Society for Neurosciences Meeting*, 1991.
- Faedda GL, Strakowski SM, Tohen M, **Suppes T**, Stoll AL, Mayer PV, Goodwin DC, Kolbrenner ML, Baldessarini RJ. Mixed and dysphoric states in bipolar patients. *American Psychiatric Association Meeting*, 1992. Poster Presentation.
- Klein DF, Nierenberg AA, Blater MB, Lasagna L, Lydiard BR, Rush JA, **Suppes T**. International Psychopharmacology Algorithm Project. Study Group. 32nd ACNP, 1993. Abstract Published in ACNP Scientific Abstract 1993.
- Tohen M, Strakowski TM, **Suppes T**, Stoll A, Hegarty J, Centorrino F, Zarate C, Weiss M. The McLean First-Episode Mania Project. *First International Conference on Bipolar Disorder*, 1994. Poster Presentation.
- Suppes T**, Rush AJ, Harrison S, Webb A, Paul B. Toward a treatment algorithm for bipolar disorder. *First International Conference on Bipolar Disorder*, 1994. Poster Presentation.
- Suppes T**, Yurgelen-Todd DA, Tohen M, Faedda G, Kolbrenner M, Weiss M, Strakowski S, Mayer P, Stoll A. Mixed bipolar states at first hospitalization. *First International Conference on Bipolar Disorder*, 1994. Poster Presentation.
- Suppes T**, Rush AJ, Harrison S, Webb A, Paul B. Treatment algorithm project for bipolar disorder. *New Clinical Drug Evaluation Unit Program (NCDEU) Annual Meeting*, 1994. Poster presentation.
- Suppes T**, Yurgelen-Todd DA, Tohen M, Faedda G, Kolbrenner M, Weiss M, Strakowski S, Mayer P, Stoll A. Mixed bipolar states at first hospitalization. *Biological Psychiatry* 1994; 35:478. Poster Presentation.
- Suppes T**, Rush AJ, Basco M, Webb A, Paul B, Harrison S. A treatment algorithm for bipolar disorder: An open trial. 33rd American College of Neuropsychopharmacology Annual Meeting, 1994. Poster Presentation.
- Armitage R, **Suppes T**, Cole D, Rush AJ. The effects of clozapine on sleep EEG in bipolar illness. 34th American College of Neuropsychopharmacology Annual Meeting, 1995. Poster Presentation.

- Trivedi MH, **Suppes T**, Devous MD, Harris TS, Rush AJ. Effects of clozapine on rCBF in severe refractory bipolar disorder. 34th American College of Neuropsychopharmacology Annual Meeting, 1995. Poster Presentation.
- Suppes T**, Rush AJ, Webb A. Clozapine to treat severe and persistent bipolar disorder: preliminary results. 34th American College of Neuropsychopharmacology Annual Meeting, 1995. Poster Presentation.
- Basco MR, Kashner TM, **Suppes T**, Turner M, Orsulak P, Battaglia J, Rush AJ. A research partnership in the community. Symposium Community Psychiatry: Public Academic Partnership, Joel Feiner, Director. American Psychiatric Association: Miami, Florida; May 1995. Paper.
- Brown ES, **Suppes T**, Khan DA. Affective symptoms from corticosteroids: A hypothesis for bipolar disorder. 35th American College of Neuropsychopharmacology Annual Meeting, 1996. Poster Presentation.
- Suppes T**, Rush AJ, Webb A, Carmody T, Kraemer H. A one-year randomized trial of clozapine vs. usual care in patients with a history of mixed mania. 35th American College of Neuropsychopharmacology Annual Meeting, 1996. Poster Presentation.
- Kowatch RA, Gilfillan SK, **Suppes T**, Fuentes RM. Clozapine treatment of children and adolescents: A four-year follow-up. *Biological Psychiatry* 1996; 39:105.
- Trivedi MH, **Suppes T**, Devous MD, Harris TS, Rush AJ. RCBF changes with clozapine treatment in refractory bipolar disorder. *Biological Psychiatry* 1996; 39:108.
- Armitage R, **Suppes T**, Cole D, Rush AJ. The effects of clozapine on sleep EEG in bipolar illness. *Biological Psychiatry* 1996;39:533.
- Suppes T**, Rush AJ, Webb A, Carmody T, Kraemer H. A one-year randomized trial of clozapine vs. usual care in bipolar I patients. *Biological Psychiatry* 1996; 39:107.
- Suppes T**. New treatments for bipolar disorder - anticonvulsants and beyond. American Psychiatric Association Annual Meeting, 1996. Symposium.
- Brown ES, **Suppes T**, Khan DA. Affective symptoms from corticosteroids: A hypothesis for bipolar disorder. American Psychiatric Association Annual Meeting, 1997.
- Suppes T**, Lee A, Paul B, Sanchez B, Mack R. The atypical antipsychotic sertindole: A case series. International Congress on Schizophrenia Research, 1997.
- Brown ES, **Suppes T**, Khan DA, Carmody TJ. Affective symptoms with corticosteroids: Preliminary data and hypothesis. New Clinical Drug Evaluation Unit Annual Meeting, 1997.
- Rush AJ, Crismon ML, Miller AL, **Suppes T**, Trivedi MH, Shon S, Toprac MG, Kashner TM, Altshuler KZ. The Texas Medication Algorithm Project (TMAP): A status report 1998. New Clinical Drug Evaluation Unit Annual Meeting, 1997. Poster Presentation.
- Brown ES, **Suppes T**, Khan DA, Carmody TJ. Mood changes during corticosteroid exposure; preliminary data. American College of Neuropsychopharmacology Annual Meeting, 1997.
- Suppes T**, Rush AJ, Webb A, Carmody T, Kraemer H. A one-year randomized trial of clozapine vs. usual care in patients with a history of mixed mania. Society for Neuroscience, 1997.
- Kowatch RA, Bucci MA, **Suppes T**, Emslie GJ, Weinberg WA, Rush AJ. A randomized trial of mood stabilizers in bipolar children and adolescents. American Academy of Child and Adolescent Psychiatry, 1997.
- Brown ES, **Suppes T**, Khan DA, Carmody TJ. Affective symptoms with corticosteroids: Preliminary data and hypothesis. International Society for Psychoneuroendocrinology Meeting, 1997.
- Suppes T**, Rush AJ, Webb A, Carmody T, Kraemer H. A one-year randomized trial of clozapine vs. usual care in patients with a history of mixed mania. Second International Conference on Bipolar Disorder, 1997.
- Calabrese JR, Bowden CL, McElroy SL, Sachs GS, **Suppes T**. Treatment of bipolar depression. European College of Neuropsychopharmacology, 1998.
- Rush AJ, Thase M, Bauer M, Nolen WA, **Suppes T**, Lavori P. Guidelines and algorithms. American College of Neuropsychopharmacology Annual Meeting, 1998. Study Group Abstract.

- Brown ES, **Suppes T**, Swann A, Rush AJ, Crismon M, Shon S, Toprac M, Kashner TM, Altshuler K. Texas Medication Algorithm Project bipolar disorder module: A status report. American College Neuropsychopharmacology Annual Meeting, 1998.
- Apter J, Ascher J, Downs J, Goldstein D, Kolin I, Lydiard B, McElroy S, Rudd D, Shiovitz T, **Suppes T**, Udelman H, Weisler R, Zarate C. Lamotrigine: Evidence for antidepressant activity in bipolar disorder. American College of Neuropsychopharmacology Annual Meeting, 1998.
- Brown ES, **Suppes T**, McElroy S, Kmetz G, Frye M, Keck PE, Kupka R, Altshuler L, Rochussen J, Haytef J, Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder: Application of the Stanley Foundation Bipolar Network prospective protocol. American College of Neuropsychopharmacology Annual Meeting, 1998.
- Crismon ML, Rush AJ, Toprac MG, Shon SP, Miller AL, **Suppes T**, Trivedi MH. Texas Medication Algorithm Project: Feasibility study of implementing medication algorithms in the public mental health sector. Second Annual International Meeting of the College of Psychiatric and Neurologic Pharmacists: February 10, 1999.
- Khan DA, Brown ES, **Suppes P**, Carmody TJ. Mood changes during prednisone bursts for asthma. American Lung Association/American Thoracic Meeting: April 23-28 1999. American Journal of Respiratory Critical Care Medicine 1999; 159: A919.
- Brown ES, **Suppes T**, McElroy S, Kmetz G, Frye M, Keck PE, Kupka R, Altshuler L, Rochussen J, Haytef J, Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Biological Psychiatry 1999; 45: 252.
- Brown ES, **Suppes T**, McElroy S, Kmetz G, Frye M, Denicoff K, Keck PE, Nolen W, Kupka R, Altshuler L, Rochussen J, Haytef J, Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Society of Biological Psychiatry Annual Meeting, 45: Washington, DC; May 13-15, 1999. Biological Psychiatry 1999; 45: 8S.
- Bowden C, Calabrese J, Greene P, McElroy S, Sachs G, **Suppes T**, Swann A. Lamotrigine in rapid cycling bipolar disorder. American College of Neuropsychopharmacology (ACNP): Acapulco, Mexico; December 12-16, 1999.
- Suppes T**. Clinical evidence on the use of antidepressants for bipolar depression. 38th Annual Meeting, American College of Neuropsychopharmacology (ACNP): Acapulco, Mexico; December 12-16, 1999.
- Brown ES, **Suppes T**, McElroy S, Kmetz G, Frye M, Keck PE, Kupka R, Altshuler L, Rochussen J, Haytef J, Leverich G, Post R. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder. Third International Conference on Bipolar Disorder: Pittsburgh, PA; June 17, 1999.
- Brown ES, **Suppes T**, Swann A, Rush AJ, Crismon M, Shon S, Toprac M, Kashner TM, Altshuler K. Texas Medication Algorithm Project bipolar disorder module: A status report. Third International Conference on Bipolar Disorder: Pittsburgh, PA; June 17, 1999.
- Ascher J, Cookson J, Huffman R, Lydiard RB, McElroy S, Monaghan E, **Suppes T**. Profile of antidepressant activity of lamotrigine (Lamictal) in bipolar depression: Results from a double-blind, placebo-controlled study. Third International Conference on Bipolar Disorder: Pittsburgh, PA; June 1999.
- Denicoff KD, Brotman MA, Leverich GS, Nolan W, Rush AJ, McElroy SL, Keck PE, **Suppes T**, Altshuler LL, Kupka R, Frye MA, Post RM. Validation of the NIMH-Life-Chart Method (NIMH-LCM™). Third International Conference on Bipolar Disorder: Pittsburgh, PA; June 17-19, 1999.
- Suppes T**, Cunningham L, Dinan T, Grounds D, Mitchell P, Sokolski K, West S, Ascher J, Babiari D, Cedrone J, Laurenza A, Monaghan E. Lamotrigine (Lamictal): Safety data from controlled monotherapy trials in depression. European College of Neuropsychopharmacology (ECNP), 1999.
- Denicoff KD, Brotman MA, Leverich GS, Nolan W, Rush AJ, McElroy SL, Keck PE, **Suppes T**, Altshuler LL, Kupka R, Frye MA and Post RM. Validation of the NIMH-Life-Chart Method (NIMH-LCM™) [abstract]. Bipolar Disorders 1999, 1(Suppl. 1):29.

- Apter J, Cutler N, Emmanuel N, Goldstein D, Kolin I, **Suppes T**, Udelman H, Zarate C Jr, Evoniuk G, Huffman R. Profile of antidepressant activity of lamotrigine in bipolar depression: Results from a double-blind, placebo-controlled study. New Clinical Drug Evaluation Unit Program (NCDEU) Annual Meeting, 1999.
- Greene P, Earl NL, Ascher J, Monahan E, **Suppes P**, Bowden C, Calabrese J. 488-Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study. American Psychiatric Association Annual Meeting: Chicago, IL; May 13-18, 2000.
- Tohen M, Chengappa KNR, **Suppes T**, Jacobs TG, Timpe TM, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Kupfer DJ, Zarate CA, Breier A. Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. Congress of Collegium Internationale Neuropsychopharmacologicum (CINP): Brussels, Belgium; July 9-13, 2000.
- Earl N, Bowden C, Calabrese J, Ketter T, McElroy S, Post R, Sachs G, **Suppes P**, Swann A, Ascher J, Chang C, Evoniuk G, Greene P. Mood stabilization with lamotrigine in rapid cycling bipolar disorder. Congress of Collegium Internationale Neuropsychopharmacologicum (CINP): Brussels, Belgium; July 9-13, 2000.
- Greene P, Calabrese J, Ketter T, McElroy S, Post R, Sachs P, **Suppes P**, Swann A, Ascher J, Earl N, Monaghan E, Smoot T. Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study. Congress of Collegium Internationale Neuropsychopharmacologicum (CINP): Brussels, Belgium; July 9-13, 2000.
- Leverich GS, Altshuler LL, McElroy S, Keck PE Jr, **Suppes T**, Denicoff KD, Nolen WA, Rush AJ, Kupka R, Frye MA, Autio KA, Post RM. Prevalence of axis II comorbidity in bipolar disorder: Relationship to mood state and course of illness. Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; Acta Neuropsychiatrica September 2000; 12: 161-162.
- Calabrese J, **Suppes P**, Post R, Greene P, Ascher RN, Monaghan E. A double-blind placebo-controlled study of lamotrigine in rapid cycling bipolar disorder. Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; September, 2000.
- Frye MA, Altshuler LL, Denicoff KD, Keck PE, McElroy SL, **Suppes T**, Nolen W, Kupka R, Pollio C, Colburn A, Leverich G, Rush AJ. Gender difference in bipolar disorder alcohol abuse comorbidity. Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; September, 2000.
- Post RM, Altshuler LL, Frye MA, **Suppes T**, Rush AJ, Keck PE, McElroy SL, Denicoff KD, Leverich GS, Kupka R, Nolen WA. Low switch rate in bipolar patients prospectively treated with third generation antidepressants as augmentation to mood stabilizers. Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; September, 2000.
- Denicoff KD, Leverich GS, Nolen WA, McElroy SL, Keck PE Jr, **Suppes T**, Altshuler LL, Kupka R, Frye MA, Pollio HC, Post RM. Morbidity in 202 patients followed for one year in the Stanley Foundation Bipolar Network (SFBN). Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; Acta Neuropsychiatrica 12:157, September, 2000.
- Leverich GS, McElroy SL, **Suppes T**, Keck PE, Jr, Denicoff KD, Nolen WA, Altshuler LL, Rush AJ, Kupka R, Frye MA, Autio KA, Post RM. Early physical or sexual abuse and the course of bipolar illness. Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; September, 2000.
- Suppes T**, Kupka R, McElroy S, Altshuler L, Frye M, Keck PE, Denicoff K, Nolen W, Rochussen J, Leverich G, Post R. Stanley Foundation Bipolar Network, USA. Incidence of co-occurrence of hypomania and depressive symptoms in the Stanley Foundation Bipolar Network. Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; Acta Neuropsychiatrica September, 2000; 12:170.
- Suppes T**, Bowden C, Calabrese J, Greene P, McElroy S, Sachs G, Swann A. Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study. Second European Stanley Foundation Conference on Bipolar Disorder: Amsterdam, Holland; September, 2000.

- Rush JA, Shon SP, Crismon LM, Toprac MG, Miller AL, Trivedi MH, **Suppes T**, Kashner M, Carmody TJ. The Texas Medication Algorithm Project (TMAP): Results of a 3-year study. 39th ACNP: Puerto Rico; December 10-14, 2000.
- Crismon LM, Rush JA, Toprac MG, Shon SP, Miller AL, **Suppes T**, Kashner M, Carmody TJ, Biggs MM, Shores-Wilson K, Altshuler KZ. Texas Medication Algorithm Project: Study Methodology. 39th ACNP: Puerto Rico; December 10-15, 2000.
- Suppes T**, Dennehy EB, Rush AJ, Crismon ML, Toprac MG, Kashner TM, Carmody TJ, Brown ES, Shores-Wilson K, Biggs MM, Witte B, Shon SP. The Texas Medication Algorithm Project (TMAP): Outcomes for persons with bipolar disorder. 39th ACNP: Puerto Rico: December 10-15, 2000.
- Suppes T**, Altshuler L, Apter J, Bowden C, Calabrese J, Ginsberg L, Goldberg J, Gyulai L, Khan A, McElroy S, Rapport M, Risch S, Sachs G, Swann A, West S, Zajecka J, Ascher J, Barrows C, Earl N, Greene P. Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double-blind placebo-controlled study. American College of Neuropsychopharmacology (ACNP): San Juan, Puerto Rico; December 10-15, 2000.
- Kusumakar V, Greene P, Ascher J, Monaghan E, Smoot T, Fouche N, Bowden C, Calabrese J, Post R, Sachs G, **Suppes P**, Gyulai L, Young T, Rapaport M. Mood stabilization with lamotrigine in rapid cycling bipolar disorder: A double blind placebo-controlled study. European College of Neuropsychopharmacology (ECNP), 2000.
- Gyulai L, **Suppes T**, Apter J, Zajecka J, Ascher J, Greene P. Lamotrigine in rapid cycling bipolar disorder: Predictors of response. New Clinical Drug Evaluation Unit Program (NCDEU) sponsored by GlaxoSmithKline: Phoenix, AZ; May 29-31, 2001, Abstract.
- Post RM, Altshuler LL, Frye MA, **Suppes T**, Rush AJ, Keck PE, McElroy SL, Denicoff KD, Leverich GS, Kupka RW, Nolen WA, Grunze H, Walden J. An Update on the Stanley Foundation Bipolar Disorder Network (SFBN). Fourth International Conference on Bipolar Disorders: Pittsburgh, PA; June 14-16 2001, Abstract.
- Greene P, **Suppes T**, Bowden CL, Calabrese JR, Gyulai L, Sachs G, Ascher J, Smoot T, Earl N. Lamotrigine in Rapid Cycling Bipolar Disorder: Predictors of Response. Fourth International Conference on Bipolar Disorders; Pittsburgh, PA; June 14-16 2001, Abstract.
- Chisholm K, Dennehy E, **Suppes T**. Clinical Response to Quetiapine Add-on for Treatment Refractory Bipolar Disorder. Fourth International Conference on Bipolar Disorders: Pittsburgh, PA; June 14-16 2001, Abstract.
- Kupka RW, Nolen WA, Drexhage HA, McElroy SL, Altshuler LL, Denicoff KD, Frye MA, Keck PE, Leverich GS, Rush AJ, **Suppes T**, Pollio C, Post RM. High Rate of Autoimmune Thyroiditis in Bipolar Disorder is Not Associated with Lithium. Fourth International Conference on Bipolar Disorders: Pittsburgh, PA; June 14-16 2002, Society of Biological Psychiatry 2002; 51: 305-311
- Suppes T**, Ascher J, Bowden C, Calabrese J, Earl N, Greene P. Lamotrigine in Rapid-Cycling Bipolar Disorders: Predictors of Response. American Psychiatric Association 154th Annual Meeting: New Orleans, LA; 2001, Poster Presentation.
- Suppes T**. Lamotrigine in Rapid-Cycling Bipolar Disorder: Predictors of Response. American Psychiatric Association 2001 Annual Meeting: New Orleans, LA; May 9, 2001, Abstract.
- Calabrese JR, **Suppes T**, Swann A, Ketter T, Bowden CL, DeVeugh-Geiss J, Evoniuk G. Lamotrigine and Rash: A Review of Evidence from Double-Blind, Placebo-Controlled Trials in Bipolar Disorder Patients. 40th ACNP, December 9-13, 2001.
- Suppes T**, Kupka R, McElroy SL, Altshuler LL, Frye MA, Keck PE, Denicoff KD, Nolen WA, Rochussen J, Leverich GS, Post RM. Incidence of Co-Occurrence of Hypomania and Depressive Symptoms in the Stanley Foundation Bipolar Network Patients. 40th ACNP, December 9-13, 2001.
- Dennehy EB, **Suppes T**, Crismon LM, Rush JA. The Measurement of Adherence to a Treatment Guideline for Bipolar Disorder. 40th ACNP, December 9-13, 2001.

- Tohen M, Chengappa R, **Suppes T**, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine Combined with Mood Stabilizers in Prevention of Recurrence in Bipolar Disorder: An 18-month Study. 40th ACNP, December 9-13, 2001.
- Baker RW, Tohen M, Altshuler L, Zarate CA, **Suppes T**, Ketter TA, Risser RC, Schuh L. Olanzapine versus Divalproex Sodium for Treatment of Acute Mania and Maintenance of Remission: A 47-week study. 40th ACNP, December 9-13, 2001.
- Sachs G, Altshuler L, Ketter T, **Suppes T**, Rasgon N, Frey M, Collins M. Divalproex versus Placebo for the Treatment of Bipolar Depression. 40th American College of Neuropsychopharmacology (ACNP): Waikoloa, Hawaii; December 9-13, 2001.
- Bowden C, **Suppes T**, McElroy S, Goldberg J, Yatham L, Goodwin F, Calabrese J, Leadbetter R, Metz A. Lamotrigine Control Bipolar Depression Without Destabilizing Mood. American College of Neuropsychopharmacology (ACNP): San Juan, Puerto Rico; December 8-12, 2002.
- Suppes T**. Treatment Approaches for Managing Anxiety Disorder in the Bipolar Patient. American Psychiatric Association: San Francisco, California; May 18-23, 2003.
- Suppes T**. An Open Add-on Study of Oxcarbazepine Versus Divalproex to Treat Hypomanic Symptoms in Patients with Bipolar Disorder, NCDEU, Boca Raton, Florida, May 28, 2003.
- Mullen JA, **Suppes T**, Chengappa KNR, Sachs GS. Quetiapine Adjunctive Therapy for Mania Associated with Bipolar Disorder. *Biological Psychiatry*, 2004; 55:180S.
- Goldberg JF, Malhotra AK, Calabrese JR, Bowden CL, **Suppes T**, Frye MA, Ketter TA. Weekly Mood Stability over 6 Months with Lamotrigine or Placebo in Bipolar Rapid Cycling. *Biological Psychiatry*, 2004; 55:141S-142S.
- Joffe H, Cohen LS, **Suppes T**, McLaughlin WL, Lavori P, Adams JM, Molay FJ, Hwang CH, Sachs GS, Hall JE. Valproate Induces Oligomenorrhea with Hyperandrogenism in Women with Bipolar Disorder. Endocrine Society. New Clinical Drug Evaluation Unit (NCDEU), 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004. Poster Presentation.
- Joffe H, Cohen LS, **Suppes T**, McLaughlin WL, Lavori P, Adams JM, Molay FJ, Hwang CH, Sachs GS, Hall JE. Valproate Induces Oligomenorrhea with Hyperandrogenism in Women with Bipolar Disorder. Endocrine Society. American Psychiatric Association, 157th American Psychiatric Association Annual Meeting, New York, NY, May 2-5, 2004. Poster Presentation.
- Joffe H, Cohen LS, McLaughlin WL, Adams JM, Molay FJ, Hwang CH, Hall JE, Sachs GS, **Suppes T**, Lavori P. Treatment of Mood Disorders Associated with the Reproductive Cycle: Benefits and Risks. New Clinical Drug Evaluation Unit (NCDEU), 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004.
- Goldberg J, Ketter T, Calabrese J, **Suppes T**, Frye M, White R. Effects of Mood Stabilizer Treatment on Mood Episode Relapse and Recurrence in Bipolar Disorder. XXIVth CIMP Congress, Paris, June 20-24, 2004.
- Suppes T**, Young A, Bowden C, Paska W, Wilson B, Stewart R. Concomitant use of Lamotrigine and Lithium as Maintenance Therapy in Patients with Bipolar I Disorder. XXIVth CIMP Congress, Paris, June 20-24, 2004.
- Ketter T, **Suppes T**, Goldberg J, Calabrese J, Frye M, White R. Effects of Mood Stabilizer Treatment on Mood Episode Relapse and Recurrence in Bipolar Disorder. XXIVth CIMP Congress, Paris, June 20-24, 2004.
- Altshuler LA, Rasgon NL, Elman S, Bitran J, Labarca R, Saad M, Kupka R, Nolen W, Frye MA, **Suppes T**, McElroy SL, Keck PE, Leverich GS, Grunze H, Walden J, Post RM, Mintz J. Reproductive endocrine function in women treated for Bipolar Disorder: reproductive hormone levels. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 3 Abstract.
- Frye MA, Levander E, McElroy S, **Suppes T**, Keck P, Nolan W, Leverich GS, Grunze H, Walden J, Kupka R, Altshuler L, Mintz J, Post RM. Additional axis I comorbidity in patients with bipolar disorder and alcoholism. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 19. Abstract.

- Kupka R, Luckenbaugh D, Post RM, Altshuler L, Denicoff K, Frye M, Grunze H, Keck P, Leverich GS, McElroy S, **Suppes T**, Walden J, Nolen W. Rapid Cycling Bipolar Disorder: a Five-Year Prospective Follow-Up. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 37 Abstract.
- Suppes T**, Kupka R, McElroy S, Altshuler L, Mintz J, Frye M, Keck P, Leverich GS, Grunze H, Nolen W, Post RM. Increased incidence of mixed symptoms in hypomania in females. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 36. Abstract.
- Grunze H, Dittmann S, Nolen W, Kupka R, Schaerer LO, Bauer M, Frye M, Altshuler LL, Keck PE, Leverich GS, McElroy SL, **Suppes T**, Post RM. Acamprosate as adjunctive treatment in rapid cycling bipolar disorder: an open pilot study. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 25. Abstract.
- Keck P, Hibbeln J, McElroy SL, Freeman M, **Suppes T**, Nolen W, Kupka R, Grunze H, Mintz J, Frye MA, Altshuler L, Denicoff K, Walden J, Dittmann S, Leverich GS, Post RM. Omega-3 fatty acid blood concentrations and response in bipolar depression and rapid cycling bipolar disorder. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 31. Abstract.
- Post RM, Altshuler LL, Leverich GS, Frye MS, Nolen WA, Kupka RW, **Suppes T**, McElroy S, Keck P, Jr, Denicoff KD, Grunze H, Walden J, Kitchen C. Switch Rate on Venlafaxine Compared with Bupropion and Sertraline. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 61. Abstract.
- Leverich GS, Altshuler LL, Frye MA, **Suppes T**, McElroy SL, Keck PE, Jr, Kupka R, Nolen WA, Grunze H, Martinez M, Post RM. The Range of Hypo/Manic Severities on Antidepressants; A randomized, double blind comparison of Bupropion, Sertraline, and Venlafaxine using daily NIMH-LCM ratings. *Acta Psychiatrica Scandinavica* 2004; Supplementum 110 (423), 39. Abstract.
- Kupka R, **Suppes T**, McElroy S, Altshuler L, Mintz J, Post R. The Incidence of Mixed Symptoms of during Hypomania may be Gender Specific. Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25, 2004.
- Suppes T**, Kupka R, McElroy S, Altshuler L, Mintz J, Frye M, Keck PE, Leverich G, Grunze H, Nolen W, Post R. Increased Incidence of Mixed Symptoms in Hypomania in Females, Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25, 2004.
- Kupka R, Luckenbaugh D, Post R, Altshuler L, Denicoff K, Frye M, Grunze H, Keck PE, Leverich G, McElroy S, **Suppes T**, Walden J, Nolen W. Rapid-Cycling Bipolar Disorder: A Five-Year Prospective Follow-up. Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25, 2004.
- Grunze H, Dittmann S, Nolen W, Kupka R, Schaerer L, Bauer M, Frye M, Altshuler L, Keck PE, Leverich G, McElroy SL, **Suppes T**, Post R. Acamprosate as Adjunctive Treatment in Rapid-cycling Bipolar Disorder: An Open Pilot Study. Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25, 2004.
- Post R, Altshuler L, Leverich G, Frye M, Nolen W, Kupka R, **Suppes T**, McElroy S, Keck PE, Denicoff K, Grunze H, Walden J, Kitchen C. Switch Rate on Venlafaxine Compared with Bupropion and Sertraline. Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25, 2004.
- Leverich G, Altshuler L, **Suppes T**, McElroy S, Keck PE, Kupka R, Nolen W, Grunze H, Martinez M, Post R. The Range of Hypo/Manic Severities on Antidepressants by the Daily LCM. Fourth European Stanley Conference on Bipolar Disorder, Scandinavian Congress Center, Aarhus, Denmark, September 23-25, 2004.
- Mitchell P, McElroy S, Cookson J, **Suppes T**, Huffman RF, Paska W, Ascher J. Open-label Use of Lamotrigine Maintenance Treatment in Bipolar Depression: Combination Therapy Experience. 17th European College of Neuropsychopharmacology, Stockholm, Sweden, October 9-13, 2004, Abstract.

- Grunze H, Calabrese J, Ketter T, **Suppes T**, Frye M, White R. Effects of Mood Stabilizer Treatment on Mood Episode Relapse and Recurrence in Bipolar Disorder. 43rd Annual Meeting of the American College of Neuropsychopharmacology, Nashville, TN, December 12-16, 2004, Abstract.
- Yatham L, Bowden C, Calabrese J, **Suppes T**, Ketter T, Frye M, Thompson T, Adams B, DeVaugh-Geiss A. The Impact of Lamotrigine Treatment on Depression in Bipolar I Disorder (5). 43rd Annual Meeting of the American College of Neuropsychopharmacology, Nashville, TN, December 12-16, 2004.
- Suppes T**, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter T, Sachs G, Swann AC. The Texas Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder. 45th Annual New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, June 6-9, 2005, Poster Presentation.
- Suppes T**, Dennehy EB, Fischer EG, Schnyer RN, Allen JJ, Kelly DI. Acupuncture to Treatment Depression in Bipolar Disorder. 45th Annual New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, June 6-9, 2005, Poster Presentation.
- Suppes T**, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter T, Sachs G, Swann AC. The Texas Implementation of Medication Algorithms: Update to the Algorithms for Treatment of Bipolar I Disorder. 6th International Conference on Bipolar Disorder, Pittsburgh, PA, June 16-18, 2005, Poster Presentation.
- Fischer EG, Dennehy EB, Schnyer RN, Allen JJ, Kelly DI, **Suppes T**. Acupuncture to Treatment Depression in Bipolar Disorder. 6th International Conference on Bipolar Disorder, Pittsburgh, PA, June 16-18, 2005, Poster Presentation.
- Shivakumar G, **Suppes T**. Bipolar Disorder Symptoms and Relationship of Menstrual Cycle. 6th International Conference on Bipolar Disorder, Pittsburgh, PA, June 16-18, 2005, Poster Presentation.
- Suppes T**, Keck PE Jr, Macfadden W, Calabrese JR, McCoy R, Minkwitz M, Wilson E, Mullen J. Quetiapine in Bipolar I Depression: Double-Blind, Placebo-Controlled Study. 8th World Congress of Biological Psychiatry, Vienna, Austria, July 1, 2005, Poster Presentation.
- Suppes T**, Vieta E, Raines S, Macfadden W. Quetiapine for the Treatment of Bipolar II Depression. 8th World Congress of Biological Psychiatry, Vienna, Austria, July 1, 2005, Poster Presentation.
- Crismon ML, Kashner M, Rush AJ, **Suppes T**, Toprac M, Carmody TJ, Wicker A. TMAP Cost Outcomes for Patients with Bipolar Disorder. 18th NIMH Conference on Mental Health Services Research (MHSR), Bethesda, MD, July 18-19, 2005.
- Marangell L, **Suppes T**, Zboyan H, Fischer EG, Martinez J, Snow D, Sureddi S. Vagus Nerve Stimulation for the Treatment of Rapid Cycling Bipolar Disorder. 44th American College of Neuropsychopharmacology (ACNP) Annual Meeting, Waikoloa, Hawaii, December 11-15, 2005. Poster Presentation.
- Kelly DI, Marangell L, **Suppes T**, Zboyan H, Fischer EG, Martinez J, Snow D, Sureddi S. Vagus Nerve Stimulation for the Treatment of Rapid Cycling Bipolar Disorder. Australasian Society for Bipolar Disorders Conference 2006, Melbourne, Australia, February 24-25, 2006. Poster Presentation.
- Suppes T**, Hirschfeld RMA, Vieta E, Carlsson A, Stening G, Macfadden W. Quetiapine Monotherapy for Bipolar II Depression: Pooled Results from Two Placebo-controlled Studies. 46th Annual Meeting New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006. Abstract.
- Shivakumar GN, Bernstein IH, **Suppes T**. Bipolar Disorder and Menstrual Cycle Mood Changes: Are They Related? 46th annual Meeting New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006. Abstract.
- Suppes T**, Kupfer D, McElroy S, Hirschfeld RMA. Metabolic Syndrome Awareness Among Psychiatrists Treating Bipolar Disorder: Results of a National Harris Interactive Survey. 46th Annual Meeting New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, Florida, June 12-15, 2006. Abstract.
- Suppes T**, Kupfer D, McElroy SL, Hirschfeld R. Metabolic syndrome awareness among psychiatrists treating bipolar disorder: Results of a national Harris Interactive survey. Second Biennial Conference of the International Society for Bipolar Disorders, Edinburgh, Scotland, August 2-4, 2006. Abstract.

- Suppes T**, Dennehy EB, Hirschfeld RMA, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs G, Swann AC. The Texas Implementation of Medication Algorithms: Update to the algorithms for treatment of bipolar I disorder. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Perla J, Marangell L, **Suppes T**, Zboyan H, Fischer EG, Martinez J, Snow D, Sureddi S. Vagus Nerve Stimulation for the Treatment of Rapid Cycling Bipolar Disorder. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Suppes T**, Mintz J, McElroy SL, Altshuler LL, Kupka RW, Frye MA, Keck PE Jr, Nolen WA, Leverich GS, Grunze H, Rush AJ, Post RM. Sex Differences in Mixed Hypomania: Results from 908 Patients Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Network. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Suppes T**, Altshuler LL, Frye MA, Grunze H, Keck PE Jr, Kupka RW, Leverich GS, McElroy SL, Mintz J, Nolen WA, Luckenbaugh D, Kelly DI, Post RM. Add-on quetiapine for the treatment of bipolar disorder: Results from the Stanley Foundation Bipolar Network. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Grunze H, Frye M, **Suppes T**, McElroy SL, Altshuler L, Leverich G, Keck PE. Modafinil in the Treatment of Bipolar Depression. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Frye M, McElroy S, Helleman G, **Suppes T**. Mixed Depression and Antidepressant-related Mania. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Kupka R, Altshuler L, Nolen W, **Suppes T**, Luckenbaugh D, Leverich G, Frye M, Keck P Jr, McElroy S, Grunze H, Post R. Three Times More Days Depressed Than Manic in Both Bipolar I and Bipolar II Disorder. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Schaerer L, Grunze H, **Suppes T**, McElroy SL, Altshuler L, Leverich G. Treatment Dependent Interepisode Residual Symptoms. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Schaerer L, Langosh, Altshuler LL, Frye M, Grunze H, Keck PE Jr, Kupka R, Leverich GS, Nolen W, McElroy S, **Suppes T**, Post RM. Detection of significant differences in interepisode residual symptoms between olanzapine and lamotrigine. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006. Abstract.
- Suppes T**, Kupfer D, McElroy SL, Hirschfeld R. Metabolic syndrome awareness among psychiatrists treating bipolar disorder: Results of a national Harris Interactive survey. Poster Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5-7, 2006. Abstract.
- Kupka R, Altshuler LL, Nolen W, **Suppes T**, Luckenbaugh D, Leverich GS, Frye M, Keck PE Jr, McElroy S, Grunze H, Post RM. Three times more days depressed than manic in both bipolar I and bipolar II disorder. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006. Abstract.
- Grunze H, Frye M, **Suppes T**, McElroy S, Altshuler LL, Leverich GS, Post RM. Modafinil in the treatment of bipolar depression. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006. Abstract.
- Frye M, McElroy S, Hellman, Nolen W, **Suppes T**, Grunze H, Altshuler LL, Leverich GS, Keck PE Jr, Kupka R, Mintz J, Post RM. Clinical correlates associated with treatment emergent mania. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006. Abstract.
- Post RM, Leverich GS, Luckenbaugh D, Altshuler LL, Frye M, Nolen W, Kupka R, **Suppes T**, Keck PE Jr, Grunze H, Walden. An excess of childhood-onset bipolar illness in the United States compared with Europe. Fifth European Stanley Conference on Bipolar Illness, Barcelona, Spain, October 5-7 2006. Abstract.

- Bauer M, Lecrubier Y, **Suppes T**, Courat J-M. Assessing European Practicing Psychiatrists' Awareness of Metabolic Syndrome Among Patients with Bipolar Disorder. Sixth International Forum on Mood and Anxiety Disorders, Vienna, Austria, November 29-December 1, 2006. Abstract.
- Bauer M, Lecrubier Y, **Suppes T**. Metabolic Syndrome Among Patients with Bipolar Disorder: Current Perspectives of European Psychiatrists. 15th European Congress of Psychiatry, Madrid, Spain, March 17-21, 2007. Abstract.
- Suppes T**, Bauer M, Hirschfeld R, Lecrubier Y, McElroy S. Awareness of metabolic syndrome in patients with bipolar disorder: A comparison of US and European psychiatrists. Annual Meeting of the American Psychiatric Association, San Diego, CA, May 19-24, 2007. Abstract.
- Sheehan DV, McElroy SL, **Suppes T**, Keck PE, Sheehan KH, Janavs J, Raj BA. The efficacy of risperidone in bipolar anxiety. Annual Meeting of the American Psychiatric Association, San Diego, CA, May 19-24, 2007. Abstract.
- Bauer M, **Suppes T**, Hirschfeld R, Lecrubier Y, McElroy S. Awareness of metabolic syndrome in patients with bipolar disorder: Comparison of US and European Psychiatrists. *Bipolar Disorders* 2007; 9(Suppl. 1):18. Abstract.
- Kelly DI, **Suppes T**, Keck PE Jr, McElroy SL, Altshuler LL, Frye MA, Nolen WA, Kupka RW, Grunze H, Leverich GS; Mintz J, Luckenbaugh DA, Fischer EG, Post RM. Quetiapine for the continuation treatment of bipolar depression: Naturalistic prospective case series from the Stanley Bipolar Treatment Network. *Bipolar Disorders* 2007; 9(Suppl. 1):57. Abstract.
- Abulseoud OA, Hellemann G, Frye MA, Altshuler LL, Keck PE Jr, McElroy SL, **Suppes T**, Nolen WA, Kupka RW, Grunze H, Leverich GS, Post RM. Mood stabilizer and subsequent need for adjunctive antidepressant: naturalistic follow up of the SFBN. *Bipolar Disorders* 2007; 9(Suppl. 1):13. Abstract.
- Gonzalez R, Tamminga C, Ivleva E, Ghose S, **Suppes T**. A pilot study examining the association between clock genes and course of illness in bipolar I disorder. *Bipolar Disorders* 2007; 9(Suppl. 1):48. Abstract.
- Suppes T**, Marangell LB, Fischer EG, Zboyan H, Peck RM, Snow DE, Martinez M, Sureddi S. Acute treatment of bipolar II depression with monotherapy lithium versus lamotrigine: an open randomized trial of 102 patients. *Bipolar Disorders* 2007; 9(Suppl. 1):101. Abstract.
- Suppes T**, Marangell LB, Fischer EG, Zboyan H, Peck RM, Snow DE, Martinez M, Sureddi S. Acute treatment of bipolar II depression with monotherapy lithium versus lamotrigine: an open randomized trial of 102 patients. The 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 11-14, 2007. Abstract.
- Gonzalez R, Tamminga C, Ivleva E, Ghose S, **Suppes T**. A pilot study examining the association between clock genes and course of illness in bipolar I disorder. The 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 11-14, 2007. Abstract.
- Sheehan D, McElroy S, **Suppes T**, Sheehan KH, Keck P, Janavs J. In Search of a Treatment for Bipolar Anxiety. The 47th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, June 11-14, 2007. Abstract.
- Gonzalez R, Ivleva E, Ghose S, Gonzalez S, Tamminga C, **Suppes T**. A Pilot Study Examining the Association Between Clock Genes and Course of Illness in Bipolar I Disorder. The 46th Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, FL, December 12, 2007. Abstract.
- Suppes T**, Liu S, Paulsson B, Brecher M. Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: A North American placebo-controlled, randomized multicenter trial (Trial 127). The 46th Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, FL, December 9-13, 2007. Abstract.
- Suppes T**, Liu S, Paulsson B, Brecher M. Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: A placebo-controlled, randomized multicenter trial. The International Society for Bipolar Disorders, Delhi and Agra, India, January 27-30, 2008. Abstract.

- Suppes T**, Liu S, Paulsson B, Brecher M. Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: A placebo-controlled, randomized multicenter trial. The European Congress of Psychiatry, Nice, France, April 5-9, 2008. Abstract.
- Suppes T**, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: A placebo-controlled, randomized multicenter trial. The International Review of Bipolar Disorders, Copenhagen, Denmark, April 14-16, 2008. Abstract.
- Vieta E, **Suppes T**, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex as maintenance treatment for bipolar I disorder. The International Review of Bipolar Disorders, Copenhagen, Denmark, April 14-16, 2008. Abstract.
- Brecher M, **Suppes T**, Vieta E, Liu S, Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term, phase III studies. The International Review of Bipolar Disorders, Copenhagen, Denmark, April 14-16, 2008. Abstract.
- Suppes T**, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. The International Review of Bipolar Disorders, Copenhagen, Denmark, April 14-16, 2008. Abstract.
- Brecher M, **Suppes T**, Vieta E, Liu S, Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term phase III studies. The Society of Biological Psychiatry, Washington, DC, May 1-3, 2008. Abstract.
- Suppes T**, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the new extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (Trial D144CC00002). The American Psychiatric Association, Washington, DC, May 3-8, 2008. Abstract.
- Brecher M, **Suppes T**, Vieta E, Liu S, Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: Combined data from two long-term phase III studies. The American Psychiatric Association, Washington, DC, May 3-8, 2008. Abstract.
- Suppes T**, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the new extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (Trial D144CC00002). The New Clinical Drug Evaluation Unit, Phoenix, AZ, May 27-30, 2008. Abstract.
- Brecher M, **Suppes T**, Vieta E, Liu S, Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: combined data from two long-term phase III studies. The New Clinical Drug Evaluation Unit, Phoenix, AZ, May 27-30, 2008. Abstract.
- Suppes T**, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: A North American placebo-controlled, randomized multicenter trial (Trial 127). The Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, July 13-17, 2008. Abstract.
- Vieta E, **Suppes T**, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium/divalproex as maintenance treatment for bipolar I disorder. The Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, July 13-17, 2008. Abstract.
- Brecher M, **Suppes T**, Vieta E, Liu S, Paulsson B. Quetiapine in the maintenance treatment of bipolar I disorder: combined data from two long-term, phase III studies. The Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, July 13-17, 2008. Abstract.
- Suppes T**, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the new extended-release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression (Trial D144CC00002). The Collegium Internationale Neuro-Psychopharmacologicum, Munich, Germany, July 13-17, 2008. Abstract.
- Swann A, **Suppes T**, Eudicone J, Tran Q, Pikalov A, and Carlson B. Factor analysis of bipolar mania: Retrospectively-assessed structure of mixed mania from randomized clinical trial subjects. *Bipolar Disorders* 2009; 11(Suppl. 1):84. Abstract.
- Suppes T**, Hellemann G, Frye M, McElroy S, Nolen W, Kupka R, Leverich G, Grunze H, Altshuler L, Keck P,

- and Post R. Mixed Depression in Bipolar Disorder: Prevalence rate and clinical correlates during naturalistic follow up. *Bipolar Disorders* 2009; 11(Suppl. 1):83. Abstract.
- Altshuler LL, Kupka RW, Helleman G, Frye MA, Grunze H, Keck Jr PE, Leverich GS, McElroy SL, Nolen WA, Sugar CA, Zermeno M, Post RM, **Suppes T**. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network. *Bipolar Disorders* 2009; 11(Suppl. 1):15. Abstract.
- Biernacka J, Veldic M, McElroy SL, Crow S, Sharp A, Benitez J, Rummans T, Krahn L, Mrazek D, Post RM, Altshuler LL, **Suppes T**, Frye MA. The genomics of treatment emergent mania: The Mayo Clinic Individualized Medicine Biobank for Bipolar Disorder. *Bipolar Disorders* 2009; 11(Suppl. 1):20. Abstract.
- Frye M, Helleman G, **Suppes T**, McElroy S, Grunze H, Altshuler L, Keck P, Kupka R, Nolen W, Leverich G, Post R. Prevalence rate of mixed depression and its impact on remission: a controlled evaluation. *Bipolar Disorders* 2009; 11(Suppl. 1):40. Abstract.
- Kupka RW, Post RM, Altshuler LL, Frye MA, Grunze H, Keck Jr PE, Leverich GS, McElroy SL, **Suppes T**, Nolen WA. Borderline personality features in rapid cycling bipolar disorder in relationship to episode frequency. *Bipolar Disorders* 2009; 11(Suppl. 1):55. Abstract.
- Post RM, Leverich GS, Kupka R, Keck Jr P, McElroy S, Altshuler L, Frye M, Luckenbaugh DA, Rowe M, Grunze H, **Suppes T**, Nolen WA. Delay to first treatment is inversely related to age of onset of bipolar disorder and an independent contributor to a poor outcome in adulthood. *Bipolar Disorders* 2009; 11(Suppl. 1):70. Abstract.
- Vieta E, **Suppes T**, Gustafsson U, Paulsson B. Maintenance treatment with quetiapine added to either lithium or divalproex in bipolar I disorder. European College of Neuropsychopharmacology Annual Meeting 2009, Istanbul, Turkey, September 12-16. Poster.
- Suppes T**. Update from the Mood Disorders Workgroup, Bipolar Disorder Subcommittee. *Bipolar Disorders* 2010; 12(Suppl. 1): 51. Abstract.
- Vieta E, **Suppes T**, Gustafsson U, Paulsson B. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. *Bipolar Disorders* 2010; 12(Suppl. 1): 56. Abstract.
- Tohen M, Frank E, Bowden CL, Colom F, Ghaemi NS, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, Kapczinski F, Goodwin GM, **Suppes T**, Sachs GS, Chengappa KNR, Grunze H, Mitchell PB, Kanba S, Berk M. The International Society for Bipolar Disorders (ISBD) Task Force on the Nomenclature of Course and Outcome in Bipolar Disorders. *Bipolar Disorders* 2010; 12(Suppl. 1): 53. Abstract.
- Suppes T**, Vieta E, Gustafsson U, Paulsson B. Maintenance treatment with quetiapine added to either lithium or divalproex in bipolar I disorder. *Bipolar Disorders* 2010; 12(Suppl. 1): 52. Abstract.
- Suppes T**, Helleman G, Frye MA, McElroy S, Nolen W, Kupka R, Leverich G, Grunze H. Mixed depression in bipolar disorder: prevalence rate and clinical correlates during naturalistic follow up. *Bipolar Disorders* 2010; 12(Suppl. 1): 52. Abstract.
- Frye MA, **Suppes T**, Swann A. The International Society for Bipolar Disorders (ISBD) work group on mixed states and treatment response. *Bipolar Disorders* 2010; 12(Suppl. 1): 21. Abstract.
- Post RM, Nolen WA, Kupka RW, Altshuler LL, Frye MA, **Suppes T**, McElroy SL, Keck PE, Grunze H, Rowe M, Leverich GS. Increased risk factors and poor long-term outcome in the U.S. compared to Holland and Germany. *Bipolar Disorders* 2010; 12(Suppl. 1): 62. Abstract.
- Suppes T**. Update from the mood disorders workgroup, Bipolar Disorder Subcommittee. American Psychiatric Association Annual Meeting 2010, New Orleans, LA, May 25, 2010. Symposium.
- Suppes T**. An update from the DSM-5 workgroup on mood disorders – a focus on bipolar symptoms. American Psychiatric Association Annual Meeting 2010, New Orleans, LA, May 25, 2010. Symposium.
- Suppes T**, Ketter T. A Double-Blind, Placebo-Controlled Trial of Quetiapine for the Treatment of Mixed Hypomania in Bipolar II Patients. New Research Approaches for Mental Health Interventions (NCDEU) Scientific Meeting, Boca Raton, FL, June 14-17, 2010. Poster.

- Suppes T**, Ketter T. A Double-Blind, Placebo-Controlled Trial of Quetiapine for the Treatment of Mixed Hypomania in Bipolar II Patients. American College of Neuropsychopharmacology (ACNP) Annual Meeting, Miami Beach, FL, December 5-9, 2010. Poster.
- Cosgrove, VE, **Suppes, TS**, & Chang, KD. Life Stress and Bipolar Disorders across the Life Span. Society of Biological Psychiatry (SOBP), San Francisco, C.A, May 12-14, 2011. Panel.
- Suppes T**. The debate on duration criteria of hypomanic episodes: agreements, disagreements, and proposed solutions in DSM-5. International Conference on Bipolar Disorder (ICBD), Pittsburgh, PA, June 9-11, 2011. Symposium.
- Suppes T**. Debates in bipolar disorder: Are atypical antipsychotics overused in bipolar disorder. International Conference on Bipolar Disorder (ICBD), Pittsburgh, PA, June 9-11, 2011. Concurrent Session.
- Seo JS, Jamieson K, Cosgrove V, Gwizdowski IS, Yang H, Sheehan DV, McElroy SL, **Suppes T**. Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. World Psychiatric Association Thematic Conference, Istanbul, Turkey, June 9-12, 2011. Poster.
- Raudabaugh BJ, Hernandez JM, Seo JS, Jamieson K, Cosgrove V, Gwizdowski IS, Yang H, Sheehan DV, McElroy SL, **Suppes T**. Clinical predictors of response versus non-response to risperidone: CGI-21 scores after one week of treatment in a bipolar disorder population with co-occurring panic disorder or generalized anxiety disorder. 5th Biennial Conference of the International Society for Bipolar Disorders (ISBD), Istanbul, Turkey, March 14-17, 2012. Poster.
- Feldman NS, Gwizdowski IS, Fischer EG, Yang H, **Suppes T**. Co-occurrence of serious or undiagnosed medical conditions with bipolar disorder preventing clinical trial randomization: A case series. 165th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 5-9, 2012. Poster.
- Suppes T**, Cosgrove V. Update from the Mood Disorders Workgroup for DSM-5: Boundaries of bipolar and schizophrenia disorders. 165th Annual Meeting of the American Psychiatric Association (APA), Philadelphia, PA, May 5-9, 2012. Symposium.
- Suppes T**. Update from the Mood Disorders Workgroup for DSM-5: Bipolar Disorder. 165th Annual Meeting of the American Psychiatric Association (APA), Philadelphia, PA, May 5-9, 2012. Symposium.
- Suppes T**, Cucchiaro J, Pikalov A, Werner P, Targum S, Loebel A. Major depressive disorder with mixed features: interim baseline characteristics of subjects enrolled in a 6 week, double-blind, placebo-controlled trial of lurasidone. 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Hollywood, FL, December 3, 2012. Poster.
- Suppes T**, McElroy SL, Sheehan DV, Hidalgo RB, Cosgrove VE, Gwizdowski IS, Feldman NS. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder. 166th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 18-22, 2013. Poster.
- Cosgrove VE, Lauder S, Berk L, Gwizdowski IS, Fischer EG, Castle D, Gliddon E, Dodd S, Feldman N, Berk M, **Suppes T**. MoodSwings 2.0 online intervention for bipolar disorder: www.moodswings.net.au. 166th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 18-22, 2013. Poster.
- Suppes T**, Frank E, DePaulo JR, Davis L, Fawcett J. DSM-5 Bipolar Disorders: Update on Revised Criteria and the Clinical Implications. **Suppes T**. Bipolar and related disorders: Changes to criteria A and issues of duration. 166th Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 18-22, 2013. Symposium.
- Swann A, **Suppes T**. Mixed Features in Bipolar Disorder: What is an Episode and How are Episodes and Illness-course Characteristics Related? **Suppes T**. How can Mixed Features be Diagnosed and Quantified, and what do they tell us about Episodes of Bipolar Disorder? 10th International Conference on Bipolar Disorders, A Meeting of the International Society for Bipolar Disorders, Miami Beach, FL, June 13-16, 2013. Brainstorming Session.

- Suppes T** (Chair). Beyond Traditional Approaches: Alternative Mechanisms to Approach Biological Treatments in Mood Disorder. 10th International Conference on Bipolar Disorders, A Meeting of the International Society for Bipolar Disorders, Miami Beach, FL, June 13-16, 2013. Symposium.
- Cosgrove V, Fischer E, Lauder S, Gwizdowski I, Feldman N, Berk M, Gliddon E, **Suppes T**. An Online Intervention for Bipolar Disorder MoodSwings 2.0: www.moodswings.net.au. 10th International Conference on Bipolar Disorders, A Meeting of the International Society for Bipolar Disorders, Miami Beach, FL, June 13-16, 2013. Poster.
- Suppes T**, McElroy S, Cosgrove V, Gwizdowski I, Feldman N. A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder with Co-Occurring Lifetime Panic or Generalized Anxiety Disorder. 10th International Conference on Bipolar Disorders, A Meeting of the International Society for Bipolar Disorders, Miami Beach, FL, June 13-16, 2013. Poster.
- Suppes T**, Gustafsson U. Maintenance Treatment with Quetiapine when Combined with either Lithium or Divalproex in Bipolar I Disorder: Analysis of 2 Large Randomized, Placebo-controlled Trials. 10th International Conference on Bipolar Disorders, A Meeting of the International Society for Bipolar Disorders, Miami Beach, FL, June 13-16, 2013. Poster.
- Suppes T**. Presentation and Prevalence of PTSD in a Population with Bipolar Disorder. 2013 APA Annual Meeting, San Francisco, CA, May 18, 2013. Poster.
- Suppes T** A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder with Co-Occurring Panic or Generalized Anxiety Disorder. APA Annual Meeting, San Francisco, CA, May 18, 2013. Poster.
- Suppes T** Major Depressive Disorder with Mixed Features: Interim Baseline Characteristics of Subjects in a Double-Blind, Placebo-Controlled Trial of Lurasidone. APA Annual Meeting, San Francisco, CA, May 18, 2013. Poster.
- Suppes T** Maintenance Treatment with Quetiapine when Combined with either Lithium or Divalproex in Bipolar I Disorder: Analysis of 2 Large Randomized, Placebo-controlled Trials. APA Annual Meeting, San Francisco, CA, May 18, 2013. Poster.
- Suppes T** DSM-5: Update to Bipolar Disorders. Columbia, symposium, August 23-24, 2013.
- Suppes T** Mixed States?. Columbia symposium, August 23-24, 2013
- Suppes T** Evidence-based Treatment of Bipolar Disorder, April 2014 Australia
- Suppes T** DSM-5 Criteria for bipolar disorder with mixed features. Are anxiety, irritability and agitation gateway symptoms for patients suffering from mania with depressive symptoms? WCP Madrid 2014
- Suppes T** Towards diagnosis of depressive symptoms during manic episodes: the DSM-5 mixed specifier ECNP Berlin 2014
- Fischer EG, Cosgrove V, **Suppes T**, Lange N, Gwizdowski I, Hambro B, Ostacher M. Efficacy and tolerability of divalproex sodium plus adjunctive quetiapine, lithium, or placebo for hypomanic or manic episodes in outpatients with bipolar I disorder. ISBD Annual Meeting, Mexico City, March 6-9, 2018. Poster.
- Earley W, Burgess M, Rekedal L, Hankinson A, McIntyre RS, **Suppes T**, Calabrese J, Yatham LN. A Pooled Post Hoc Analysis Evaluating the Safety of Cariprazine in Bipolar Depression. ISBD Annual Meeting, Sydney, March 19-23, 2019. Abstract.

Selected CDs and Videos

- Suppes T**. CD-ROM Educational Program: Zyprexa in Bipolar Mania. Dallas, Texas: Eli Lilly and Company; January 11, 2000.
- Suppes T**, Dennehy ED. Video: Recent Studies on the Treatment of Bipolar Disorder. Dallas, Texas: Distance Learning Center; March 28, 2000.
- Rush AJ, **Suppes T**, Swann Alan. Audio: Biological Therapies for Bipolar & Schizoaffective Disorders. ACNP Psychiatric Update.

- Bowden C, Calabrese J, Goodwin F, Keck PE, Jusumakar V, **Suppes T**. Long-Term Use of Mood Stabilizers in Bipolar Disorder. *Journal of Clinical Psychiatry Audiograph Series*, Vol. 5, No. 6, July 2002.
- Suppes T**, Genecom Slide Kit: Optimizing the Treatment of Bipolar Depression, 2002, CME provided by Johns Hopkins Medical School. Co-Chair with Dr. Terry Ketter.
- Suppes T**. CME, Inc. Slide Kit: Using Antipsychotics in Treating Mania: Key Factors for Successful Outcomes, 2002, Co-Chair with Steve Strakowski.
- Suppes T**, Glazer W, Strakowski S. Video: New Developments in the Treatment of Bipolar Mania. Dallas, Texas: PsychLINK, January 28, 2004.
- Suppes T**, Altman C. Video: Bipolar 360 Degrees Experience. Dallas, Texas: Cadient Group, March 10, 2004.
- Suppes T**. Video: Battling Bipolar Disorder: Evidence for New Treatments and Tactics. Dallas, Texas: psychCME, March 10, 2004.

Selected Invited Presentations

- 1991 "Discontinuation of Lithium in Bipolar Patients: How Safe is It?" Psychopharmacology Lunch Program, McLean Hospital, October 10th.
- 1991 "Risk of Discontinuation of Lithium in Bipolar Disorder." Scientific Advisory Committee Research Symposium, McLean Hospital, November 18th -19th.
- 1992 "New Generation of Programs to Treat Mental Illness – Newly Refined Community Approaches." National Alliance for the Mentally Ill, Texas Chapter, May.
- 1992 "Bipolar, Depressive and Manic-Depressive Illnesses." National Alliance for the Mentally Ill, Texas Chapter, May.
- 1992 "Risk of Recurrence with Lithium Discontinuation." Physician's Evening Seminar, Zale Lipshy University Hospital, UT Southwestern Medical Center, August 20th.
- 1992 "Clinical Risks and Scientific Issues in Discontinuing Psychotic Agents." American College of Neuropsychopharmacology 30th Meeting, December.
- 1993 "Day Hospitalization/Pharmacology." Mental Health Connections Didactic Seminar, St. Paul University, January 14th.
- 1993 "Maintenance Treatment and Risk of Relapse with Discontinuation." Dallas, Texas, Abbott, January 16th.
- 1993 "Clozapine in Treatment of Dysphoric Mania, Psychotic Mood Disorders, S-A and Schizophrenia." UT Southwestern Medical Center, February 8th.
- 1993 Case Conference. Mental Health Connections, March 31st.
- 1993 "Pharmacological Treatment of Bipolar Disorder." Terrell State Hospital, April 15th.
- 1993 "New Treatment in Bipolar Disorders." UT Southwestern Medical Center, July 15th.
- 1993 "In Your Interest." "Manic Depression." KHSX-TV, Dallas, Texas, July 29th.
- 1993 "Bipolar Disorder." Dallas Area Women Psychiatrists, October 16th.
- 1993 "Update on Bipolar Disorder: Should Medications be Continued Indefinitely?" Austin, Texas, Texas Psychological Association, November 6th.
- 1993 "Maintenance Treatment in Bipolar Disorder: Risks and Implications." Dallas, Texas, St. Paul Medical Center, November 13th.
- 1993 "New Management Options in Bipolar Disorder." Terrell, Texas, Terrell State Hospital, November 18th.
- 1993 The Mental Health Forum with Gary Lefkof, M.D. KGBS Talk Radio, Dallas, Texas, December 8th.
- 1993 International Psychopharmacology Algorithm Project Study Group, American College of Neuropsychopharmacology (ACNP), December 13th.
- 1994 "Schizophrenia." Health Matters, WFAA-TV. Dallas, Texas, January 16th.
- 1994 "New Management Options in Bipolar Disorder." Waco, Texas, Heart of Texas Pharmacy Association, January 20th.

- 1994 "Treatment-Resistant Bipolar Disorder." UT Southwestern Medical Center Grand Rounds, Dallas, Texas, January 28th.
- 1994 "Can Medications Change Personality?" Texas State Network Radio Program, 1080 AM, Dallas, Texas, February 10th.
- 1994 "New Management Options in Bipolar Disorder." Vernon State Hospital, Vernon, Texas, February 17th.
- 1994 "Bipolar Disorder: Diagnostic Challenges, Treatment Optimization." Discovery International, Dallas, Texas, April 28th.
- 1994 "New Management Options in Bipolar Disorder." Mississippi State Hospital, Whitfield, Mississippi, May 24th.
- 1994 "Medications and Miracles: Advances in Treating Severe Mental Illness." TEXAMI, UT Southwestern Medical Center, Dallas, Texas, May 28th.
- 1994 "New Management Options in Bipolar Disorder." Central Oklahoma Psychiatric Society, Oklahoma City, Oklahoma, July 12th.
- 1994 "Recent Advances and Innovations in the Treatment of Bipolar Disorder." Zale Lipshy University Hospital Grand Rounds, Dallas, Texas, August 4th.
- 1994 "Clozapine Treatment of Schizoaffective and Bipolar Disorder Patients." Texas State Alliance for Mentally Ill, Fort Worth, Texas, September 23rd.
- 1994 "New Management Options in Bipolar Disorder." Southern Psychiatric Association, New Orleans, Louisiana, September 29th.
- 1994 "Petition of the Psychiatrist." AMI Candlelight Vigil for Mental Awareness Week, Dallas, Texas, October 2nd.
- 1995 Grand Rounds Presentation. Terrell State Hospital, Terrell, Texas, January 26th.
- 1995 Grand Rounds Presentation. Texas Tech University, Amarillo, Texas, March 23rd.
- 1995 "Bipolar Depression." Terrell State Hospital Grand Rounds, Terrell, Texas, May 4th.
- 1995 "Changing Medications." Dallas AMI, Dallas, Texas, May 4th.
- 1995 "Treatment Update on Bipolar Disorder: Focus on Bipolar Depression." UT Health Science Center, San Antonio, Texas, May 9th.
- 1995 Grand Rounds Presentation, Texas Tech Health Science Center, Lubbock, Texas, May 26th.
- 1995 "Treatment and Management of Bipolar Patients: The Old and the New." Maricopa Medical Center, Phoenix, Arizona, August 30th.
- 1995 "Critical Clinical Issues in Bipolar Disorder." UT Southwestern Medical Center, Dallas, Texas, September 30th.
- 1995 "Treatment of Bipolar Disorder." University of New Mexico Grand Rounds, New Mexico, October 6th.
- 1996 "New Management Options in Bipolar Disorder." St. Vincent Hospital, Santa Fe, New Mexico, January 30th.
- 1996 "Risk and Implications of Interrupting Long-term Maintenance Treatment with Lithium and Other Psychotropic Drugs. UT Southwestern Medical Center, February 7th.
- 1996 "Treatment and Management of Bipolar Patients: The Old and the New." Griffin Memorial Hospital, Norman, Oklahoma, February 22nd.
- 1996 "Treatment-Resistant Schizoaffective Illness and Bipolar Disorder." Laureate Psychiatric Clinic and Hospital, Tulsa, Oklahoma, March 20th.
- 1996 "Treatment-Resistant Schizoaffective Illness and Bipolar Disorder." Community Mental Health Center, Tulsa, Oklahoma, March 20th.
- 1996 "Advancing the Treatment of Mania Associated with Bipolar Disorder." Big Spring State Hospital, Big Spring, Texas, March 27th.

- 1996 “New and Innovative Ways of Examining Treatment Strategies.” Stanford University Medical Center, Stanford, California, April 5th.
- 1996 “Lifetime Treatment of Manic-Depressive Illness.” American Psychiatric Association, New York City, New York, May.
- 1996 “Treatment and Management of Bipolar Patients: The Old and the New.” Texas Alliance for Mental Illness, Dallas, Texas, September 28th.
- 1996 “The Early Detection for Bipolar Disorder.” UT Southwestern Medical Center, Dallas, Texas, October 10th.
- 1996 “Treatment-Resistant Schizoaffective Illness with an Overview of Antipsychotics.” Texas Tech University, Lubbock, Texas, October 18th.
- 1996 “Bipolar Disorder.” Brigham and Women’s Hospital, Boston, Massachusetts, October 22nd.
- 1997 “Bipolar Disorder.” Fort Worth DMDA, Fort Worth, Texas, March 7th.
- 1997 “Update on Schizophrenia: A Specialist’s Perspective.” Kerrville State Hospital Grand Rounds, Kerrville, Texas, March 12th.
- 1997 “Update in the Diagnosis and Treatment of Bipolar Disorder.” St. Elizabeth’s Hospital, Washington D.C., May 1st.
- 1997 “Better Treatments: Subtypes and Outcomes, Bipolar Depression and Comorbid Substance Abuse.” Dallas, Texas, May 31st.
- 1997 **Suppes T**, Swann A, Crismon ML, Shon S, Rush AJ, Altshuler KZ. Will medication algorithms provide adequate information on treatment response in bipolar disorder? New Clinical Drug Evaluation Unit Annual Meeting, June.
- 1997 “Better Treatments: Subtypes and Outcomes, Bipolar Depression, and Comorbid Substance Abuse.” Chicago, Illinois, June 29th.
- 1997 UCLA Bipolar Disorder Intensive Workshop, Redondo Beach, California, September 11th-13th.
- 1997 “Bipolar Disorder: Its Course and Consequences for Treatment.” Psychiatric University of Utrecht (PUK), Utrecht, Netherlands, October 10th.
- 1997 “An Intensive Educational Experience for Psychiatrists.” Stanford University, Stanford, California, November 13th-15th.
- 1998 “Bipolar Disorder and use of the Texas Medication Algorithm.” TMAP, Houston, Texas, February 13th.
- 1998 “Bipolar Disorders.” Dallas Area Women Psychiatrists, Dallas, Texas, March 14th.
- 1998 “Better Diagnosis of Bipolar Disorder and Enhanced Treatment for Bipolar Depression.” U.S. Bipolar Disorders Update, San Diego, California, April 19th.
- 1998 “Better Diagnosis of Bipolar Disorder and Enhanced Treatment for Bipolar Depression.” U.S. Bipolar Disorders Update, Los Angeles, California, May 9th.
- 1998 “Managing Treatment Resistant Patients Using Combination Medication.” UT Southwestern Medical Center, Dallas, Texas, May 15th-16th.
- 1998 “Treatment Options for Acute Mania.” Consultant Meeting, Newport Beach, California, June 26th-28th.
- 1998 “New Options in Bipolar Disorders.” Houston, Texas, July 18th.
- 1998 “New Options in Bipolar Disorders.” New Orleans, Louisiana, July 25th.
- 1998 “New Treatment Options in Bipolar Disorder.” Depressive and Manic Depressive Association, Dallas, Texas, September 17th.
- 1998 “The Use of Anticonvulsants and Atypical Antipsychotics in Bipolar Disorder.” Texas Society of Psychiatric Physicians Annual Convention, Houston, Texas, November 14th.
- 1998 “Update on Treatment of Bipolar Disorder.” Abbott Laboratories, Little Rock, Arkansas, November 19th.
- 1998 “New Options in Bipolar Disorders.” Austin, Texas, December 5th.

- 1999 "New Options in Bipolar Disorders." Tucson, Arizona, February 20th.
- 1999 "Use of Mood Stabilizers in the Treatment of Bipolar Disorder." Menninger Clinic, Incorporated, Kansas City, Missouri, March 20th.
- 1999 "Anticonvulsant Drugs in Psychiatry: Bipolar Disorders and Beyond." Medical Education Systems, April 15th.
- 1999 "Diagnosis and Treatment of Bipolar Depression." SCP Communications, San Francisco, California, April 30th.
- 1999 "Bipolar Disorder." Scott and White Hospital Grand Rounds, Temple, Texas, June 4th.
- 1999 "Bipolar Treatment Update." Glaxo Wellcome, Dallas, Texas, June 24th.
- 1999 "Bipolar Disorders and Substance Abuse: Toward Improved Outcomes." St. Louis, Missouri, July 10th.
- 1999 "Anticonvulsant Drugs in Psychiatry: Bipolar Disorders and Beyond." The Mansion on Turtle Creek, Dallas, Texas, August 10th.
- 1999 "Update on Treatment of Bipolar Disorder." NARSAD Symposium, Dallas, Texas, September 14th.
- 1999 "Update on Treatment of Bipolar Disorder." National DMDA Conference, Houston, Texas, October 3rd.
- 1999 "Bipolar Depression: Clinical Physiologic, and Therapeutic Specificity." ACNP, Acapulco, Mexico, December 12th-16th.
- 2000 "Treatment Update on Bipolar Disorder." Dallas Area Women Psychiatrists, Dallas, Texas, January 28th.
- 2000 "Balancing Treatment Alternatives for Bipolar Disorder: Maximizing Efficacy, Minimizing Side Effects." Dallas, Texas, April 15th.
- 2000 "Bipolar Depression: Clinical, Biological, and Treatment Specificity." American Psychiatric Association, Chicago, Illinois, May 15th.
- 2000 "Clinical Evidence on Antidepressants for Bipolar Disorder." American Psychiatric Association, Chicago, Illinois, May 15th.
- 2000 "How Useful are Third-Generation Anticonvulsants?" American Psychiatric Association, Chicago, Illinois, May 17th.
- 2000 "Restoring Balance: Long-Term Mood Stabilization in the Bipolar Patient." San Francisco, California, April 28th.
- 2000 "Differential Diagnosis of Bipolar Disorder vs Unipolar Depression." Dallas, Texas, June 28th.
- 2000 "Efficacy of Topiramate in Bipolar Disorder: First Clinical Results." Collegium Internationale Neuro-Psychopharmacologicum Congress, Brussels, Belgium, July 10th.
- 2000 "Clinical Update on Novel Treatment for Rapid Cycling Bipolar Disorder." Collegium Internationale Neuro-Psychopharmacologicum Congress, Brussels, Belgium, July 11th.
- 2001 "Minimizing the Impact of Adverse Reactions from Medications Used to Treat Bipolar Disorder." Genecom, Dallas, Texas, February 9th.
- 2001 "Treatment of Bipolar Disorder with Atypical Antipsychotics." International Congress Centre, Berlin, Germany, July 3rd.
- 2001 "Prevention 2001: Crisis in Changing Times." Suicide and Crisis Center, Dallas, Texas, September 21st.
- 2001 "Bipolar Disorder." Mental Illness Awareness Week, UT Southwestern Medical Center, Dallas, Texas, October 6th.
- 2001 "Novel Treatments for Bipolar Disorder." Texas Society of Psychiatric Physicians, Galveston, Texas, November 3rd.
- 2002 "Exploring Novel Treatment Strategies for Bipolar Disorder." Psychiatric Nursing Symposium, Arlington, Texas, March 8th.

- 2002 “Practical Considerations in Stabilizing Mania Associated with Bipolar Disorder.” GlaxoSmithKline, Arlington, Texas, March 15th.
- 2002 “The Management of Mania Associated with Bipolar Disorder.” GlaxoSmithKline, Arlington, Texas, April 12th.
- 2002 “Medication Strategies for Treatment of Refractory Patients with Bipolar Disorder.” American Psychiatric Association, Philadelphia, Pennsylvania, May 19th.
- 2002 “Customizing Care for Patients with Bipolar Disorder.” American Psychiatric Association, Philadelphia, Pennsylvania, May 19th.
- 2002 “The Role of Atypicals in Mania.” Seroquel Standalone Meeting, Seville, Spain, September 5th.
- 2002 “The Role of Atypicals in Mania.” International Forum on Mood and Anxiety, Monte Carlo, November 28th.
- 2002 “Clinical Effectiveness in Bipolar Disorder.” International Forum on Mood and Anxiety, Monte Carlo, November 28th.
- 2003 “Optimizing Drug Treatment in Bipolar Depression,” Johns Hopkins University and GlaxoSmithKline Training, UT Southwestern Medical Center, February 10th.
- 2003 “Antipsychotic Use in Special Populations,” Dallas, Texas, AstraZeneca, April 2nd.
- 2003 “Bipolar II Disorder: The Concept of Dysphoric Hypomania”, UCLA Neuropsychiatric Institute and Hospital, UCLA School of Medicine, Grand Rounds. April 15th
- 2003 “Evolving Treatment Strategies for Bipolar Disorder,” Bristol-Myers Squibb, Dallas, Texas, May 7th.
- 2003 “Treatment Approaches for Managing Anxiety Disorder in the Bipolar Patient,” American Psychiatric Association, May 19th-22nd.
- 2003 “Clinical Predictors of Response to Maintenance Treatment in Bipolar I Disorder,” American Psychiatric Association, May 19th-22nd.
- 2003 “Service Utilization Among Patients with Bipolar Disorder in the Texas Medication Algorithm Project,” NCDEU, Boca Raton, Florida, May 29, 2003.
- 2003 “Assessing the Efficacy of Antipsychotics in Acute Mania,” CME, Dallas, Texas, June 7th.
- 2003 “Practical Considerations in Stabilizing Mania Associated with Bipolar Disorder,” GlaxoSmithKline, Dallas, Texas, August 20th.
- 2003 “Stabilization for the Long Term,” GlaxoSmithKline, Dallas, Texas, August 23rd.
- 2003 “Long-Term Management of Bipolar Disorder,” GlaxoSmithKline, Dallas, Texas, August 25th.
- 2004 “Bipolar I Disorder: Stabilization for the Long-Term.” GlaxoSmithKline, Dallas, Texas, January 13th.
- 2004 “Antipsychotic Use in Special Populations.” AstraZeneca, Dallas, Texas, January 15th.
- 2004 “Stabilizing Bipolar Disorder: Key Factors in Achieving Patient Acceptance.” CME, Inc., Las Vegas, Nevada, January 24th.
- 2004 “Practical Considerations for Choosing Long-Term Agents for the Management of Bipolar I Disorder.” GlaxoSmithKline, Dallas, Texas, January 27th.
- 2004 “Antipsychotic Use in Special Populations.” AstraZeneca, Tulsa, Oklahoma, March 1st.
- 2004 “Antipsychotic Use in Special Populations.” Laureate Psychiatric Clinic and Hospital, Tulsa, Oklahoma, March 1st.
- 2004 “Antipsychotic Use in Special Populations.” The Polo Grill, Tulsa, Oklahoma, March 1st.
- 2004 “Antipsychotic Use in Special Populations.” AstraZeneca, Muskogee, Oklahoma, March 2nd.
- 2004 “Antipsychotic Use in Special Populations.” Jasper’s, Muskogee, Oklahoma, March 2nd.
- 2004 “Stabilizing Bipolar Disorder: Key Factors in Achieving Successful Outcomes.” AstraZeneca, Terrell State Hospital, Terrell, Texas, April 19th.
- 2004 “Bipolar Disorder.” University of Texas Medical Branch, Grand Rounds, Galveston, Texas, September 14th.

- 2004 "Latest Advances in the Multi-dimensional Assessment and Treatment of Bipolar Disorder." Stanford University School of Medicine and GlaxoSmithKline, Oklahoma City, Oklahoma, November 4th.
- 2005 "Update on Maintenance Treatment of Bipolar Disorder." Depression Bipolar Support Alliance of Dallas, Dallas, Texas, January 20th.
- 2005 "Latest Advances in the Multi-dimensional Assessment and Treatment of Bipolar Disorder," Stanford University and GlaxoSmithKline, Dallas, TX, February 22nd.
- 2005 "Diagnosis of Bipolar II Disorder and Mixed Hypomania: Prevalence and Gender Specificity." University of Mexico School of Medicine, Grand Rounds, Albuquerque, NM, April 29th.
- 2005 "Diagnosis of Bipolar II Disorder and Mixed Hypomania: Prevalence and Gender Specificity." McLean Hospital, Harvard Medical School, Grand Rounds, Boston, MA, May 5th.
- 2005 "Treatment and Monitoring Guidelines and the Management of Patients with Psychiatric Comorbidities in Bipolar Disorder." American Psychiatric Association, Atlanta, GA, May 21st.
- 2005 "The Acute Setting: Achieving Stabilization." American Psychiatric Association, Atlanta, GA, May 22nd.
- 2005 "Treatment Algorithms of Bipolar Disorder." Sixth International Conference on Bipolar Disorder, Pittsburgh, PA, June 16th.
- 2005 "The Role of Complementary and Alternative Medicine (CAM) in Bipolar Disorder." Sixth International Conference on Bipolar Disorder, Pittsburgh, PA, June 17th.
- 2005 "Bipolar Depression." Psychopharmacology Update Series: Foundations and Innovations in the Treatment of Bipolar Disorder, UT Health Science Center, San Antonio, TX, August 26th.
- 2005 "Management of Rapid Cycling in Patients with Bipolar Disorder." Psychopharmacology Update Series: Foundations and Innovations in the Treatment of Bipolar Disorder, UT Health Science Center, San Antonio, TX, August 26th.
- 2005 "Treating Bipolar Disorder: Clinical Applications of the Texas Medication Algorithm Project (TMAP), Dallas Group Psychotherapy Society for Continuing Education, Dallas, TX, October 28th.
- 2005 "Optimizing Treatment of Bipolar Disorder: Guideline-Driven Pharmacotherapy," The Center for Medical Knowledge CME Teleconference, November 15 – December 15.
- 2006 "The Impact of Bipolar Illness," Foundations and Innovations in the Treatment of Bipolar Disorder, Arizona Psychopharmacology Update Series, Scottsdale, AZ, April 28.
- 2006 "Psychopharmacologic Treatment of Mania," Foundations and Innovations in the Treatment of Bipolar Disorder, Arizona Psychopharmacology Update Series, Scottsdale, AZ, April 28.
- 2006 "Mixed Hypomania: Prevalence and Gender Specificity," University of Arizona Grand Rounds, Tucson, AZ, April 29.
- 2006 "Mood Disorders in Women," Texas Medical Association, TexMed 2006, Houston, TX, May 5.
- 2006 "Diagnostic Dilemmas in Mixed States in Bipolar Disorder," Understanding the Complexity of Bipolar Mixed Episodes, psychCME and Postgraduate Institute for Medicine CME Program, San Francisco, CA, May 13.
- 2006 "Bipolar Summit 2006: A Critical Appraisal of Current Practice," Statement 8, Medical Summit Series, San Diego, CA, June 19-20.
- 2006 "Examining Options and Issues in the Treatment of Bipolar Disorder," Life Long Learning Initiative Bipolar Disorder, CME, LLC program, San Jose, CA, June 22.
- 2006 "Introduction: Bipolar Disorder Clinical Challenges," Bipolar Disorder Think Tank, Novartis Pharmaceuticals Corporation, Philadelphia, PA, July 26.
- 2006 The Future of Psychiatric Diagnosis: Refining the Research Agenda, Dimensional Psychiatry, National Institutes of Health, Bethesda, MD, July 26-28.

- 2006 “Gender differences in bipolar disorder and a recent Stanley Bipolar network study on mixed hypomania,” Management of Women with Bipolar Disorder, 2nd Biennial Conference of the International Society for Bipolar Disorders, Edinburgh, Scotland, August 4.
- 2006 “Bipolar Guidelines, Algorithms, Consensus Statements – Are They Worth the Paper They Are Written On?” Global Expert Forum, Eli Lilly Co., Barcelona, Spain, October 4.
- 2006 “Efficacy for depressive episodes in patients with bipolar II disorder: Quetiapine monotherapy,” Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Spain, October 5.
- 2006 “The Current Essentials in Diagnosing Bipolar Disorder Today,” Texas Society of Psychiatric Physicians (CME), Austin, Texas, November 4.
- 2007 “Update on the Diagnosis and Treatment of Bipolar Disorder,” Medical University of South Carolina, Grand Rounds, Charleston, South Carolina, March 23.
- 2007 “Diagnosis and Update to the Treatment Algorithms,” University of Oklahoma Health Sciences Center, Grand Rounds, Oklahoma City, Oklahoma, April 12.
- 2007 “Managing Mixed Mania: Diagnostic Dilemmas and Therapeutic Challenges,” US Psychiatric and Mental Health Congress, Regional Extension, CME LLC, San Francisco, CA, April 21.
- 2007 “Recent Research Findings in Bipolar Disorder,” NAMI-Dallas Coalition Advocates in Action, Dallas, Texas, May 10.
- 2007 “Categories and Dimensions in Clinical & Research Contexts of Diagnostic Classifications of DSM-V,” Invited Symposium, Annual Meeting of the American Psychiatric Association, San Diego, CA, May 21.
- 2007 “Treatment of bipolar II disorder and consideration of the bipolar spectrum,” Invited Symposium: The Bipolar Spectrum and Bipolar II Disorder; chair: Joseph Calabrese, MD. International Conference on Bipolar Disorders, Pittsburgh, PA, June 7.
- 2007 “New trends for outpatient treatment of bipolar disorder,” NAMI Mental Illness Awareness Week Conference, Plano, Texas, October 4.
- 2008 “Diagnosis and Treatment of Bipolar II Disorder,” University of Michigan, Grand Rounds, Ann Arbor, Michigan, April 9.
- 2008 Chair, Invited Symposium: Mood Disorders II: Neural and Genetic Mechanisms; Annual Meeting for Society of Biological Psychiatry, Washington, DC, May 2.
- 2008 “Quetiapine As Maintenance Therapy in Bipolar I Disorder,” Oral Report, Annual Meeting of the American Psychiatric Association, Washington, DC, May 3-8.
- 2008 “Clinical trial design in the long-term treatment of bipolar disorder: patient considerations,” Invited Symposium, 21st European College of Neuropsychopharmacology Congress, Barcelona, Spain, September 2nd.
- 2008 “Sample Selection and Inclusion Criteria for Generalizability in Studies of Bipolar I & II” Bipolar Statistical Summit, Bethesda, MD, October 29.
- 2009 “Evidence-Based Care for a Complex Illness: Treatment Guidelines for Bipolar Disorder,” Stanford University School of Medicine, Grand Rounds, Palo Alto, CA, March 26th.
- 2009 “Depression/Bipolar Disorder and its Impact on the Family” Department of Veterans Affairs Support and Family Education, Palo Alto, CA, April 23rd.
- 2009 “Bipolar Disorder and Treatment Guidelines” Santa Clara County Psychological Association, Santa Clara, CA June 11th.
- 2009 “Sample Selection and Inclusion Criteria for Generalizability in Studies of Bipolar Disorder,” 49th Annual Meeting New Clinical Drug Evaluation Unit (NCDEU), Hollywood, FL, June 29th.
- 2009 “Bipolar Spectrum and Bipolar II Disorders,” Eighth International Conference on Bipolar Disorder, Pittsburgh, PA, June 27.

- 2009 “Diagnosis Roundtable,” Eighth International Conference on Bipolar Disorder, Pittsburgh, PA, June 27th.
- 2009 “Applying Novel Methodologies to Long-Term Intervention Trials in Bipolar Disorder,” 49th Annual NCDEU Meeting, Hollywood, FL, June 29th.
- 2009 “Klerman Award Presentation” and “Ask the Doctor” Q&AQ Panel, DBSA 2009 National Conference, Indianapolis, IN, September 11th.
- 2009 “New APA Guidelines for Bipolar Disorder,” DBSA 2009 National Conference, Indianapolis, IN, September 12th.
- 2010 “VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults,” Department of Veterans Affairs, VA National PTSD Center educational series, Palo Alto, CA, August 17, 2010.
- 2010 “Bipolar Disorder: A Complex Illness” and Ask the Expert, Depression and Bipolar Support Alliance (DBSA) support group meeting, Palo Alto, CA, November 17, 2010.
- 2011 “Proposed Changes to DSM 5 for Bipolar Disorder: Will it Matter?,” Grand Rounds, Department of Psychiatry, University of New Mexico, Albuquerque, NM, April 8, 2011.
- 2011 “What do we know about Veterans with bipolar disorder?” Research Seminar Series, VA Palo Alto Health Care System, Palo Alto, CA, May 6, 2011.
- 2012 “Update on DSM-5 Mood Disorders,” 8th Annual Mood Disorders Education Day, Stanford School of Medicine, Stanford, CA, July 28, 2012.
- 2012 “VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults,” Department of Veterans Affairs, Employee Education System and Office of Public Health and Environmental Hazards, VA Palo Alto Health Care System, Palo Alto, CA September 20, 2012.
- 2013 “Mixed States?” International Society of Bipolar Disorders. Columbia. August 22, 2013
- 2013 “SSM-5 Criteria for Bipolar Disorder: What HAS Changed?” Florida Medicaid Drug Guideline. September 20, 2013.
- 2013 “Challenging new perspectives in Mania” Expert Focus Meeting, Barcelona. October 13, 2013
- 2014 “DSM-5: Update to Bipolar Disorders” Stanford Psychiatry Grand Rounds. February 27, 2014
- 2014 “DSM-5: Update to Bipolar Disorders” Aztra Zeneca Speaker Tour. April 2014. Australia: Perth, Melbourne, Sydney, and Brisbane
- 2014 “DSM-5: Update to Bipolar Disorders” Global Medical Education. May 2014. Rhode Island.
- 2015 “DSM-5: Update to Bipolar Disorders” INNOPSY. November 2015. Milan.
- 2015 “Diagnosis in Bipolar Disorders?” MQ Health. November 2015. London.
- 2017 “Recent Guideline Developments in the Veterans Administration – How Far Do Guidelines Take Us?” ADDA. April 2017. San Francisco.
- 2017 “Discussion forum engagement within an internet-based program for bipolar disorder: impacts on social support, stigma, quality of life and mood severity.” ISBD 2017. Washington D.C.
- 2017 “Efficacy and Safety of Lurasidone in Bipolar Depression: Treatment Review” WFSBP Congress, June 18-22, 2017
- 2018 “Controversies in Bipolar Depression Across the Lifespan.” ASCP Annual Meeting May 29 – June 1, 2018
- 2018 “Treatment of Bipolar Depression: Is there more to do?” 2018 International Society of Affective Disorders Conference, being held in conjunction with the Houston Mood Disorders Conference, on September 20-22, 2018
- 2019 “Update on Treatment of Bipolar Disorder” ASCP-ISBD Workshop at the 2019 Annual ASCP Meeting, May 28-31, 2019
- 2019 “What's Up with Mixed States in Bipolar Disorder and Major Depression” and “What’s New in Innovative Medications and Approaches to Identify New Therapies for Mood Disorders” WFSBP Congress Vancouver June 2019.